 AGREEMENT AND PLAN OF MERGER      

  



  

[CORINDUS VASCULAR ROBOTICS, INC. 8-K](cvrs-8k_080719.htm)

  

Exhibit 2.1

  



  

EXECUTION COPY

     
--- 
   



  

AGREEMENT AND PLAN OF MERGER

  



  

by and among

  



  

SIEMENS MEDICAL SOLUTIONS USA, INC.,

  



  

CORPUS MERGER, INC.,

  



  

and

  



  

CORINDUS VASCULAR ROBOTICS, INC.

  



  

Dated as of August 7, 2019

     
--- 
  



    



 



    



  

TABLE OF CONTENTS

  



  

       |   | _Page_ 
---|---|--- 
     |   | 
   ARTICLE I 
     |   | 
   THE MERGER 
     |   | 
   Section 1.1  | The Merger  | 6 
   Section 1.2  | The Closing  | 7 
   Section 1.3  | Effective Time  | 7 
   Section 1.4  | Certificate of Incorporation; Bylaws  | 7 
   Section 1.5  | Board of Directors; Officers  | 7 
     |   | 
   ARTICLE II 
     |   | 
   EFFECT OF THE MERGER ON CAPITAL STOCK; EXCHANGE OF CERTIFICATES 
     |   | 
   Section 2.1  | Effect on Capital Stock  | 8 
   Section 2.2  | Surrender of Certificates  | 9 
   Section 2.3  | Company Warrants  | 11 
   Section 2.4  | Company Equity Awards  | 11 
   Section 2.5  | Lost Certificates  | 13 
   Section 2.6  | Dissenting Shares  | 13 
   Section 2.7  | Transfers; No Further Ownership Rights  | 14 
   Section 2.8  | Further Action  | 14 
     |   | 
   ARTICLE III 
     |   | 
   REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
     |   | 
   Section 3.1  | Organization; Qualification  | 14 
   Section 3.2  | Capitalization; Subsidiaries  | 15 
   Section 3.3  | Authority Relative to Agreement  | 18 
   Section 3.4  | Vote Required  | 19 
   Section 3.5  | No Conflict; Required Filings and Consents  | 19 
   Section 3.6  | Company SEC Documents; Financial Statements  | 20 
   Section 3.7  | Absence of Certain Changes or Events  | 22 
   Section 3.8  | No Undisclosed Liabilities  | 23 
   Section 3.9  | Litigation  | 23 
   Section 3.10  | Permits; Compliance with Laws  | 24 
   Section 3.11  | Proxy Statement  | 24 
   Section 3.12  | Employee Benefit Plans  | 25 
   Section 3.13  | Labor Matters  | 27 
   Section 3.14  | Taxes  | 28 
  



  

   

ii

 



    



     Section 3.15  | Material Contracts  | 30 
---|---|--- 
   Section 3.16  | Intellectual Property  | 33 
   Section 3.17  | Real and Personal Property  | 37 
   Section 3.18  | Environmental  | 38 
   Section 3.19  | Customers, Distributors, and Suppliers  | 39 
   Section 3.20  | Product Warranty  | 40 
   Section 3.21  | Foreign Corrupt Practices Act; Anti-Corruption  | 40 
   Section 3.22  | Customs and International Trade Laws  | 41 
   Section 3.23  | FDA and Related Matters  | 42 
   Section 3.24  | Healthcare Regulatory Compliance  | 44 
   Section 3.25  | Insurance  | 46 
   Section 3.26  | Takeover Statutes  | 46 
   Section 3.27  | Brokers  | 46 
   Section 3.28  | Opinion of Financial Advisors  | 46 
   Section 3.29  | No Other Representations or Warranties  | 47 
     |   | 
   ARTICLE IV 
     |   | 
   REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB 
     |   | 
   Section 4.1  | Organization; Qualification  | 47 
   Section 4.2  | Authority Relative to Agreement  | 47 
   Section 4.3  | No Conflict; Required Filings and Consents  | 48 
   Section 4.4  | Litigation  | 48 
   Section 4.5  | Information Supplied  | 49 
   Section 4.6  | Brokers  | 49 
   Section 4.7  | Sufficient Funds  | 49 
   Section 4.8  | Merger Sub  | 49 
   Section 4.9  | No Interested Stockholder  | 49 
   Section 4.10  | No Vote of Parent Shareholders  | 50 
   Section 4.11  | No Other Representations or Warranties  | 50 
     |   | 
   ARTICLE V 
     |   | 
   COVENANTS AND AGREEMENTS 
     |   | 
   Section 5.1  | Conduct of Business by the Company Pending the Merger  |
51 
   Section 5.2  | Proxy Statement; Company Stockholders' Meeting  | 55 
   Section 5.3  | Appropriate Action; Consents; Filings  | 57 
   Section 5.4  | Access to Information; Confidentiality  | 59 
   Section 5.5  | No Solicitation  | 59 
   Section 5.6  | Directors' and Officers' Indemnification and Insurance 
| 62 
   Section 5.7  | Notification of Certain Matters  | 64 
   Section 5.8  | Public Disclosure  | 65 
   Section 5.9  | Intellectual Property Matters  | 65 
   Section 5.10  | Employee Matters  | 66 
  



  

   

iii

 



    



     Section 5.11  | Merger Sub  | 68 
---|---|--- 
   Section 5.12  | Rule 16b-3 Matters  | 68 
   Section 5.13  | Repayment and Termination of Existing Credit Agreement 
| 68 
   Section 5.14  | Stock Exchange Delisting; Deregistration  | 68 
   Section 5.15  | State Takeover Laws  | 68 
   Section 5.16  | Stockholder Litigation  | 69 
   Section 5.17  | Resignations  | 69 
   Section 5.18  | Tax Returns  | 69 
     |   | 
   ARTICLE VI 
     |   | 
   CONDITIONS TO THE MERGER 
     |   | 
   Section 6.1  | Conditions to the Obligations of Each Party  | 69 
   Section 6.2  | Conditions to the Obligations of Parent and Merger Sub 
| 70 
   Section 6.3  | Conditions to the Obligations of the Company  | 71 
   Section 6.4  | Frustration of Closing Conditions  | 71 
     |   | 
   ARTICLE VII 
     |   | 
   TERMINATION, AMENDMENT AND WAIVER 
     |   | 
   Section 7.1  | Termination  | 71 
   Section 7.2  | Effect of Termination  | 73 
   Section 7.3  | Termination Fees  | 73 
   Section 7.4  | Amendment  | 74 
   Section 7.5  | Extension; Waiver  | 75 
     |   | 
   ARTICLE VIII 
     |   | 
   GENERAL PROVISIONS 
     |   | 
   Section 8.1  | Non-Survival of Representations and Warranties  | 75 
   Section 8.2  | Expenses  | 75 
   Section 8.3  | Notices  | 75 
   Section 8.4  | Interpretation; Certain Definitions  | 76 
   Section 8.5  | Severability  | 77 
   Section 8.6  | Assignment  | 77 
   Section 8.7  | Entire Agreement  | 77 
   Section 8.8  | No Third-Party Beneficiaries  | 78 
   Section 8.9  | Governing Law  | 78 
   Section 8.10  | Specific Performance  | 78 
   Section 8.11  | Consent to Jurisdiction  | 78 
   Section 8.12  | Counterparts  | 79 
   Section 8.13  | WAIVER OF JURY TRIAL  | 79 
   Section 8.14  | Definitions  | 79 
  



  

   

iv

 



    



  

EXHIBITS

  



     Exhibit A  | Voting and Support Agreement 
---|--- 
   Exhibit B  | Certificate of Incorporation of the Surviving Corporation 
   Exhibit C  | Bylaws of the Surviving Corporation 
   Exhibit D  | Preferred Stockholder Letter 
    



  

   

v

 



    

     



  

AGREEMENT AND PLAN OF MERGER

  



  

THIS AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of August 7,
2019, is made by and among Siemens Medical Solutions USA, Inc., a Delaware
corporation ("Parent"), Corpus Merger, Inc., a Delaware corporation and a
wholly owned Subsidiary of Parent ("Merger Sub"), and Corindus Vascular
Robotics, Inc., a Delaware corporation (the "Company"). Defined terms used in
this Agreement have the respective meanings ascribed to them in _Section
8.14_.

  



  

 _W_ _I_ _T_ _N_ _E_ _S_ _S_ _E_ _T_ _H_ :

  



  

WHEREAS, the respective boards of directors of Parent, the Company (the
"Company Board") and Merger Sub have approved and declared advisable and in
the best interests of their respective stockholders, this Agreement and the
transactions contemplated by this Agreement, including the merger of Merger
Sub with and into the Company, with the Company surviving as a wholly owned
Subsidiary of Parent (the "Merger"), upon the terms and subject to the
conditions and limitations set forth in this Agreement and in accordance with
the General Corporation Law of the State of Delaware (the "DGCL");

  



  

WHEREAS, the Company Board has, subject to _Section 5.5(d)_ and _5.5(e)_ ,
resolved to recommend that the Company's stockholders approve the adoption of
this Agreement;

  



  

WHEREAS, concurrently with the execution and delivery of this Agreement and
as an inducement to Parent's willingness to enter into this Agreement, each
of Parent and certain stockholders of the Company have entered into a voting
and support agreement in the form attached as  _Exhibit A_ hereto (the
"Voting and Support Agreement"), pursuant to which, and subject to the terms
and limitations thereof, among other things, the foregoing stockholders
agreed to vote the shares of Company Common Stock beneficially owned by each
of them in favor of the adoption of this Agreement and approval of the Merger
and the other transactions contemplated hereby at the Company Stockholders'
Meeting; and

  



  

WHEREAS, each of Parent, Merger Sub and the Company desire to make certain
representations, warranties, covenants and agreements in connection with
the Merger and also to prescribe various conditions to the Merger.

  



  

NOW, THEREFORE, in consideration of the foregoing and the mutual
representations, warranties, agreements and covenants, and subject to the
conditions, herein contained, and intending to be legally bound hereby, the
parties hereto hereby agree as follows:

  



  

ARTICLE I 
  
 THE MERGER

  



  

Section 1.1 _The Merger_. Upon the terms and subject to the
conditions set forth in this Agreement, and in accordance with the DGCL, at
the Effective Time, the Company and Merger Sub shall consummate the Merger
pursuant to which (a) Merger Sub shall be merged with and into the Company and
the separate corporate existence of Merger Sub shall thereupon cease; (b) the
Company shall be the surviving corporation in the Merger and shall continue to
be governed by the Laws of the State of Delaware; and (c) the separate
corporate existence of the Company with all its rights, privileges,
immunities, powers and franchises shall continue as a wholly owned subsidiary
of Parent. The corporation surviving the Merger is hereinafter referred to as
the "Surviving Corporation." The Merger shall have the effects set forth
herein and in the applicable provisions of the DGCL.

  



  

   

6

 



    



  

Section 1.2 _The Closing_. The closing of the Merger (the
"Closing") shall take place at 10:00 a.m. (local time) on a date to be
specified by the parties hereto, but no later than the second (2nd) Business
Day after the satisfaction or (to the extent permitted by Law) waiver of the
conditions set forth in _Article VI_  (other than those conditions that by
their terms are to be satisfied at the Closing, but subject to the
satisfaction or (to the extent permitted by Law) waiver of such conditions),
unless another time, date or place is agreed to in writing by the
parties hereto (such date being the "Closing Date"). The Closing shall take
place at the offices of Blank Rome LLP, 1271 Avenue of the Americas, New
York, NY 10020, or by the electronic transmission of signature pages.

  



  

Section 1.3 _Effective Time_. Concurrently with the Closing, the Company
shall cause an appropriate certificate of merger with respect to the Merger
(the "Certificate of Merger") to be executed, acknowledged and filed with the
Delaware Secretary of State as provided under the DGCL. The Merger shall
become effective at the time the Certificate of Merger has been duly filed
with the Delaware Secretary of State or at such later date and time as is
agreed between Parent and the Company and specified in the Certificate of
Merger (the time the Merger becomes effective being hereinafter referred to
as the "Effective Time").

  



  

Section 1.4 _Certificate of Incorporation; Bylaws_.

  



  

(a) At the Effective Time, the Certificate of Incorporation, as in
effect immediately prior to the Effective Time, shall, by virtue of the
Merger, be amended and restated in its entirety as set forth in _Exhibit B_
hereto and, as so amended and restated, shall be the certificate of
incorporation of the Surviving Corporation, until thereafter amended as
provided by Law and such certificate of incorporation (subject to _Section
5.6_ ).

  



  

(b) At the Effective Time, the bylaws of Merger Sub, as in effect
immediately prior to the Effective Time, shall, by virtue of the Merger, be
amended and restated in its entirety as set forth in _Exhibit C_ hereto and,
as so amended and restated, shall be the bylaws of the Surviving Corporation,
until thereafter amended as provided by Law, the certificate of
incorporation of the Surviving Corporation and such bylaws.

  



  

Section 1.5 _Board of Directors; Officers_. The members of the board of
directors of Merger Sub immediately prior to the Effective Time shall, from
and after the Effective Time, be the members of the board of directors of the
Surviving Corporation, and the officers of the Surviving Corporation shall be
designated by Parent immediately prior to the Effective Time, in each case to
hold office, in accordance with the certificate of incorporation and
bylaws of the Surviving Corporation, until the earlier of their death,
resignation or removal or until their respective successors shall have been
duly elected, designated or qualified.

  



  

   

7

 



    



  

ARTICLE II 
  
 EFFECT OF THE MERGER ON CAPITAL STOCK; EXCHANGE OF CERTIFICATES

  



  

Section 2.1 _Effect on Capital Stock_.

  



  

(a) _Effect of Merger_. At the Effective Time, by virtue of the
Merger and without any action on the part of the Company, Parent, Merger Sub
or the holders of any Securities of the Company or Merger Sub:

  



  

(i) _Company Common Stock_. Each share of Company Common Stock
issued and outstanding immediately prior to the Effective Time (other than
Canceled Shares and Dissenting Shares) shall be converted into the right to
receive, in accordance with the terms of this Agreement, $4.28 per share in
cash, without interest (the "Common Stock Consideration").

  



  

(ii) _Company Preferred Stock_. Each share of (A) Company Preferred
Stock issued and outstanding immediately prior to the Effective Time and (B)
Series A-1 Preferred Stock that has accrued and accumulated on a daily basis
until the Effective Time, in accordance with the provisions of the Company
Certificate of Designation, but which is not otherwise issued or
outstanding immediately prior to the Effective Time, in each case other than
Canceled Shares and Dissenting Shares, shall be converted into the right to
receive, in accordance with the terms of this Agreement, an amount in cash
equal to $85.60 per share, without interest (the "Preferred Stock
Consideration").

  



  

(iii) _Cancellation of Company Securities_. Each share of Company
Stock held by the Company as treasury stock or held directly by Parent or any
Subsidiary of Parent (including Merger Sub) immediately prior to the
Effective Time shall no longer be outstanding and shall automatically be
canceled and retired and shall cease to exist, and no consideration or
payment shall be delivered in exchange therefor or in respect thereof (such
shares, "Canceled Shares").

  



  

(iv) _Conversion of Merger Sub Capital Stock_. Each share of common
stock, par value $0.0001 per share, of Merger Sub issued and outstanding
immediately prior to the Effective Time shall be converted into and become
one (1) fully paid share of common stock, par value $0.0001 per share, of the
Surviving Corporation and constitute the only outstanding shares of capital
stock of the Surviving Corporation.

  



  

(b) _Certificates; Book Entry Shares_. Each share of Company Stock
to be converted into the right to receive the applicable Merger Consideration
as provided in _Section 2.1(a)_ shall no longer be outstanding and shall be
automatically canceled and shall cease to exist, and the holders of
certificates (the "Certificates") or book-entry shares ("Book-Entry Shares"),
which immediately prior to the Effective Time represented such Company Stock,
shall cease to have any rights with respect to such Company Stock other than
the right to receive, upon surrender of such Certificates or Book-
Entry Shares in accordance with _Section 2.2_ , the applicable Merger
Consideration.

  



  

   

8

 



    



  

(c) _Adjustments_. Without limiting the other provisions of this
Agreement, if at any time during the period between the date of this
Agreement and the Effective Time, any change in the number or type of
outstanding shares of Company Stock shall occur as a result of a
reclassification, recapitalization, exchange, stock split (including a reverse
stock split) or combination or readjustment of shares or any similar event or
any stock dividend or stock distribution with a record date during such
period, the applicable Merger Consideration and any other similarly dependent
amounts and items, as the case may be, shall be appropriately adjusted to
provide the same economic effect as contemplated by this Agreement prior to
such event. Nothing in this _Section 2.1(c)_ shall be construed to permit the
Company to take any action that is otherwise prohibited or restricted by any
other provision of this Agreement.

  



  

Section 2.2 _Surrender of Certificates_.

  



  

(a) _Designation of Paying Agent; Deposit of Funds_. Prior to the
Closing, Parent shall, at its sole cost and expense, enter into a customary
paying agent agreement with a nationally recognized financial institution
designated by Parent that is reasonably acceptable to the Company (the
"Paying Agent") for the payment of the Aggregate Merger Consideration as
provided in _Section 2.1(a)(i)_ and _Section 2.1(a)(ii)_. At or prior to the
Effective Time, Parent shall deposit or cause to be deposited with the Paying
Agent, for payment in accordance with this _Article II_ through the Paying
Agent, cash in immediately available funds in an amount sufficient to pay (i)
the Aggregate Merger Consideration in exchange for all of the shares of
Company Stock outstanding immediately prior to the Effective Time (other than
Canceled Shares or Dissenting Shares) and (ii) the Warrant Consideration (the
"Payment Fund"). The Payment Fund shall be invested by the Paying Agent if and
as directed by Parent or the Surviving Corporation pending payment thereof by
the Paying Agent to the holders of the shares of Company Stock,  _provided_ ,
_however_ , that no such investment or loss thereon shall affect the amounts
payable to the holders of the shares of Company Stock pursuant to _Section
2.1(a)_ and to the extent of any such loss, Parent shall promptly fund
additional cash amounts to the Paying Agent sufficient to enable payment of
such amounts. Earnings from such investments shall be the sole and exclusive
property of Parent and the Surviving Corporation, and no part of such earnings
shall accrue to the benefit of holders of shares of Company Stock.

  



  

(b) As promptly as reasonably practicable after the Effective Time
(and in any event within five (5) Business Days after the Effective Time),
Parent shall cause the Paying Agent to mail to each holder of record of a
Certificate that immediately prior to the Effective Time represented
outstanding shares of Company Stock (i) a letter of transmittal (which shall
specify that delivery of Certificates shall be effected, and risk of loss and
title to the Certificates shall pass only upon proper delivery of the
Certificates (or affidavits of loss in lieu thereof as provided in _Section
2.5_ ) to the Paying Agent, and which shall be in the form and have such
other customary provisions as Parent may reasonably specify) and (ii)
instructions (which instructions shall be in the form and have such other
customary provisions as Parent may reasonably specify) for use in effecting
the surrender of the Certificates in exchange for cash in an amount equal to
the applicable Merger Consideration multiplied by the number of shares of
Company Stock previously represented by such Certificates.

  



  

   

9

 



    



  

(c) Upon surrender of a Certificate (or affidavit of loss in lieu
thereof as provided in _Section 2.5_ ) for cancellation to the Paying Agent,
together with a letter of transmittal duly completed and validly executed in
accordance with the instructions thereto, and such other documents as may
reasonably be required by the Paying Agent, the holder of such Certificate
shall be entitled to receive in exchange therefor, and Parent shall cause the
Paying Agent to pay and deliver in exchange therefor as promptly
as reasonably practicable cash in an amount equal to the applicable Merger
Consideration multiplied by the number of shares of Company Stock previously
represented by such Certificate, and the Certificate (or affidavit of loss in
lieu thereof as provided in _Section 2.5_ ) so surrendered shall be forthwith
cancelled. Each Book-Entry Share shall automatically upon the Effective Time
be entitled to receive, and Parent shall cause the Paying Agent to pay and
deliver in exchange therefor as promptly as reasonably practicable after the
Effective Time, cash in an amount equal to the applicable Merger Consideration
multiplied by the number of shares of Company Stock previously represented by
such Book-Entry Share. Until surrendered, in the case of a Certificate, or
paid, in the case of a Book-Entry Share, in each case, as contemplated by
this _Section 2.2(c)_ , each Certificate or Book-Entry Share shall be deemed,
from and after the Effective Time, to represent only the right to receive the
applicable Merger Consideration as contemplated by this _Section 2.2(c)_. The
Paying Agent shall accept such Certificates (or affidavits of loss in lieu
thereof as provided in _Section 2.5_ ) and make such payments and deliveries
with respect to Book-Entry Shares upon compliance with such reasonable terms
and conditions as the Paying Agent may impose to effect an orderly exchange
thereof in accordance with customary exchange practices. No interest shall be
paid or accrued for the benefit of holders of the Certificates or Book-Entry
Shares on the cash amounts payable pursuant to this _Section 2.2(c)_.

  



  

(d) _Unregistered Transfers_. In the event of a transfer of
ownership of Company Stock, as applicable, that is not registered in the
transfer records of the Company, payment of the appropriate amount of the
applicable Merger Consideration may be made to a Person other than the Person
in whose name the Certificate or Book-Entry Share so surrendered is
registered, if such Certificate shall be properly endorsed or otherwise be in
proper form for transfer (and accompanied by all documents
reasonably required by the Paying Agent) or such Book-Entry Share shall be
properly transferred and the Person requesting such payment shall pay any
transfer or other Taxes required by reason of the payment to a Person other
than the registered holder of such Certificate or Book-Entry Share or
establish to the satisfaction of Parent that such Tax has been paid or is not
applicable.

  



  

(e) _Termination of Fund_. Any portion of the Payment Fund made
available to the Paying Agent, which remains undistributed to the holders of
the Certificates or Book-Entry Shares six (6) months after the Effective Time,
shall be delivered to the Surviving Corporation or its designee upon demand,
and any such holders prior to the Merger who have not theretofore complied
with this _Article II_ shall thereafter look only to the Surviving
Corporation as general creditor thereof for payment of their claims for
the applicable Merger Consideration.

  



  

(f) _No Liability_. None of Parent, Merger Sub, the Company or the
Paying Agent shall be liable to any Person in respect of any applicable
Merger Consideration delivered to a Governmental Authority pursuant to any
applicable abandoned property, escheat or similar Law. If any Certificate
shall not have been surrendered or Book-Entry Share not paid, in each case, in
accordance with _Section 2.2(c)_ , immediately prior to the date on which any
Common Stock Consideration or Preferred Stock Consideration in respect of
such Certificate or Book-Entry Share would otherwise escheat to or become the
property of any Governmental Authority under applicable Law, any such Common
Stock Consideration or Preferred Stock Consideration in respect of such
Certificate or Book-Entry Share shall, to the extent permitted by applicable
Law, become the property of the Surviving Corporation free and clear of
all claims or interest of any Person previously entitled thereto.

  



  

   

10

 



    



  

(g) _Withholding_. Parent, the Company, the Surviving Corporation,
any of their applicable Subsidiaries and the Paying Agent shall be entitled
to deduct and withhold from the applicable Merger Consideration and any
amounts otherwise payable pursuant to this Agreement such amounts as Parent,
the Company, the Surviving Corporation, any of their applicable
Subsidiaries or the Paying Agent is required to deduct and withhold with
respect to the making of such payment under the Code or any provision of
applicable Tax Law. Any amounts so withheld and paid over to an applicable
Governmental Authority as required by applicable Law shall be treated for all
purposes of this Agreement as having been paid to the Person in respect of
which such deduction and withholding was made by Parent, the Company, the
Surviving Corporation, any of their applicable Subsidiaries or the Paying
Agent.

  



  

Section 2.3 _Company Warrants_. Neither Parent nor Merger Sub
shall assume any Company Warrant or substitute for any Company Warrant any
similar warrant for Parent Common Stock in connection with the Merger or any
of the other transactions contemplated by this Agreement. At the Effective
Time, each Company Warrant that is outstanding and unexercised immediately
prior thereto shall by virtue of the Merger and without any further action on
the part of any holder of any Company Warrant be cancelled and converted into
the right to receive from the Company at the Effective Time a cash payment
(without interest) equal to (i) the product of (A) the excess, if any, of (1)
the Common Stock Consideration over (2) the per share exercise price of such
Company Warrant, and (B) the number of shares of Company Common Stock subject
to such Company Warrant as of the Effective Time (the "Warrant
Consideration"), less (ii) any applicable withholding Taxes required by
applicable Law to be withheld. As of the Effective Time, all Company Warrants
shall no longer be outstanding and shall automatically cease to exist, and
each holder of a Company Warrant shall cease to have any rights with respect
thereto, except the right to receive the Warrant Consideration. For the
avoidance of doubt, if the exercise price payable in respect of a share of
Company Common Stock underlying a Company Warrant equals or exceeds the Common
Stock Consideration, such Company Warrant shall be cancelled for no
consideration immediately prior to the Effective Time and the holder thereof
shall have no further rights with respect thereto.

  



  

Section 2.4 _Company Equity Awards_.

  



  

(a) _Treatment of Company Options_. Neither Parent nor Merger Sub
shall assume any Company Option or substitute for any Company Option any
similar award for Parent Common Stock in connection with the Merger and any of
the other transactions contemplated by this Agreement. At the Effective Time,
each Company Option that is outstanding and unexercised immediately
prior thereto, whether vested or unvested, shall by virtue of the Merger and
without any action on the part of any holder of any Company Option be
cancelled and converted into the right to receive from the Company at the
Effective Time a cash payment (without interest) equal to (i) the product of
(A) the excess, if any, of (1) the Common Stock Consideration over (2) the per
share exercise price of such Company Option, and (B) the number of shares of
Company Common Stock subject to such Company Option as of the Effective Time
(the "Option Consideration"), less (ii) any applicable withholding Taxes
required by applicable Law to be withheld. As of the Effective Time, all
Company Options shall no longer be outstanding and shall automatically cease
to exist, and each holder of a Company Option shall cease to have any rights
with respect thereto, except the right to receive the Option Consideration.
For the avoidance of doubt, if the exercise price payable in respect of a
share of Company Common Stock underlying a Company Option equals or exceeds
the Common Stock Consideration, such Company Option shall be cancelled for no
consideration immediately prior to the Effective Time and the holder thereof
shall have no further rights with respect thereto.

  



  

   

11

 



    



  

(b) _Treatment of Company RSU Awards_. Neither Parent nor Merger Sub
shall assume any Company RSU Award or substitute for any Company RSU Award
any similar award for Parent Common Stock in connection with the Merger and
the other transactions contemplated by this Agreement. As of the Effective
Time, each Company RSU Award that is outstanding immediately prior to the
Effective Time, whether vested or unvested, shall by virtue of the Merger and
without any action on the part of any holder of any Company RSU Award be
cancelled and converted into the right to receive from the Company at the
Effective Time a cash payment (without interest) equal to (i) the product of
(A) the Common Stock Consideration and (B) the number of shares of Company
Common Stock subject to such Company RSU Award as of the Effective Time (the
"RSU Consideration"), less (ii) any applicable withholding Taxes required by
applicable Law to be withheld; _provided_ , that, notwithstanding anything to
the contrary contained in this Agreement, any payment in respect of any
Company RSU Award which immediately prior to such cancellation is
"deferred compensation" subject to Section 409A of the Code shall be made on
the applicable settlement date(s) for such Company RSU Award if required in
order to comply with Section 409A of the Code.

  



  

(c) _Method of Payment_. Any Option Consideration or RSU
Consideration to which an employee or former employee of the Company or one
of its Subsidiaries becomes entitled pursuant to _Section 2.4(a)_ or _Section
2.4(b)_ , together with the employer portion of any payroll Taxes on such
payment, shall be paid through the payroll of the Surviving Corporation or
one of its Subsidiaries, or the Paying Agent, as applicable, as soon as
reasonably practicable following the Effective Time (and in any event, within
ten (10) Business Days after the Closing Date). Any Option Consideration or
RSU Consideration to which any other person becomes entitled pursuant to
_Section 2.4(a)_ or _Section 2.4(b)_ shall be paid by the Surviving
Corporation or one of its Subsidiaries, as applicable (or, at the option of
the Surviving Corporation, by the Paying Agent), as soon as
reasonably practicable following the Effective Time (and in any event, within
ten (10) Business Days after the Closing Date).

  



  

(d) _Company Actions_. Prior to the Effective Time, the Company
shall provide such notice, if any, to the extent required under the terms of
any of the Company Equity Plans, Company Warrants or Company Preferred Stock,
as applicable, obtain any necessary consents or waivers, adopt applicable
resolutions, amend the terms of any of the Company Equity Plans (or any
outstanding awards thereunder), Company Warrants or Company Preferred Stock,
as applicable, including obtaining an executed letter, substantially in the
form attached hereto as _Exhibit D_ ("Preferred Stockholder Letter"), from
each holder of Company Preferred Stock, and take all other appropriate
actions to (i) give effect to the transactions contemplated herein; (ii)
terminate each of the Company Equity Plans as of the Effective Time; and
(iii) ensure that after the Effective Time, no holder of a Company Equity
Award, any beneficiary thereof nor any other participant in any of the Company
Equity Plans and no holder of a Company Warrant or Company Preferred Stock or
any beneficiary thereof shall have any right thereunder to acquire any
Securities of the Company or to receive any payment or benefit with respect
to (x) any award previously granted under any of the Company Equity Plans
or (y) any Company Warrant or Company Preferred Stock, as applicable, except
as provided in _Section 2.3_ and _Section 2.4_. The Company shall provide
Parent with documentation evidencing the completion of the foregoing actions
(the form and substance of such documentation shall be subject to review and
approval by Parent, such approval not to be unreasonably withheld,
conditioned or delayed) no later than the Business Day preceding the
Effective Time.

  



  

   

12

 



    



  

Section 2.5 _Lost Certificates_. If any Certificate shall have been lost,
stolen or destroyed, then upon the making of an affidavit of that fact by the
Person claiming such Certificate to be lost, stolen or destroyed and, if
required by the Paying Agent or Parent, the posting by such Person of a bond,
in such reasonable and customary amount as the Paying Agent or Parent may
direct, as indemnity against any claim that may be made against it
with respect to such Certificate, the Paying Agent will issue in exchange for
such lost, stolen or destroyed Certificate the applicable Merger
Consideration to which the holder thereof is entitled pursuant to this
_Article II_.

  



  

Section 2.6 _Dissenting Shares_. Notwithstanding anything in
this Agreement to the contrary, to the extent that holders of Company Stock
are entitled to appraisal rights under Section 262 of the DGCL, any shares of
Company Stock issued and outstanding immediately prior to the Effective Time
and held by a holder who has properly exercised and perfected his, her or its
demand for appraisal rights under Section 262 of the DGCL and not effectively
withdrawn or lost such holder's rights to appraisal (the "Dissenting
Shares"), shall not be converted into or represent the right to receive the
applicable Merger Consideration, but the holders of such Dissenting Shares
shall instead be entitled to receive such consideration as may be determined
pursuant to Section 262 of the DGCL (it being understood and acknowledged
that at the Effective Time, such Dissenting Shares shall no longer be
outstanding, shall automatically be canceled and shall cease to exist and
such holder shall cease to have any rights with respect thereto other than the
right to receive the consideration therefor as may be determined in
accordance with Section 262 of the DGCL); _provided_ , _however_ , that if any
such holder shall have failed to timely perfect or shall have waived,
effectively withdrawn or lost his, her or its right to appraisal and
payment under the DGCL (whether occurring before, at or after the Effective
Time), or a court of competent jurisdiction shall have determined that such
holder is not entitled to such right to appraisal and payment under Section
262 of the DGCL, such holder's shares of Company Stock shall thereupon be
deemed to have been converted as of the Effective Time into the right to
receive the applicable Merger Consideration, without any interest thereon,
and such shares shall no longer be deemed to be Dissenting Shares. The
Company shall give prompt notice to Parent of any demands for appraisal of
any shares of Company Stock, effective or attempted withdrawals of such
demands and any other instruments served pursuant to the DGCL received by the
Company relating to appraisal demands, and Parent shall have the opportunity
and right to participate in all discussions, negotiations and Proceedings,
with respect to such demands. Prior to the Effective Time, the Company shall
not, without the prior written consent of Parent (such consent not to
be unreasonably conditioned, delayed or withheld), voluntarily make any
payment with respect to or settle or compromise or offer to settle or
compromise any such demand or Proceeding, or agree in writing to do any of the
foregoing.

  



  

   

13

 



    



  

Section 2.7 _Transfers; No Further Ownership Rights_. At the
Effective Time, the stock transfer books of the Company shall be closed, and
from and after the Effective Time, there shall be no registration of
transfers on the stock transfer books of the Company of shares of Company
Stock that were outstanding immediately prior to the Effective Time. If
Certificates or Book-Entry Shares are presented to the Surviving Corporation,
Parent or the Paying Agent for transfer following the Effective Time, they
shall be canceled against delivery of the applicable Merger Consideration, as
provided for in _Section 2.1(a)_ , for each share of Company Stock formerly
represented by such Certificates or Book Entry Shares.

  



  

Section 2.8 _Further Action_. If, at any time after the Effective Time
any further action is determined by Parent or the Surviving Corporation to be
necessary or desirable to carry out the purposes of this Agreement or to vest
the Surviving Corporation or Parent with full right, title and possession of
and to all rights and property of Merger Sub and the Company with respect to
the Merger, the officers and directors of Parent shall be fully
authorized (in the name of Merger Sub, the Company, the Surviving Corporation
and otherwise) to take such action.

  



  

ARTICLE III 
  
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  



  

Except (a) as disclosed in the Company Disclosure Letter referenced therein
(it being understood and agreed that any disclosure set forth in one
section or subsection of the Company Disclosure Letter also shall be deemed
to apply to each other section and subsection of the Company Disclosure
Letter to which its applicability is reasonably apparent) or (b) other than
with respect to _Section 3.2(a)_ and  _Section 3.2(g)_ , as disclosed in the
Company SEC Documents filed with (or furnished to) the SEC by the Company on
or after December 31, 2018 and at least two (2) Business Days prior to the
date of this Agreement (but in each case excluding any disclosure contained
under the heading "Risk Factors," or "Cautionary Note Regarding Forward-
Looking Statements" or safe harbor or in any "forward-looking statements"
legend or any similar non-specific, predictive, precautionary or forward-
looking statements) and to the extent publicly available on the SEC's
Electronic Data Gathering Analysis and Retrieval System, the Company hereby
represents and warrants to Parent and Merger Sub as follows:

  



  

Section 3.1 _Organization; Qualification_.

  



  

(a) The Company is (i) a corporation duly organized and validly
existing under the Laws of the State of Delaware and has the requisite
corporate power and authority to conduct its business as it is now being
conducted and to own, lease and operate its properties and assets in the
manner in which its properties and assets are currently operated and (ii) duly
qualified or licensed to do business and is in good standing in each
jurisdiction in which the character or location of the property owned, leased
or operated by it or the nature of the business conducted by it makes such
qualification or licensing necessary, except where the failure to be so duly
qualified or licensed and in good standing has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. The Company's Certificate of Incorporation (the
"Certificate of Incorporation") and Bylaws (the "Bylaws"), each as amended as
of the date of this Agreement, have been made available to Parent and are in
full force and effect, and the Company is not in violation of any of the
provisions thereof.

  



  

   

14

 



    



  

(b) Each of the Company's Subsidiaries is (i) a legal entity duly
organized and validly existing under the Laws of the jurisdiction of its
incorporation, formation or organization, as applicable, and has the requisite
corporate or similar power and authority to conduct its business as it is now
being conducted and to own, lease and operate its properties and assets in
the manner in which its properties and assets are currently operated and (ii)
duly qualified or licensed to do business and is in good standing in each
jurisdiction in which the character or location of the property owned, leased
or operated by it or the nature of the business conducted by it makes such
qualification or licensing necessary, except where the failure to be so
duly qualified or licensed and in good standing has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. Except as has not had, and would not reasonably be
expected to have, individually or in the aggregate, a Company Material
Adverse Effect, the organizational or governing documents of each of the
Company's Subsidiaries are in full force and effect, and none of the
Company's Subsidiaries is in violation of any of the respective
provisions thereof.

  



  

Section 3.2 _Capitalization; Subsidiaries_.

  



  

(a) As of the close of business on August 5, 2019 (the
"Capitalization Date"), the authorized capital stock of the Company consisted
of (i) 350,000,000 shares of Company Common Stock, 208,533,915 of which were
issued and outstanding and none of which were held by the Company as treasury
stock, and (ii) 10,000,000 shares of preferred stock of the Company,
par value $0.0001 per share, 1,000,000 shares of which constitute a series of
preferred stock designated as Series A Convertible Preferred Stock, 1,000,000
of which were issued and outstanding ("Series A Preferred Stock"), and
1,000,000 shares of which constitute a series of preferred stock designated
as Series A-1 Convertible Preferred Stock, 167,248 of which were issued and
outstanding (or, to the extent not issued or outstanding, had otherwise
accrued until the Capitalization Date) ("Series A-1 Preferred Stock" and
together with Series A Preferred Stock, "Company Preferred Stock").
Except for the foregoing, there are no other classes of capital stock of the
Company and, except for Company Equity Awards, Company Warrants and Company
Preferred Stock, there are no bonds, debentures, notes or other Indebtedness
or Securities of the Company having the right to vote (or convertible into or
exercisable for Securities having the right to vote) on any matters on which
holders of capital stock of the Company may vote authorized, issued or
outstanding. As of the close of business on the Capitalization Date,
there were (A) outstanding Company Options to purchase 26,426,312 shares of
Company Common Stock; (B) outstanding Company RSU Awards representing 124,422
shares of Company Common Stock; (C) 8,611,196 shares of Company Common Stock
reserved for future issuance under the Company Equity Plans; (D) 9,191,287
shares of Company Common Stock reserved for issuance upon exercise of Company
Warrants; and (E) 23,344,957 shares of Company Common Stock reserved for
issuance upon conversion of Company Preferred Stock. As of the close of
business on the Capitalization Date, the 2014 Warrant had been exercised in
full and was no longer outstanding. From the close of business on the
Capitalization Date through the date of this Agreement, there have been (1) no
issuances of any Company Common Stock, Company Preferred Stock or any other
Securities of the Company other than issuances of shares of Company Common
Stock pursuant to (i) the conversion of any of Company Preferred Stock
outstanding as of the close of business on the Capitalization Date in
accordance with the terms of the Certificate of Incorporation, or (ii) the
exercise, vesting or settlement, as applicable, of any Company Equity Awards
or Company Warrants outstanding as of the close of business on the
Capitalization Date in accordance with the terms of such Company Equity
Awards or Company Warrants and (2) no grants of any Company Equity Awards or
any other equity or equity-based awards.

  



  

   

15

 



    



  

(b) All of the issued and outstanding shares of Company Common Stock
have been, and all of the shares of Company Common Stock that may be issued
pursuant to any of the Company Equity Awards, the Company Equity Plans,
Company Warrants and Company Preferred Stock will be, when issued in
accordance with the respective terms thereof, duly authorized and validly
issued and are, or will be when issued, fully paid, nonassessable and free of
preemptive rights. All of the issued and outstanding shares of Company
Preferred Stock have been duly authorized, validly issued, fully paid and
nonassessable. The Company has made available to Parent or its counsel
accurate and complete copies of each of the Company Warrants (which copies are
executed) and the forms of stock option and restricted stock unit award
agreements evidencing the Company Equity Awards (together with the forms of
such award agreements filed with the SEC and publicly available), and in
respect of the foregoing forms, other than differences with respect to the
number of shares of Company Common Stock covered thereby, the grant date, the
exercise price, regular vesting schedule and expiration date applicable
thereto, no such stock option or restricted stock unit award agreement
contains material terms that are inconsistent with, or in addition to, such
forms. _Section 3.2(b)_ of the Company Disclosure Letter sets forth, as of the
close of business on the Capitalization Date, each outstanding Company Equity
Award and to the extent applicable, (i) the name and country of residence (if
outside the U.S.) of the holder thereof, (ii) the number of shares of Company
Common Stock issued or issuable thereunder, (iii) the expiration date, (iv)
the exercise price relating thereto, (v) the grant date, (vi) the amount
vested and outstanding and the amount unvested and outstanding, and (vii) the
Company Equity Plan pursuant to which the award was made. Each grant of a
Company Option was duly authorized no later than the date on which the grant
of such Company Option was by its terms to be effective (the "Company Option
Grant Date") by all necessary corporate action, including, as applicable,
approval by the Company Board (or a duly constituted and authorized committee
thereof or other authorized designee) and any required stockholder
approval by the necessary number of votes or written consents. The Company
does not have any liability in respect of any Company Option that was granted
with a per share exercise price that was less than the fair market value of a
share of Company Common Stock on the applicable Company Option Grant Date,
and the Company has not granted any Company Options that are subject to the
provisions of Section 409A of the Code. Each grant of a Company Equity Award
and Company Warrant was made in all material respects, as applicable, in
accordance with (A) the terms of the applicable Company Equity Plan, (B) all
applicable securities Laws, including the NYSE American Company Guide, (C)
the Code, and (D) all other applicable Laws. The Company has the requisite
authority under the terms of the applicable Company Equity Plan, the
applicable award agreements and any other applicable Contract to take the
actions contemplated by _Section 2.3_ and _Section 2.4_ , and the treatment
of Company Warrants and Company Equity Awards described in _Section 2.3_ and
_Section 2.4_ , shall, as of the Effective Time, be binding on the holders of
Company Warrants and Company Equity Awards purported to be covered thereby.
All of the outstanding Company Stock has been sold pursuant to an effective
registration statement filed under the federal securities Laws or an
appropriate exemption therefrom. No Subsidiary of the Company owns
any Securities of the Company.

  



  

   

16

 



    



  

(c) As of the date of this Agreement, other than as set forth in
_Section 3.2(c)_ of the _Company Disclosure Letter_ , the Company Equity
Awards, Company Warrants or in the Company Certificate of Designation, there
are no (i) existing options, warrants, calls, preemptive rights,
subscriptions or other Securities or rights, stock appreciation rights,
restricted stock awards, restricted stock unit awards, convertible
Securities, agreements, arrangements or commitments of any kind obligating the
Company or any of its Subsidiaries to issue, transfer, register or sell, or
cause to be issued, transferred, registered or sold, any shares of
capital stock of, or other Securities of, the Company or any of its
Subsidiaries or Securities convertible into or exchangeable for such shares
or other Securities, or obligating the Company or any of its Subsidiaries to
grant, extend or enter into such options, warrants, calls, preemptive rights,
subscriptions or other Securities or rights, stock appreciation rights,
restricted stock awards, restricted stock unit awards, convertible
Securities, agreements, arrangements or commitments; (ii) outstanding
obligations of the Company or any of its Subsidiaries to repurchase, redeem
or otherwise acquire any Securities of the Company or any of its
Subsidiaries, or any Securities representing the right to purchase or
otherwise receive any other Securities of the Company or any of its
Subsidiaries; or (iii) outstanding or authorized equity or equity-based
compensation awards, including any equity appreciation rights, Security-
based performance units, "phantom" stock, profit-participation or other
Security rights issued by the Company or any of its Subsidiaries, or other
agreements, arrangements or commitments of any character (contingent or
otherwise) to which the Company or any of its Subsidiaries is party, in each
case pursuant to which any Person is entitled to receive any payment from the
Company or any of its Subsidiaries based in whole or in part on the value of
any Securities of the Company or any of its Subsidiaries.

  



  

(d) Each Subsidiary of the Company existing on the date of this
Agreement is listed on _Section 3.2(d)_ of the _Company Disclosure Letter_.
The Company owns, beneficially and of record, directly or indirectly, all of
the issued and outstanding company, partnership, corporate or similar (as
applicable) ownership, voting or similar Securities or interests in each such
Subsidiary, free and clear of all Liens, and all company, partnership,
corporate or similar (as applicable) ownership, voting or similar
Securities or interests of each of the Subsidiaries are duly authorized and
validly issued and are fully paid, nonassessable and free of
preemptive rights. The Company has made available to Parent true and correct
copies of the currently effective corporate or other organizational documents
for each Subsidiary. Except for investments in cash equivalents (and ownership
by the Company or its Subsidiaries of Securities of the Subsidiaries of the
Company), none of the Company or any of its Subsidiaries (i) owns directly or
indirectly any Securities or interests or (ii) has any obligation or has made
any commitment to acquire any Securities or interests of any Person or to
provide funds to or make any investment (in the form of a loan, capital
contribution or otherwise) in any Person.

  



  

(e) All dividends or distributions on any Securities of the Company
or any of its Subsidiaries that have been declared or authorized have been
paid in full.

  



  

   

17

 



    



  

(f) As of the date of this Agreement, there are no existing (i)
agreements or commitments of any kind with any Person to which the Company or
any of its Subsidiaries is party (A) restricting the transfer of the
Securities of the Company or any of its Subsidiaries or (B) affecting the
voting rights of Securities of the Company or any of its Subsidiaries
(including stockholder agreements, voting trusts or similar agreements), (ii)
agreements or commitments of any kind obligating the Company or any of
its Subsidiaries to register (other than pursuant to currently effective
resale shelf registration statements listed on _Section 3.2(f)_ of the
_Company Disclosure Letter_ or "piggy-back" rights) or cause to be further
registered (other than pursuant to currently effective resale shelf
registration statements listed on _Section 3.2(f)_ of the _Company
Disclosure Letter_ or "piggy-back" rights), any shares of capital stock of,
or other Securities of, the Company or any of its Subsidiaries or Securities
convertible into or exchangeable for such shares or other Securities ("Demand
Registration Rights Agreements") or (iii) stockholder rights plans or similar
plans commonly referred to as a "poison pill," under which the Company is or
may become obligated to sell or otherwise issue any shares of its capital
stock or any other Securities.

  



  

(g) The exercise price of each Company Option and each Company
Warrant is set forth on _Section 3.2(g)_ of the Company Disclosure Letter as
of the date of this Agreement.

  



  

Section 3.3 _Authority Relative to Agreement_.

  



  

(a) The Company has all necessary corporate power and authority to
execute, deliver and perform its obligations under this Agreement and,
subject (in the case of the Merger) to obtaining the Company Stockholder
Approval, to consummate the transactions contemplated by this Agreement. The
execution, delivery and performance of this Agreement by the Company, and the
consummation by the Company of the transactions contemplated by this
Agreement, have been duly and validly authorized by all necessary
corporate action by the Company, and (in the case of the Merger, except for
the (i) receipt of the Company Stockholder Approval and (ii) filing of the
Certificate of Merger with the Delaware Secretary of State) no other corporate
action or proceeding on the part of the Company is necessary to authorize the
execution, delivery and performance of this Agreement by the Company and the
consummation by the Company of the transactions contemplated by this
Agreement. This Agreement has been duly executed and delivered by the
Company and, assuming due authorization, execution and delivery of this
Agreement by the other parties hereto, constitutes a legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, except that (A) such enforcement may be subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar Laws, now
or hereafter in effect, affecting creditors' rights and remedies generally
and (B) the remedies of specific performance and injunctive and other forms
of equitable relief may be subject to equitable defenses and to the discretion
of the court before which any Proceeding therefor may be brought (the
"Enforceability Exceptions").

  



  

(b) The Company Board has, by resolutions adopted by the Company
Board, (i) approved this Agreement and the Merger and the transactions
contemplated by this Agreement; (ii) determined that this Agreement and the
Merger and the transactions contemplated by this Agreement are advisable and
in the best interests of the Company and its stockholders; (iii)
directed that the adoption of this Agreement be submitted to a vote at the
Company Stockholders' Meeting; and (iv) resolved to make the Company
Recommendation. As of the date of this Agreement, none of the aforesaid
actions by the Company Board has been amended, rescinded or modified.

  



  

   

18

 



    



  

Section 3.4 _Vote Required_. The affirmative vote of the holders of a
majority of the outstanding shares of Company Common Stock and Company
Preferred Stock voting together as a single class, with holders of Company
Preferred Stock entitled to vote on an as-converted-to-common stock basis and
cast a number of votes per share of Company Preferred Stock as determined in
accordance with Section 11(a) of the Company Certificate of Designation
(the "Company Stockholder Approval") is the only vote or consent, as
applicable, of holders of Securities of the Company that is required to
authorize this Agreement or to consummate the Merger and the other
transactions contemplated by this Agreement.

  



  

Section 3.5 _No Conflict; Required Filings and Consents_.

  



  

(a) Neither the execution and delivery of this Agreement by the
Company nor the consummation by the Company of the transactions contemplated
by this Agreement, nor compliance by the Company with any of the terms or
provisions of this Agreement, will (i) violate any provision of (A) the
Company's Certificate of Incorporation or Bylaws or (B) the certificate of
incorporation or bylaws (or equivalent organizational documents) of any
Subsidiary of the Company (assuming, in each case, with respect to the
consummation of the Merger that the Company Stockholder Approval is
obtained), (ii) assuming that the Consents, registrations,
declarations, filings and notices referenced in _Section 3.5(b)_ have been
obtained or made, conflict with or violate any Law applicable to the Company
or any of its Subsidiaries or by which any property or asset of the Company or
any of its Subsidiaries is bound or affected or (iii) violate, conflict with
or result in any breach of any provision of, or loss of any benefit, or
constitute a default (with or without notice or lapse of time, or both)
under, give rise to any right of termination, acceleration or cancellation of
or require the Consent of, notice to or filing with any third Person pursuant
to any of the terms or provisions of any material Contract to which the
Company or any of its Subsidiaries is a party (other than a Benefit Plan) or
by which any property or asset of the Company or any of its Subsidiaries is
bound, or result in the creation of a Lien, other than any Permitted Lien,
upon any of the property or assets of the Company or any of its Subsidiaries,
other than, in the case of clauses, (i)(B), (ii) and (iii), that has not had,
and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

  



  

(b) No consent, approval, license, permit, waiver, Order or
authorization (a "Consent") of, registration, submission, declaration or
filing with or notice to any Governmental Authority is required to be obtained
or made by or with respect to the Company or any of its Subsidiaries in
connection with the execution, delivery and performance of this Agreement or
the consummation of the transactions contemplated by this Agreement, other
than (i) applicable requirements of and filings with the SEC under the
Exchange Act or the Securities Act; (ii) the filing of the Certificate of
Merger with the Delaware Secretary of State; (iii) applicable requirements
under foreign qualification, state securities or "blue sky" laws of various
states; (iv) compliance with applicable rules and regulations of the NYSE
American; (v) compliance with and filings or notifications under the HSR Act
and any other applicable United States or foreign competition, antitrust,
merger control or investment Laws (together with the HSR Act, "Antitrust
Laws"); and (vi) such other Consents, registrations, declarations, filings or
notices the failure of which to be obtained or made has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

  



  

   

19

 



    



  

Section 3.6 _Company SEC Documents; Financial Statements_.

  



  

(a) Since January 1, 2016, the Company has timely filed with (or
furnished to) the SEC all forms, reports, schedules, statements, exhibits and
other documents (including exhibits, financial statements and schedules
thereto and all other information incorporated therein and amendments and
supplements thereto) required by it to be filed (or furnished) under the
Exchange Act or the Securities Act (collectively, but excluding the Proxy
Statement, the "Company SEC Documents"). As of its filing (or furnishing)
date or, if amended prior to the date of this Agreement, as of the date of the
last such amendment (or in the case of Company SEC Documents that are
registration statements filed pursuant to the requirements of the Securities
Act, as of their respective effective dates), each Company SEC Document
complied in all material respects with the applicable requirements of the
Exchange Act and the Securities Act, as the case may be. As of its filing date
or, if amended or superseded by a filing or amendment prior to the date of
this Agreement, as of the date of the last such amendment, each Company SEC
Document filed pursuant to the Exchange Act did not contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements made therein, in
light of the circumstances under which they were made, not misleading. Each
Company SEC Document that is a registration statement, as amended or
supplemented, if applicable, filed pursuant to the Securities Act, as of the
date such registration statement or amendment became effective prior to the
date of this Agreement, did not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein not misleading. As of
the date of this Agreement, there are no amendments or modifications to the
Company SEC Documents that are required to be filed with (or furnished to) the
SEC, but that have not yet been filed with (or furnished to) the SEC. No
Subsidiary of the Company is subject to the periodic reporting requirements of
the Exchange Act. All of the consolidated audited financial statements and
unaudited interim financial statements of the Company included in the Company
SEC Documents (i) have been derived from the accounting books and records of
the Company and its Subsidiaries; (ii) comply in all material respects with
the applicable accounting requirements and with the published rules and
regulations of the SEC with respect thereto; (iii) have been prepared in
accordance with GAAP, in all material respects, applied on a consistent basis
during the periods involved (except (A) as may be indicated in such financial
statements or in the notes thereto and (B) in the case of the unaudited
interim statements of the Company, as may be permitted under Form 10-Q of the
Exchange Act); and (iv) present fairly, in all material respects, the
financial position of the Company, and the results of operations and cash
flows of the Company, as of the times and for the periods referred to therein
(except as may be indicated in the notes thereto and subject, in the case of
unaudited interim financial statements, to normal and recurring year-end
adjustments and the absence of footnote disclosure, none of which,
individually or in the aggregate, will be material).

  



  

(b) Prior to the date of this Agreement, the Company has furnished to
Parent complete and correct copies of all comment letters from the SEC since
January 1, 2016 through the date of this Agreement with respect to any of the
Company SEC Documents, together with all written responses of the Company
thereto. As of the date of this Agreement, there are no outstanding or
unresolved comments in comment letters received from the SEC staff with
respect to any of the Company SEC Documents, and, to the Knowledge of the
Company, none of the Company SEC Documents are subject to ongoing SEC review.

  



  

   

20

 



    



  

(c) The Company is in compliance in all material respects with the
applicable provisions of the Sarbanes-Oxley Act and the applicable listing
and governance rules and regulations of the NYSE American.

  



  

(d) The Company maintains a system of internal control over financial
reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act)
designed to provide reasonable assurance regarding the reliability of the
Company's financial reporting and the preparation of financial statements for
external purposes in conformity with GAAP. The Company has evaluated the
effectiveness of the Company's internal control over financial reporting and,
to the extent required by applicable Law, presented in any applicable Company
SEC Document that is a report on Form 10-K or Form 10-Q or any amendment
thereto its conclusions about the effectiveness of the internal control over
financial reporting as of the end of the period covered by such report or
amendment based on such evaluation. The Company has disclosed, based on the
most recent evaluation of internal control over financial reporting prior
to the date of this Agreement, to the Company's auditors and the audit
committee of the Company Board (i) all "significant deficiencies" and
"material weaknesses" (as such terms are defined in Auditing Standard No. 5 of
the Public Company Accounting Oversight Board, as in effect on the date of
this Agreement) in the design or operation of internal control over
financial reporting that are reasonably likely to adversely affect the
Company's ability to record, process, summarize and report
financial information and (ii) any fraud, whether or not material, that
involves the Company's management or other employees who have a significant
role in the Company's internal control over financial reporting. Except as
described in the Company SEC Reports, since January 1, 2016, the Company has
not identified any material weaknesses in the design or operation of the
Company's internal control over financial reporting.

  



  

(e) The Company maintains disclosure controls and procedures (as
defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to
ensure that all information required to be disclosed by the Company in the
reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the
rules and forms of the SEC, and that all such information is accumulated and
communicated to the Company's management as appropriate to allow
timely decisions regarding required disclosure and to make the certifications
of the chief executive officer and chief financial officer of the Company
required under the Exchange Act with respect to such reports.

  



  

(f) As of the date of this Agreement, there are no SEC Proceedings
pending or, to the Knowledge of the Company, threatened, in each case
regarding any accounting practices of the Company or any of its Subsidiaries
or any malfeasance by any director or executive officer of the Company or any
of its Subsidiaries. Since January 1, 2016 through the date of this Agreement,
there have been no investigations regarding accounting, auditing or revenue
recognition discussed with, reviewed by or initiated at the direction of the
chief executive officer, chief financial officer, chief accounting officer or
general counsel of the Company or any of its Subsidiaries or the Company
Board, any board of directors of any of its Subsidiaries or any committee of
the Company Board or any board of directors of any of its Subsidiaries.

  



  

   

21

 



    



  

(g) Each of the principal executive officer of the Company and the
principal financial officer of the Company (or each former principal
executive officer of the Company and each former principal financial officer
of the Company, as applicable) has made all certifications required by Rule
13a-14 or 15d-14 under the Exchange Act and Sections 302 and 906 of the
Sarbanes-Oxley Act with respect to the Company SEC Documents, and the
statements contained in such certifications are true and correct. For
purposes of this Agreement, "principal executive officer" and "principal
financial officer" shall have the meanings given to such terms in the
Sarbanes-Oxley Act. The Company does not have, and has not arranged any,
outstanding "extensions of credit" to directors or executive officers within
the meaning of Section 402 of the Sarbanes-Oxley Act.

  



  

(h) Since January 1, 2016, (i) neither the Company nor any of its
Subsidiaries has received any written or, to the Knowledge of the Company,
oral complaint, allegation, assertion or claim regarding accounting, internal
accounting controls, auditing practices, procedures, methodologies or methods
of the Company or any of its Subsidiaries, or unlawful accounting or auditing
matters with respect to the Company or any of its Subsidiaries and (ii) no
attorney representing the Company or any of its Subsidiaries, whether or not
employed by the Company or any of its Subsidiaries, has reported evidence of a
violation of securities Laws, breach of fiduciary duty or similar violation
by the Company or any of its Subsidiaries or any of their respective officers,
directors, employees or agents to the Company Board or any committee thereof
or to the general counsel or chief executive officer of the Company
pursuant to the rules of the SEC adopted under Section 307 of the Sarbanes-
Oxley Act.

  



  

(i) Neither the Company nor any of its Subsidiaries is a party to,
or is subject to any commitment to become a party to, any joint venture, off-
balance sheet partnership or any similar Contract (including any Contract or
arrangement relating to any transaction or relationship between or among the
Company and any of its Subsidiaries, on the one hand, and any
unconsolidated Affiliate, on the other hand), including any structured
finance, special purpose or limited purpose entity or Person, or any "off-
balance sheet arrangements" (as defined in Item 303(a) of Regulation S-K
under the Securities Act), in each case, where the result, purpose or effect
of such Contract is to avoid disclosure of any material transaction involving,
or material liabilities of, the Company or any of its Subsidiaries in the
Company SEC Documents (including any audited financial statements and
unaudited interim financial statements of the Company included therein).

  



  

Section 3.7 _Absence of Certain Changes or Events_. Since December 31,
2018 through the date of this Agreement, (a) except for the negotiation,
execution and delivery of this Agreement, the respective businesses of the
Company and its Subsidiaries have been conducted in the ordinary course of
business consistent with past practice in all material respects, (b) (i) the
Company has not suffered a Company Material Adverse Effect and (ii) there has
been no effect, change, development, event, circumstance, occurrence,
condition, fact or state of facts that would reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect and
(c) neither the Company nor any of its Subsidiaries has taken any action
that, if taken after the date of this Agreement, would have constituted a
breach of subsections (a), (b), (d), (g), (h), (i), (j), (l), (m), (n), (p),
(q), (u), (v), (w) or (x) of _Section 5.1_.

  



  

   

22

 



    



  

Section 3.8 _No Undisclosed Liabilities_. Except for liabilities or
obligations (a) reflected or reserved against in the Company's consolidated
balance sheet as of June 30, 2019 (or the notes thereto), a copy of which was
delivered to Parent on August 6, 2019; (b) incurred in connection with or
contemplated by this Agreement or the transactions contemplated by this
Agreement; (c) incurred in the ordinary course of business since June 30,
2019; (d) set forth in any Contract existing as of the date hereof, which are
not required to be disclosed or provided for in such consolidated balance
sheet described in the foregoing clause (a), except to the extent such
liabilities or obligations resulted from a breach of such Contract; or (e)
that have not had, and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, none of the Company
or any of its Subsidiaries has any liabilities or obligations of any nature,
whether or not accrued, contingent, absolute or otherwise and whether or not
required to be reflected on a consolidated balance sheet of the Company (or
the notes thereto) in accordance with GAAP.

  



  

Section 3.9 _Litigation_. As of the date of this Agreement, (a) there is
no Proceeding pending or, to the Knowledge of the Company, threatened against
the Company or any of its Subsidiaries or any asset or property of the
Company or any of its Subsidiaries, and (b) there is no Order outstanding
against, or involving, the Company or any of its Subsidiaries or any asset or
property of the Company or any of its Subsidiaries that, in each case of
clauses (a) and (b), (i) has been, or would reasonably be expected to be,
individually or in the aggregate, material to the Company and its
Subsidiaries, taken as a whole or (ii) would reasonably be expected to,
individually or in the aggregate, impair in any material respect the ability
of the Company to perform its obligations under this Agreement or to
consummate the Merger, or prevent or materially delay the consummation of any
of the Merger and the other transactions contemplated by this Agreement. As of
the date of this Agreement, except as has not had, or would not reasonably be
expected to have, individually or in the aggregate, a Company Material
Adverse Effect (i) there is no Proceeding pending or, to the Knowledge of the
Company, threatened against any officer or director of the Company or any of
its Subsidiaries, and (ii) there is no Order outstanding against, or
involving, any officer or director of the Company or any of its Subsidiaries.
Since January 1, 2016, except as has not had, or would not reasonably be
expected to have, individually or in the aggregate, a Company Material
Adverse Effect, there have not been any product liability, manufacturing
or design defect, warranty, field repair or other material product-related
claims by any third Person (whether based on contract or tort and whether
relating to personal injury, including death, property damage or economic
loss) arising from (A) services rendered by the Company or any of its
Subsidiaries or (B) the sale, distribution or manufacturing of products,
including medical products and devices, by the Company or any of its
Subsidiaries that have been, or would reasonably be expected to be,
individually or in the aggregate, material to the Company and its
Subsidiaries, taken as a whole. As of this date hereof, neither the Company
nor any of its Subsidiaries has any material Proceedings pending or
threatened against any other Person. This _Section 3.9_ shall not be
construed as a representation with respect to Tax matters, which are the
subject of _Section 3.14_.

  



  

   

23

 



    



  

Section 3.10 _Permits; Compliance with Laws_.

  



  

(a) The Company and its Subsidiaries are in possession of all
franchises, grants, authorizations, licenses, permits, easements, variances,
exceptions, exemptions, consents, certificates, approvals, product listings,
registrations, clearances, Orders and other authorizations necessary for the
Company and its Subsidiaries to own, lease and operate their respective
properties and assets pursuant to all applicable Laws as currently owned,
leased and operated, or to carry on their respective businesses as now being
conducted under and pursuant to all applicable Laws (the "Company Permits"),
(ii) all such Company Permits are in full force and effect and (iii) as of
the date of this Agreement, no suspension, cancellation, withdrawal or
revocation thereof is pending or, to the Knowledge of the Company,
threatened, except in each of clauses (i) - (iii) where the failure to be in
possession of, failure to be in full force and effect or the suspension,
cancellation, withdrawal or revocation thereof (A) has not been, and would
not reasonably be expected to be, individually or in the aggregate, material
to the Company and its Subsidiaries, taken as a whole and (B) would not
reasonably be expected to, individually or in the aggregate, impair in any
material respect the ability of the Company to perform its obligations under
this Agreement or to consummate the Merger, or prevent or materially delay
the consummation of any of the Merger and the other transactions contemplated
by this Agreement.

  



  

(b) The Company and its Subsidiaries have been since January 1, 2016,
and are in compliance with (i) all applicable Laws and (ii) all Company
Permits, except where any failure to be in such compliance (A) has not been,
and would not reasonably be expected to be, individually or in the aggregate,
material to the Company and its Subsidiaries, taken as a whole and (B) would
not reasonably be expected to, individually or in the aggregate, impair in
any material respect the ability of the Company to perform its
obligations under this Agreement or to consummate the Merger, or prevent or
materially delay the consummation of any of the Merger and the other
transactions contemplated by this Agreement.

  



  

(c) Since January 1, 2016, none of the Company or any of its
Subsidiaries or, to the Knowledge of the Company, any of their respective
directors or officers (only in their capacity as such directors or officers)
has received any written or, to the Knowledge of the Company, oral
notification from a Governmental Authority asserting that the Company or any
of its Subsidiaries, or any officer or director of the Company or any of its
Subsidiaries is under investigation for not being in compliance in
all material respects with any Laws or Company Permits.

  



  

Section 3.11 _Proxy Statement_. None of the information supplied or to be
supplied by or on behalf of the Company for inclusion or incorporation by
reference in the proxy statement of the Company (as amended or supplemented
from time to time, the "Proxy Statement") to be filed with the SEC for use in
connection with the solicitation of proxies from the stockholders of the
Company in connection with the Merger and the Company Stockholders' Meeting
will contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they are
made, not misleading at the time such Proxy Statement is first mailed to
stockholders of the Company and at the time of the Company
Stockholders' Meeting. The Proxy Statement will comply as to form in all
material respects with the requirements of the Exchange Act and the rules and
regulations promulgated thereunder. No representation or warranty is made by
the Company with respect to statements made or incorporated by reference in
the Proxy Statement based on information supplied by Parent, Merger Sub or
their respective Affiliates for inclusion or incorporation by reference
therein.

  



  

   

24

 



    



  

Section 3.12 _Employee Benefit Plans_.

  



  

(a) _Section 3.12(a)_ of the _Company Disclosure Letter_ contains a
true, complete and correct list of all material Benefit Plans. "Benefit Plan"
shall mean (i) each "employee pension benefit plan" (as defined in Section
3(2) of the Employee Retirement Income Security Act of 1974, as amended
("ERISA")); (ii) each "employee welfare benefit plan" (as defined in Section
3(1) of ERISA); and (iii) all other benefit plans, policies, programs,
agreements or arrangements, including any bonus, deferred compensation,
severance pay, retention, change in control, employment, consulting, pension,
profit-sharing, retirement, insurance, stock purchase, stock option, incentive
or equity compensation or other fringe benefit plan, program, policy,
agreement, arrangement or practice maintained, contributed to or required to
be contributed to, by the Company or any of its Subsidiaries, for the benefit
of any current or former employees, officers or directors (or any
beneficiary or dependent thereof) of the Company or any Subsidiary. The
Company has delivered or made available to Parent and Merger Sub
true, complete and correct copies of (A) each material Benefit Plan
(including all amendments thereto) or written description of each Benefit
Plan that is not otherwise in writing; (B) the most recent annual reports on
Form 5500 and all schedules thereto filed with respect to each Benefit Plan,
to the extent applicable; (C) the most recent summary plan description and
summary of material modifications for each Benefit Plan, to the extent
applicable; (D) each current trust agreement, insurance contract or
policy, group annuity contract and any other funding arrangement relating to
any Benefit Plan, to the extent applicable; (E) the most recent actuarial
report, financial statement or valuation report, to the extent applicable; (F)
a current Internal Revenue Service opinion or favorable determination letter,
to the extent applicable; (G) all material non-routine correspondence to or
from any Governmental Authority relating to any Benefit Plan; and (H) all
discrimination tests for each Benefit Plan for the most recent plan years, to
the extent applicable.

  



  

(b) Each Benefit Plan is and has at all times been operated and
administered in all material respects in accordance with its terms and in
compliance in all material respects with applicable Law, including ERISA, the
Code and the Patient Protection and Affordable Care Act. All material claims
incurred with a date of service on or before the Closing Date under any
Benefit Plan that is an "employee welfare benefit plan" as defined in Section
3(1) of ERISA that is self-insured will be paid by the Company or accrued on
the Company financial statements no later than the Closing Date.

  



  

(c) Each Benefit Plan intended to be "qualified" within the meaning
of Section 401(a) of the Code has received a recent and currently effective
determination letter or can rely on an opinion letter for a prototype plan
from the Internal Revenue Service that such Benefit Plan is so qualified and
exempt from taxation under Sections 401(a) and 501(a) of the Code, and, to
the Knowledge of the Company, no condition exists that would be expected to
adversely affect such qualification.

  



  

   

25

 



    



  

(d) None of the Benefit Plans is, and none of the Company, its
Subsidiaries or any ERISA Affiliate has ever maintained or had an obligation
to contribute to, (i) a "single employer plan" (as such term is defined in
Section 4001(a)(15) of ERISA) subject to Section 412 of the Code or Title IV
of ERISA; (ii) a "multiple employer plan" or "multiple employer welfare
arrangement" (as such terms are defined in ERISA); (iii) a welfare benefit
fund (as such term is defined in Section 419 of the Code); (iv) a
"multiemployer plan" (as such term is defined in Section 4001(a)(3) of
ERISA); or (v) a voluntary employees' beneficiary association under Section
501(c)(9) of the Code. There are no material unpaid contributions due prior
to the date of this Agreement with respect to any Benefit Plan that are
required to have been made under the terms of such Benefit Plan, any related
insurance contract or any applicable Law and all material contributions due
have been timely made, or to the extent not yet due, have been properly
accrued on the applicable balance sheet in accordance with the terms of the
applicable Benefit Plan and applicable Law.

  



  

(e) None of the Company or any of its Subsidiaries has engaged in a
non-exempt "prohibited transaction" (as such term is defined in Section 406
of ERISA and Section 4975 of the Code) or breached any fiduciary duties with
respect to any Benefit Plan that reasonably would be expected to subject the
Company, any of its Subsidiaries or the Surviving Corporation to any material
tax or penalty.

  



  

(f) With respect to any Benefit Plan, there is no Proceeding
pending, or, to the Knowledge of the Company, threatened or anticipated with
or by the Internal Revenue Service, the United States Department of Labor or
any other Governmental Authority, other than routine claims for benefits, in
each case, that would reasonably be expected to subject the Company, any of
its Subsidiaries or the Surviving Corporation to any material liability.

  



  

(g) Neither the Company nor any of its Subsidiaries has any
obligations to provide any health or other welfare benefits (whether or not
insured) to retired or other former employees, directors or consultants,
except as specifically required by Part 6 of Title I of ERISA ("COBRA") or,
pursuant to an applicable employment agreement or severance agreement,
plan or policy listed in _Section 3.12(g)_ of the _Company Disclosure Letter_
requiring the Company or any Subsidiary to pay or subsidize COBRA premiums
for a terminated employee following the employee's termination.

  



  

(h) Each Benefit Plan that is a group health plan is being and has
been operated and administered in material compliance with the Patient
Protection and Affordable Care Act (including the reporting requirements of
Sections 6055 and 6056 of the Code). None of the Company or its Subsidiaries
has incurred or will incur any material liability under Sections 4980D and
4980H of the Code and its governing regulations and no event has occurred and
no circumstance exists or has existed that could reasonably be expected to
give rise to the incurrence of such material liability.

  



  

(i) Except as set forth on _Section 3.12(i)_ of the _Company
Disclosure Letter_ , neither the execution and delivery of this Agreement nor
the consummation of the Merger or any of the other transactions contemplated
hereby, or any termination of employment or service (or other event or
occurrence) in connection therewith will (i) entitle any current or former
employee, director or consultant of the Company or any of its Subsidiaries to
any payment or benefit (or result in the funding of any such payment or
benefit) or result in any forgiveness of Indebtedness with respect to any such
persons; (ii) increase the amount of any compensation, equity award or other
benefits otherwise payable by the Company or any of its Subsidiaries; or (iii)
result in the acceleration of the time of payment, funding or vesting of any
compensation, equity award or other benefits except as required under Section
411(d)(3) of the Code.

  



  

   

26

 



    



  

(j) Except as set forth on _Section 3.12(j)_ of the _Company
Disclosure Letter_ , no amounts payable by the Company or any of its
Subsidiaries in connection with the transactions contemplated hereby will be
an "excess parachute payment" within the meaning of Section 280G of the Code.
Neither the Company nor any of its Subsidiaries has any obligation to gross-
up, indemnify or otherwise reimburse any individual with respect to any Tax
under Sections 409A or 4999 of the Code.

  



  

(k) To the extent applicable, each Benefit Plan has been maintained
in documentary compliance with, and has been operated and administered in
material compliance with, Section 409A of the Code.

  



  

(l) None of the Company or any of its Subsidiaries has used the
services or workers provided by third Person contract labor suppliers,
temporary employees, "leased employees" (as that term is defined in Section
414(n) of the Code), or individuals who have provided services as independent
contractors to an extent that would reasonably be expected to result in
the disqualification of any of the Benefit Plans or the imposition of
material penalties or excise taxes with respect to the Benefit Plans by the
Internal Revenue Service, the United States Department of Labor or the Pension
Benefit Guaranty Corporation, and no such individuals are entitled to any
benefits under any Benefit Plan that they have been improperly denied by
reason of their misclassification as independent contractors.

  



  

Section 3.13 _Labor Matters_.

  



  

(a) (i) There is no labor strike, material dispute, organized
slowdown, stoppage or lockout pending, or, to the Knowledge of the
Company, threatened against or affecting the Company or any of its
Subsidiaries, nor has there been any such action or event since January 1,
2016; (ii) neither the Company nor any of its Subsidiaries is a party to,
bound by or in the process of negotiating any labor, collective bargaining,
works council or similar agreement regarding the employees of the Company or
any of its Subsidiaries (each, a "Labor Agreement"); (iii) as of the date
hereof, there are no unfair labor practice charges or material
grievances relating to any current or former employee or consultant of the
Company or any of its Subsidiaries (relating to their services for or
relationship with the Company or its Subsidiaries); and (iv) as of the date
hereof, none of the employees of the Company or any of its Subsidiaries is
represented by any labor union, works council, employee representative group
or similar organization (whether in or outside the United States) with
respect to their employment with the Company or any of its Subsidiaries and,
to the Knowledge of the Company, there are not, as of the date hereof, any
union organizing activities, either by or on behalf of any employee or union
or similar labor organization with respect to employees of the Company or any
of its Subsidiaries. There is no labor union, work council, employee
representative group or similar organization which, pursuant to applicable Law
or any governing agreement, must be notified, consulted or with which
negotiations need to be conducted in connection with the Merger.

  



  

   

27

 



    



  

(b) The Company and its Subsidiaries are, and since January 1, 2016,
have been, in compliance, in all material respects, with all applicable Laws
relating to labor and employment matters, including fair employment practices,
equal employment opportunity, disability rights, affirmative action, terms
and conditions of employment, consultation with employees, immigration and
work authorization, wages, hours (including, but not limited to, overtime and
minimum wage requirements and child labor restrictions), social
contributions (including the payment and withholding of U.S. social security
and similar Taxes), compensation, workers' compensation,
unemployment insurance, classification of employees, workers and individual
independent contractors, employee leaves of absence, data
protection, privacy, occupational safety and health, collective or mass
layoffs and plant closings. Neither the Company nor any of its
Subsidiaries has taken any action within the past two (2) years requiring
notice to employees or any other obligations under the Worker
Adjustment Retraining Notification Act of 1988, as amended (the "WARN Act"),
unless the Company or any such Subsidiary materially complied with the
requirements of the WARN Act.

  



  

(c) To the Knowledge of the Company, no executive officer or employee
at the level of Vice President (or any similarly-leveled employee) or above
of the Company or any of its Subsidiaries (i) is subject to any noncompete,
nonsolicitation, nondisclosure, confidentiality, employment, consulting or
similar agreement with any other Person in conflict with the present and
proposed business activities of the Company and its Subsidiaries, except
agreements between the Company or any Subsidiary of the Company; or (ii) as
of the date hereof, is in violation of any common law nondisclosure obligation
or fiduciary duty relating to the ability of such individual to work for the
Company or any of its Subsidiaries.

  



  

(d) Since January 1, 2016, none of the Company or its Subsidiaries
has entered into a settlement agreement with a current or former officer or
employee of the Company or its Subsidiaries that substantially involves
allegations relating to sexual harassment.

  



  

Section 3.14 _Taxes_. Except as would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect:

  



  

(a) The Company and each of its Subsidiaries have (i) duly and timely
filed or caused to be duly and timely filed (taking into account any
extension of time within which to file) all U.S. federal income and other Tax
Returns required to be filed by any of them and all such filed Tax Returns
(taking into account all amendments thereto) are true, complete and accurate
in all respects and (ii) paid all Taxes due and owing (whether or not shown
on such Tax Returns) except to the extent that such Taxes are being contested
in good faith and by appropriate proceedings and for which adequate reserves
have been maintained in accordance with GAAP.

  



  

(b) As of the date of this Agreement, there are no pending, ongoing
or, to the Knowledge of the Company, threatened, audits, examinations,
investigations or other Proceedings by any Governmental Authority in respect
of Taxes of the Company or any of its Subsidiaries. No deficiencies for an
amount of Taxes have been claimed, proposed, assessed or, to the Knowledge of
the Company, threatened, against the Company or any of its Subsidiaries by
any Governmental Authority that have not been fully paid, settled or
withdrawn. None of the Company or any of its Subsidiaries has waived any
statute of limitations with respect to Taxes or agreed to any extension of
time with respect to any Tax assessment, deficiency or collection, which
waiver or extension currently remains in effect. Neither the Company nor its
Subsidiaries have received within the past five years a written claim from any
Governmental Authority in a jurisdiction where the Company or any of its
Subsidiaries does not currently file a Tax Return that it is or may be
subject to taxation by that jurisdiction in respect of Taxes that would be
covered by or the subject of such Tax Return, which claim has not been
resolved in full. No power of attorney that would be in force after the
Closing Date has been granted by the Company or any of its Subsidiaries with
respect to Taxes.

  



  

   

28

 



    



  

(c) There are no Tax rulings, requests for Tax rulings, applications
for change in accounting methods or closing agreements with respect to Taxes,
in each case with a Governmental Authority, that could reasonably be expected
to affect liabilities for Taxes of the Company or any of its Subsidiaries for
any period after the Effective Time.

  



  

(d) None of the Company or any of its Subsidiaries will be required
to include any item of income in, or exclude any item of deduction from,
taxable income for any taxable period (or portion thereof) beginning after the
Closing Date as a result of: (i) any installment sale or open transaction
disposition made prior to the Effective Time; (ii) any prepaid amount
received on or prior to the Effective Time; (iii) Section 481(a) of the Code
(or an analogous provision of state, local, or foreign Law) by reason of a
change in accounting method prior to the Effective Time; or (iv) any election
under Section 108(i) of the Code. To the Knowledge of the Company, none of
the Company or any of its Subsidiaries has any excess loss account described
in Treasury Regulations under Section 1502 of the Code (or any corresponding
provision of state, local or foreign Tax Law). None of the Company or any of
its Subsidiaries will be obligated to pay any Tax after the Effective Time as
a result of an election to defer the payment of Taxes under Section 965
pursuant to Section 965(h).

  



  

(e) All amounts of Taxes that the Company or any of its Subsidiaries
is or was required by Law to withhold or collect have been duly and timely
withheld or collected and have been duly and timely paid to the proper
Governmental Authority or other proper Person or properly set aside in
accounts for this purpose.

  



  

(f) None of the Company or any of its Subsidiaries has ever been a
member of a consolidated, combined or unitary Tax group (other than such a
group the common parent of which is or was the Company or any of its
Subsidiaries), and none of the Company or any of its Subsidiaries has any
liability for Taxes of any other Person (other than Taxes of the Company or
any of its Subsidiaries) under Section 1.1502-6 of the Treasury Regulations
(or any similar provision of foreign, state or local Law) or as a
transferee or successor or, to the Knowledge of the Company, otherwise as a
matter of Law.

  



  

(g) None of the Company or any of its Subsidiaries is a party to or
is bound by any Tax sharing, Tax allocation or Tax indemnification agreement
or arrangement (other than such an agreement or arrangement exclusively
between or among the Company and its Subsidiaries or customary commercial
Contracts, the principal subject matter of which is not Taxes) that will not
be terminated on or before the Closing Date without any future liability to
the Company or any of its Subsidiaries.

  



  

   

29

 



    



  

(h) There are no Liens for Taxes on any of the assets of the Company
or any of its Subsidiaries other than Liens for Taxes that are not yet due
and delinquent or that are being contested in good faith and by appropriate
proceedings and for which adequate reserves have been maintained in
accordance with GAAP.

  



  

(i) None of the Company or any of its Subsidiaries has participated
in or been a party to a transaction that, as of the date of this Agreement,
constitutes a "listed transaction" within the meaning of Section 6707A(c)(2)
of the Code or Section 1.6011-4(b) of the Treasury Regulations.

  



  

(j) Within the last two (2) years, none of the Company or any of its
Subsidiaries has been a "distributing corporation" or "controlled
corporation" in any transaction intended to qualify for tax-free treatment
under Section 355 of the Code.

  



  

(k) The Company and each of its Subsidiaries are and have at all
times been in compliance in all material respects with the medical device
excise tax provisions imposed by Section 4191 of the Code since the effective
date of such provisions to the extent applicable to their operations.

  



  

(l) The Company and each of its Subsidiaries are and have at all
times been in compliance in all material respects with all applicable
transfer pricing laws and regulations. All related party transactions
involving the Company or any of its Subsidiaries are and have been at arm's
length in compliance with Section 482 of the Code, the Treasury Regulations
promulgated thereunder, and any similar provision of state, local or foreign
Law.

  



  

(m)  None of the Company's Subsidiaries that are classified as
"controlled foreign corporations" as defined in Section 957 of the Code has
generated any "subpart F" income (within the meaning of Section 952 of the
Code) outside the ordinary course of business in 2017 or 2018.

  



  

Section 3.15 _Material Contracts_.

  



  

(a) _Section 3.15(a)_ of the _Company Disclosure Letter_ sets forth
a complete and correct list, with items arranged according to the relevant
subsection of this _Section 3.15_ , as of the date of this Agreement, of each
Company Material Contract. A complete and correct copy of each Company
Material Contract has been made available to Parent, except to the
extent such Contract is publicly filed as an exhibit to the Company SEC
Documents. For purposes of this Agreement, "Company Material Contract" means
any Contract to which the Company or any of its Subsidiaries is a party or to
or by which any asset or property of the Company or any of its Subsidiaries
is bound, except for this Agreement, that:

  



  

(i)  except for purchase orders or invoices in the ordinary course of
business, is a Contract with a supplier or customer involving payments in
excess of $100,000 in the twelve (12) months ended December 31, 2018 or
reasonably expected to involve payments in excess of $100,000 in the twelve
(12) months ending December 31, 2019;

  



  

   

30

 



    



  

(ii)  constitutes a "material contract" (as such term is defined in Item
601(b)(10) of Regulation S-K under the Securities Act);

  



  

(iii)  is a joint venture, alliance, partnership, collaboration,
shareholder, material development Contract or similar Contract;

  



  

(iv)  is an agency, sales, marketing, commission, distribution, international
or domestic sales representative or similar Contract;

  



  

(v)  is a Contract (other than those solely between or among the Company and
any of its wholly owned Subsidiaries) relating to Indebtedness of the Company
or any of its Subsidiaries (whether outstanding or as may be incurred
thereunder);

  



  

(vi)  is a Contract (other than those solely between or among the Company and
any of its wholly owned Subsidiaries) relating to Indebtedness of a third
Person having a principal amount reasonably expected to be in excess of
$100,000 owed to the Company or any of its Subsidiaries;

  



  

(vii)  is a Contract that contains any payment obligations that are outside
the ordinary course of business and are off-balance sheet arrangements;

  



  

(viii) is a Contract that creates or would create a Lien (other than a
Permitted Lien) on any asset of the Company or any of its Subsidiaries, or
restricts the payment of dividends;

  



  

(ix)  is a Contract representing Company Warrants or that relates to ongoing
obligations in connection with Company Warrants;

  



  

(x)  is a Demand Registration Rights Agreement;

  



  

(xi)  is a Contract that obligates the Company or any of its Subsidiaries to
conduct any business on an exclusive basis with any third Person, or upon
consummation of the Merger, will obligate Parent or any of its Subsidiaries to
conduct business with any such third Person on an exclusive basis, or is a
non-competition or non-solicitation Contract or any other Contract (including
a Contract related to the sale of products or the provision of services by
the Company or any of its Subsidiaries) that limits, restricts or prohibits,
or purports to limit, restrict or prohibit, (A) the manner or the localities
in which any business of the Company and its Subsidiaries is or could be
conducted or (B) the lines or types of businesses that the Company or any of
its Subsidiaries conducts or has a right to conduct (each a "Restrictive
Business Arrangement");

  



  

(xii)  is a Contract with any Governmental Authority;

  



  

(xiii)  is a Contract relating to the acquisition or disposition of any
Person, business or operations or assets constituting a business (whether by
merger, sale of stock, sale of assets, consolidation or otherwise) entered
into since January 1, 2016 (including any such Contract under which
contemplated transactions were consummated) under which one or more of the
parties thereto has material obligations remaining to be performed;

  



  

   

31

 



    



  

(xiv) is an Intellectual Property Agreement;

  



  

(xv)  is a Contract that imposes any co-promotion or collaboration
obligations with respect to any product or product candidate,
which obligations are material to the Company and its Subsidiaries, taken as
a whole;

  



  

(xvi) is a hedging, derivative or similar Contract (including interest rate,
currency or commodity swap agreements, cap agreements, collar agreements and
any similar Contract designed to protect a Person against fluctuations in
interest rates, currency exchange rates or commodity prices);

  



  

(xvii) is a service or supply Contract, including a "single, sole source"
supply Contract, pursuant to which goods or materials in excess of $100,000
for the rolling twelve (12) month period beginning on the date hereof are
expected to be supplied to the Company or any of its Subsidiaries from an
exclusive source;

  



  

(xviii) is a Labor Agreement;

  



  

(xix) is a Contract which provides for a loan or advance of any amount to any
employee of the Company or any temporary agency employee, consultant or other
independent contractor of the Company or any of its Subsidiaries, other than
in the ordinary course of business; or

  



  

(xx) is a Contract, under which the Company or any of its Subsidiaries is, or
may become, obligated to sell or otherwise issue any shares of its capital
stock or any other Securities.

  



  

(b) None of the Company or any of its Subsidiaries is in material
breach of or default (or, with the giving of notice or lapse of time or both,
would be in default) under the terms of, and has not taken any action
resulting in the termination of, the acceleration of performance required by,
or a right of termination or acceleration under, any Company Material Contract
to which it is a party. As of the date of this Agreement, to the Knowledge of
the Company, no other party to any Company Material Contract is in material
breach of or default (or, with the giving of notice or lapse of time or both,
would be in default) under the terms of, and has not taken any action
resulting in the termination of, the acceleration of performance required by,
or a right of termination or acceleration under, any Company Material
Contract. Each Company Material Contract is (i) a valid and
binding obligation of the Company or any of its Subsidiaries that are a party
thereto, as applicable, and, to the Knowledge of the Company, the other
parties thereto ( _provided_ , _however_ , that such enforcement may be
subject to the Enforceability Exceptions) and (ii) in full force and effect,
except in the case of clauses (i) and (ii), to the extent any such Company
Material Contract expires by its terms or is terminated in accordance with
its terms in the ordinary course of business in compliance with _Section 5.1_
and except as would not reasonably be expected to be material to the business
of the Company and its Subsidiaries, taken as a whole.

  



  

   

32

 



    



  

(c) No (i) current or former officer or director of the Company; (ii)
beneficial owner of five percent (5%) or more of any voting Securities of the
Company; or (iii) any "affiliate" or "associate" of any such Person, has
any interest in any Contract or property (real or personal, tangible or
intangible), used in, or pertaining to the business of the Company or any of
its Subsidiaries, which interest would be required to be disclosed pursuant to
Item 404(a) of Regulation S-K under the Securities Act and that has not been
so disclosed in the Company SEC Documents.

  



  

Section 3.16 _Intellectual Property_.

  



  

(a) _Section 3.16(a)_ of the _Company Disclosure Letter_ sets forth
a true, complete and correct list, as of the date of this Agreement, of all
Company Registered IP. For each item of Company Registered IP, _Section
3.16(a)_ of the  _Company Disclosure Letter_ lists the owner, country(ies) or
region, and registration and application numbers.

  



  

(b) The Company or one or more of its Subsidiaries owns, or has a
valid right to use, all Intellectual Property used in the conduct of the
Company's and its Subsidiaries' respective businesses as such businesses are
conducted as of the Closing and as such businesses are intended to be
conducted after the Closing. The Surviving Corporation will own or
possess sufficient rights to all Intellectual Property as of the Closing that
are necessary to the operation of the Company's and its Subsidiaries'
respective businesses, as conducted as of immediately prior to the Closing.

  



  

(c) With respect to Company Owned IP, (i) the Company or one of its
Subsidiaries is the sole and exclusive owner of each item free and clear of
all Liens other than Permitted Liens and (ii) the Company and its Subsidiaries
have taken commercially reasonable actions to maintain each item. With
respect to Company Registered IP, each item is registered in the name of the
Company or one or more of its Subsidiaries.

  



  

(d) _Section 3.16(d)_ of the _Company Disclosure Letter_ sets forth
a true, complete and correct list, as of the date of this Agreement, of all
Contracts pursuant to which the Company or one or more of its Subsidiaries
receives a license or otherwise obtains a right to use any of the Company
Licensed IP, other than commercially available, non-customized, off-the-
shelf software subject to "shrink-wrap" or "click-through" type terms and
available to the Company or any of its Subsidiaries, as applicable. The
rights, licenses and interests of the Company or any of its Subsidiaries in
and to all Company Licensed IP are free and clear of all Liens or similar
restrictions that restrict the use of the Company Licensed IP or the
operation of the Company's and its Subsidiaries' respective businesses, other
than Permitted Liens and restrictions contained in the applicable Contracts
with the licensor of such Company Licensed IP, as set forth in _Section
3.16(d)_ of the _Company Disclosure Letter_.

  



  

(e) To the Knowledge of the Company, none of the activities or
business currently conducted by the Company or any of its Subsidiaries at any
time since January 1, 2017 infringes, misappropriates or otherwise violates
any valid and enforceable Intellectual Property of any third Person. Neither
the Company nor any of its Subsidiaries is subject to any Order that
materially restricts or impairs the use of any Company Intellectual Property.

  



  

   

33

 



    



  

(f) There is not now and has not been since January 1, 2016 a
pending or threatened claim or Proceeding by any Person asserting the alleged
infringement, misappropriation or violation of any Intellectual Property of
any Person by the Company or any of its Subsidiaries, or contesting the
validity, ownership, enforceability or right of the Company or any of its
Subsidiaries in or to any of the Company Owned IP, including in the nature of
being offered a license or covenant not to sue, and to the Knowledge of the
Company, there is no basis for any such Proceeding with respect to any
Intellectual Property of any Person. Since January 1, 2016, neither the
Company nor any of its Subsidiaries has received any written notice of any
conflict or pending conflict with, or infringement, misappropriation or
violation of, the rights of any Person with respect to any Intellectual
Property or any license to any Intellectual Property, or challenging the
validity, ownership, enforceability, or right of the Company or any of its
Subsidiaries to use any Intellectual Property.

  



  

(g) There is not now and has not been since January 1, 2016 a pending
or threatened claim or Proceeding by the Company or any of its Subsidiaries
asserting the alleged infringement, misappropriation or violation of any
Company Intellectual Property by any Person, or contesting the validity,
ownership, enforceability or right of any Person in or to any Intellectual
Property, including in the nature of offering a license or covenant not to
sue, and to the Knowledge of the Company, there is no basis for any such
Proceeding with respect to any Company Intellectual Property. Since January 1,
2014, neither the Company nor any of its Subsidiaries has asserted rights in
any of the Company Intellectual Property against any Person in any Proceeding,
cease and desist letter, or other written notice, including in the nature of
offering a license or covenant not to sue.

  



  

(h) The Company and each of its Subsidiaries have taken reasonable
measures to protect and preserve the confidentiality of all material
confidential information and all Trade Secrets that are Company Owned IP, or
any Trade Secrets disclosed to the Company or its Subsidiaries for which the
Company or any of its Subsidiaries had or has an obligation of secrecy,
against unauthorized access, disclosure, use, modification or other misuse.
To the Knowledge of the Company, there has been no material
unauthorized access, disclosure or use of any material Trade Secrets that are
Company Owned IP, or any Trade Secrets disclosed to the Company or its
Subsidiaries for which the Company or any of its Subsidiaries had or has an
obligation of secrecy, against unauthorized access, disclosure, use,
modification or other misuse.

  



  

(i) Except as would not, individually or in the aggregate, be
material to the business of the Company and its Subsidiaries, the Company and
each of its Subsidiaries have used reasonable measures to protect the Trade
Secrets included in the Company Intellectual Property and have secured from
all of their employees and consultants who independently or jointly
contributed to the conception, reduction to practice, creation or development
of any Company Owned IP unencumbered and unrestricted exclusive ownership of
all such employee's or consultant's, as applicable, Intellectual Property in
such contribution that the Company or any of its Subsidiaries do not already
own by operation of Law and such employee or consultant, as applicable, has
not retained any rights or licenses with respect thereto. Without limiting
the foregoing, except as would not, individually or in the aggregate, be
material to the business of the Company and its Subsidiaries, the Company and
its Subsidiaries have obtained proprietary information and assignment
Contracts from all current and former employees, consultants, contractors, and
other Persons involved in the development of any Intellectual Property with
or for the Company or any of its Subsidiaries, and those Contracts assign and
require assignment to the Company or one or more of its Subsidiaries all
right, title and interest in and to Intellectual Property developed by
such employees, consultants, contractors, and other Persons.

  



  

   

34

 



    



  

(j) There are no settlements, forbearances to sue, consents, Orders
or similar obligations to which the Company or any of its Subsidiaries is a
party or is subject that (i) restrict the Company's or any of its
Subsidiaries' rights to use, enjoy or exploit any material Company
Intellectual Property; (ii) materially restrict the Company's or any of its
Subsidiaries' business in order to accommodate any Person's right in or to
any Intellectual Property; or (iii) permit any Person to use any Company
Intellectual Property.

  



  

(k) Except as set forth on _Section 3.16(k)_ of the _Company
Disclosure Letter_ , neither the Company nor any of its Subsidiaries has
entered into any contractual obligation requiring it to indemnify any other
Person against infringement or other violation of any Intellectual Property
of any Person, nor has the Company or any of its Subsidiaries entered into
any contractual obligation requiring the Company or one of its Subsidiaries
to grant any Person the right to bring infringement actions or otherwise
enforce rights with respect to any of the Company Owned IP.

  



  

(l) To the Knowledge of the Company, since January 1, 2016, no
current or former employee or consultant of the Company or any of its
Subsidiaries (i) is in violation of any (A) term or covenant of any
contractual or other obligation to the Company or any of its Subsidiaries
relating to invention disclosure, invention assignment, non-disclosure,
limitation of use, or non-competition, or (B) any applicable material non-
disclosure obligation or restrictive covenant obligation for the benefit of
any other Person, including any former employer of such employee or
consultant, by virtue of such employee or consultant being employed by or
performing services for the Company or any of its Subsidiaries, or using
Trade Secrets or proprietary information of such Person, including any former
employer, for the benefit of the Company or any of its Subsidiaries, or (ii)
has developed any technology, Software or other copyrightable, patentable or
otherwise proprietary work for the Company or any of its Subsidiaries that is
subject to any agreement under which such employee or consultant has assigned
or otherwise granted to any Person any rights other than the Company
(including rights in or to Intellectual Property) in or to such technology,
Software or other copyrightable, patentable or otherwise proprietary work or
which has been subject to any confidentiality or use restrictions. To the
Knowledge of the Company, all disclosures by the Company or any of its
Subsidiaries to any Person of material Company-owned confidential information
and Trade Secrets, or confidential information and Trade Secrets as to which
the Company or any of its Subsidiaries had or has an obligation of secrecy,
have been made pursuant to the terms of a written contractual obligation
between the Company or its applicable Subsidiaries and such third Person
requiring that such third Person not disclose or otherwise use such
confidential information or Trade Secrets for any purpose other than those
expressly authorized in writing by the Company or any of its Subsidiaries, as
applicable.

  



  

   

35

 



    



  

(m)  With regard to proprietary Software that is developed or used by
the Company or any of its Subsidiaries, or is currently in development by the
Company or any of its Subsidiaries, and other than as has not been, and would
not reasonably be expected to be, individually or in the aggregate, material
to the business of the Company and its Subsidiaries, taken as a whole: (i)
neither the Company nor any of its Subsidiaries has assigned, delivered,
licensed or made available, and does not have any obligation to assign,
deliver, license or make available, the source code for any such Software to
any third Person, including any escrow agent or similar Person; (ii) neither
the Company nor any of its Subsidiaries has experienced any material defects
or disruptions in such Software, including any material error or omission in
the processing of any transactions that have not been corrected; (iii) no
such Software (A) contains any code designed or intended to disrupt, disable,
harm or otherwise impede in any manner the operation of, or provide
unauthorized access to, a computer system or network or other device on which
such code is stored or installed, or to damage or destroy data or files
without the user's consent, or (B) incorporates, embeds or is distributed or
installed with, statically or dynamically links with, or otherwise interacts
with any Software that is distributed as free software, open source software,
or pursuant to similar licensing or distribution models, including pursuant to
any GNU general public license or limited general public license, in a manner
that would require any Software included in the Company Owned IP, including
any source code associated with such Software, to be disclosed, licensed, or
divulged to any other Person; (iv) current copies of the source code for all
such material Software are recorded on machine readable media, clearly
identified and securely stored (together with the applicable documentation)
by the Company or any of its Subsidiaries; and (v) no capital expenditures are
necessary with respect to such Software or its use.

  



  

(n) No item of Company Owned IP has been held to be invalid or
unenforceable in any Order. The Company Owned IP (and, to the Knowledge of
the Company, the Company Licensed IP) is subsisting (or in the case of
applications, applied for) and to the Knowledge of the Company, valid and
enforceable. No issued Patents or pending patent applications included in the
Company Owned IP are subject to any interference, reissue, reexamination,
opposition, inter parties review, covered business method review, post-grant
review, or other post-grant proceeding. No Trademark that is included in the
Company Owned IP is subject to any opposition, invalidation, cancellation, or
other administrative proceeding. Neither the Company nor any of its
Subsidiaries is undertaking any interference, reissue, reexamination,
opposition, _inter partes_ review, covered business method review, post-grant
review, invalidation, cancellation, or other administrative proceeding with
respect to Intellectual Property of any Person. The Company and its
Subsidiaries have not knowingly made any material misrepresentations in the
filings submitted to the applicable Governmental Authorities with respect to
any Company Registered IP and, to the Knowledge of the Company, neither the
Company nor any of its Subsidiaries has engaged in misuse, including patent
or copyright misuse or any fraud or inequitable conduct, in connection with
any Company Owned IP.

  



  

(o) No Company Intellectual Property is being used or enforced by the
Company or any of its Subsidiaries in a manner that would reasonably be
expected to result in the abandonment, cancellation or unenforceability of any
Intellectual Property used in and necessary for or otherwise material to the
conduct of the Company's and any of its Subsidiaries' businesses as currently
conducted.

  



  

(p) Except as set forth on _Section 3.16(p)_ of the _Company
Disclosure Letter_ , no Governmental Authority, in the United States or any
other jurisdiction, has acquired or has a right to acquire, including upon the
occurrence of any pending conditions, any right, title, or interest in or to
any of the Company Owned IP, including any "limited rights" or
"restricted rights" as defined in the Federal Acquisition Regulations and
related agency supplements, including the Defense Federal
Acquisition Regulation Supplement.

  



  

   

36

 



    



  

(q) The Company and each of its Subsidiaries have at all times been
and are in compliance in all material respects with (i) all Laws or Orders
applicable to the Company and each of its Subsidiaries that govern or regulate
the privacy, security, processing, protection, destruction, breach
notification, or transfer of or with respect to individually identifiable
information, including the Health Insurance Portability and Accountability
Act (HIPAA), the EU General Data Protection Regulation (GDPR), and similar
international, foreign, national, state and local data protection Laws and
the regulations that implement the foregoing, as may be amended from time to
time (collectively, "Data Protection Laws"), and (ii) all contractual
commitments made by it with respect to the privacy or security of Personal
Information (collectively, (i) and (ii), the "Privacy Requirements"). No
claims are pending or have been threatened in writing or, to the Knowledge of
the Company, threatened other than in writing, against the Company or any of
its Subsidiaries alleging any violation of the Privacy Requirements or any
violation of any Person's privacy, personal information, or data rights.

  



  

(r) During the three (3) years prior to the date hereof, (i) there
have been no material security breaches in the Company's or any of its
Subsidiaries' information technology systems, (ii) to the Knowledge of the
Company, there have been no material security breaches in the information
technology systems used in the operation of the products or services provided
or rendered by the Company or any of its Subsidiaries, and (iii) there have
been no disruptions in information technology systems that
materially adversely affected the Company's or any of its Subsidiaries'
business or operations. The Company has used commercially reasonable efforts
to evaluate the disaster recovery and backup needs of the Company and its
Subsidiaries and has implemented plans and systems that are reasonably
designed to address its assessment risk. The Company and each of its
Subsidiaries: (A) have implemented, maintains, and complies with written
privacy and security policies with respect to any Personal Information
processed by it or on its behalf; (B) employ reasonable and appropriate
safeguards sufficient to protect all Personal Information that is
processed by it or on its behalf from loss, misappropriation, or unauthorized
or unlawful use, disclosure, access, or other processing; (C) have provided
any notice, and obtained any consent, required by any Privacy Requirement for
any collection, use, disclosure, cross-border transfer, retention, or other
processing of Personal Information by it or on its behalf; and (D) have
entered into an agreement with each service provider or other Person that
processes Personal Information for it or on its behalf, which agreement
complies with applicable Privacy Requirements. There has been no unauthorized
access, loss, use, or disclosure of any Personal Information in the
possession or under the control of the Company or any of its Subsidiaries in
violation of any Privacy Requirement. Neither the Company nor any of its
Subsidiaries has notified, nor has the Company or any Company Subsidiary been
required to notify (whether pursuant to applicable Law or otherwise), any
Person of any information security breach or incident involving Personal
Information.

  



  

Section 3.17 _Real and Personal Property_.

  



  

(a) The Company and its Subsidiaries do not own any real property.

  



  

   

37

 



    



     

   



  

(b)   _Section 3.17(b)_ of the _Company Disclosure Letter_ sets
forth a complete and accurate list as of the date of this Agreement of each
lease, sublease, license or similar use and occupancy Contract (including any
assignments, amendments, extensions and modifications thereto, each, a
"Lease") pursuant to which the Company or any of its Subsidiaries leases,
subleases or otherwise uses or occupies, as applicable, any real or personal
property from any other Person (whether as a tenant, subtenant or pursuant to
other occupancy arrangements) (collectively, the "Company Leased
Property"). The Company has made available to Parent a true, correct and
complete copy of each such Lease to date.

  



  

(c)  Except as set forth on _Section 3.17(c)_ of the _Company
Disclosure Letter_ , (i) the Company and its Subsidiaries have valid
leasehold interests under each of the Leases, free and clear of all Liens,
except for Permitted Liens and (ii) the Company and its Subsidiaries enjoy
peaceful and undisturbed possession under all of the Leases for any Company
Leased Property.

  



  

(d)  Each Lease for any Company Leased Property is in full force and
effect and is a valid and binding obligation of the Company or any of its
Subsidiaries that is a party thereto, as applicable, and to the Knowledge of
the Company, the other parties thereto.

  



  

(e)  No event has occurred and no condition exists, which with the
giving of notice or the passage of time, or both, will constitute a default
under a Lease by the Company or any of its Subsidiaries, or, to the Knowledge
of the Company, any counterparty under such Lease, that would, individually
or in the aggregate, materially impair or be reasonably likely to materially
impair the continued use and operations of the Company Leased Property to
which they relate in the conduct of the business of the Company and its
Subsidiaries as presently conducted.

  



  

(f)  (i) no Person, other than the Company or a Subsidiary of the
Company, possesses, uses or occupies, as applicable, all or any portion of
any Company Leased Property and (ii) neither the Company nor any Subsidiary of
the Company is a party to any agreement, right of first offer, right of first
refusal or option with respect to the purchase or sale of any real
property or interest therein. As of the date hereof, there are no pending or,
to the Knowledge of the Company, threatened Proceedings to take all or any
portion of the Company Leased Property or any interest therein by eminent
domain or any condemnation proceeding (or the jurisdictional equivalent
thereof) or any sale or disposition in lieu thereof.

  



  

Section 3.18   _Environmental_.

  



  

(a)  Except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect:

  



  

(i) since January 1, 2016, the Company and its Subsidiaries have been and
are in compliance with all applicable Environmental Laws,
including possessing and complying with the terms of all Company Permits
required for their operations as currently conducted under
applicable Environmental Laws;

  



   

38

 



    



  

  

(ii) (A) there is no pending or, to the Knowledge of the Company, threatened
Proceeding pursuant to any Environmental Law against the Company or any of
its Subsidiaries; (B) none of the Company or any of its Subsidiaries has
received notice or a request for information from any Person, including any
Governmental Authority, alleging that the Company or any of its Subsidiaries
has been or is in actual or potential violation of any applicable
Environmental Law or otherwise may be liable under any applicable
Environmental Law, which violation or liability is unresolved; and (C) none
of the Company or any of its Subsidiaries is a party or subject to any
Order pursuant to Environmental Law that is currently in effect;

  



  

(iii) there have been no Releases of Hazardous Materials by the Company or
any of its Subsidiaries (and, to Knowledge of the Company, Releases of
Hazardous Materials have not otherwise occurred) at, on, under or from any
location that have resulted in or are reasonably likely to result in an
obligation by the Company or any of its Subsidiaries to remediate such
Releases pursuant to applicable Environmental Law or otherwise have resulted
in or are reasonably likely to result in liability to the Company or any of
its Subsidiaries pursuant to applicable Environmental Law with respect to
such Releases; and

  



  

(iv) neither the Company nor any of its Subsidiaries has entered into any
written agreement or incurred any legal obligation that would reasonably be
expected to require it to pay to, reimburse, or indemnify any other Person
from or against liabilities or costs arising in connection with or pursuant
to Environmental Law, or relating to impacts on human health or the
environment arising from the generation, manufacture, use, transportation or
disposal of or exposure to Hazardous Materials.

  



  

(b)  The Company has delivered or otherwise made available for
inspection to the Parent copies of any reports, investigations, audits,
assessments (including Phase I or II environmental assessments), studies or
other material documents in the possession of or reasonably available to the
Company or any of its Subsidiaries pertaining to: (i) any unresolved claims
arising under or relating to any Environmental Law; or (ii) any Hazardous
Materials in, on, beneath or adjacent to any property currently or
formerly owned, operated or leased by the Company or any of its Subsidiaries.

  



  

Section 3.19 _Customers, Distributors, and Suppliers_. _Section 3.19_ of
the _Company Disclosure Letter_ sets forth (a) the ten (10) largest customers
(by revenue) of the businesses of the Company and its Subsidiaries (on a
consolidated basis) during the twelve months ended December 31, 2018; (b) the
ten (10) largest distributors or sales agents (by revenue) of the businesses
of the Company and its Subsidiaries (on a consolidated basis) during the
twelve months ended December 31, 2018; (c) (i) "single, sole source"
suppliers, (ii) each supplier that together with other suppliers ranked by
purchasing volume represent 80% of the total purchasing volume of the Company
and its Subsidiaries (on a consolidated basis) during the twelve months ended
December 31, 2018, (iii) each supplier where the purchasing volume of the
Company or its Subsidiaries, as applicable, to the Knowledge of the Company,
is greater than 50% of such supplier's total sales volume (on a consolidated
basis, if applicable) during the twelve months ended December 31, 2018, (iv)
each supplier that, to the Knowledge of the Company, owns or uses unique or
specialized technologies or procedures for the production, handling
or service of the products delivered or services provided by the Company or
any of its Subsidiaries, and (v) to the Knowledge of the Company, any other
supplier of the businesses of the Company and its Subsidiaries, the loss of
which is expected to cause material disruption to such businesses (on a
consolidated basis) (each supplier set forth in (i) - (v), a "Material
Supplier"); and (d) each distributor, sales agent, and supplier of the
businesses of the Company and each of its Subsidiaries with whom the Company
or any of its Subsidiaries is obligated by Contract to conduct any business on
an exclusive basis, or upon consummation of the Merger, with whom Parent or
any of its Subsidiaries will be obligated to conduct business on an exclusive
basis. _Section 3.19(d)_ of the _Company Disclosure Letter_ lists, for each
distributor, sales agent, and supplier disclosed pursuant to clause (d) of
this _Section 3.19_ , (i) the applicable product(s), geographic
territory(ies), and customer(s) subject to the exclusivity arrangement; and
(ii) whether the exclusivity arrangement provides the distributor, sales
agent, or supplier, as applicable, any exclusive right to market, promote,
sell, distribute the Company's or any of its Subsidiary's products or
services. Since January 1, 2019, through the date of this Agreement, no
customer, supplier, distributor, or sales agent, as applicable, listed on
_Section 3.19_ of the _Company Disclosure Letter_ has canceled or otherwise
terminated, or to the Knowledge of the Company, threatened to cancel or
otherwise terminate, its relationship with the Company or any of its
Subsidiaries, or has decreased materially, or to the Knowledge of the
Company, threatened to decrease materially, the quantity of products or
services purchased from or sold to, as the case may be, the businesses of the
Company or any of its Subsidiaries. _Section 3.19_ of the _Company Disclosure
Letter_ also sets forth (i) customers, suppliers, distributors, or sales
agents, as applicable, that had entered into a Contract with the Company or
any of its Subsidiaries, which expired, lapsed or was terminated, and with
whom the Company or any of its Subsidiaries continues to do business as of
the date hereof, and (ii) the terms of such continued business arrangements.

  



   

39

 



    



  

  

Section 3.20 _Product Warranty_. Each product manufactured,
sold, leased, delivered or distributed (including the featured and
functionality offered thereby) or service provided or rendered by the Company
or any of its Subsidiaries complies in all material respects with all
applicable contractual specifications, requirements and covenants and all
express and implied warranties made by the Company or any of its Subsidiaries
and is not subject to any term, condition, guaranty, warranty or other
indemnity beyond the applicable standard terms and conditions for such product
or service.  _Section 3.20_ of the _Company Disclosure Letter_ sets forth any
material claims for replacement, repair or other damages in connection with
the Company's or any of its Subsidiaries' material products or services since
January 1, 2019.

  



  

Section 3.21 _Foreign Corrupt Practices Act; Anti-Corruption_.

  



  

(a) Since January 1, 2016, none of the Company, any of its
Subsidiaries or any of their respective officers, directors, employees or,
to the Knowledge of the Company, agents, distributors, consultants or
independent contractors (to the extent acting on behalf of the Company or any
of its Subsidiaries) has directly or indirectly made, promised, or authorized
or offered to make, promise or authorize any contribution, gift, bribe,
rebate, payoff, influence payment, kickback, or other payment or thing of
value to any Person, private or public, regardless of what form, whether in
money, property or services, in violation of, to the extent applicable, the
FCPA, the U.S. Travel Act, the U.K. Bribery Act 2010, applicable Laws
implementing the OECD Convention on Combating Bribery of Foreign Public
Officials in International Business Transactions or any other applicable Law,
rule or regulation relating to anti-corruption or anti-bribery in any
jurisdiction where the Company operates (collectively, the "Anti-Corruption
Laws"). Without limiting the foregoing, since January 1, 2016, none of the
Company, any of its Subsidiaries, or any of their respective officers,
directors, employees or, to the Knowledge of the Company, agents,
distributors, consultants or independent contractors (to the extent acting on
behalf of the Company or any of its Subsidiaries) has directly or indirectly
offered or given anything of value corruptly to (i) any official, political
party or official thereof or any candidate for political office or (ii)
any Person, while knowing that all or a portion of such thing of value will
be offered, given or promised, directly or indirectly, to any official, to
any political party or official thereof or to any candidate for political
office for the purpose of the following: (A) influencing any act or decision
of such official, political party, party official or candidate in his, her or
its official capacity, including influencing such official, political party,
party official or candidate to do or omit to do any act in violation of his,
her or its lawful duty, or securing any improper advantage for the benefit of
the Company or any of its Subsidiaries or (B) inducing such official,
political party, party official or candidate to use his, her or its influence
with a Governmental Authority or instrumentality thereof to affect or
influence any act or decision of such Governmental Authority or
instrumentality, in order to assist the Company or any of its Subsidiaries in
obtaining or retaining business for or with, or directing business to, any
Person or securing an improper advantage for the benefit of the Company or any
of its Subsidiaries.

  



  

   

40

 



    



  

(b)  Since January 1, 2016, neither the Company, nor any of its
Subsidiaries, nor, to the Knowledge of the Company, any of the Company's or
its Subsidiaries' respective agents, distributors, consultants or independent
contractors (to the extent acting on behalf of the Company or any of its
Subsidiaries) (i) is or has been the subject of an unresolved claim or
allegation relating to (A) any potential violation of the Anti-Corruption
Laws or (B) any potentially unlawful contribution, gift, bribe, rebate,
payoff, influence payment, kickback or other payment or the provision of
anything of value, directly or indirectly, to an official, to any political
party or official thereof or to any candidate for political office, or (ii)
has received any notice or other communication (in writing) from, or made a
voluntary disclosure to, any Governmental Authority regarding any actual,
alleged or potential violation of, or failure to comply with, any Anti-
Corruption Laws.

  



  

(c)  The Company and its Subsidiaries maintain a system or systems
of internal controls that are reasonable and customary for companies
similarly situated as the Company to (i) ensure compliance with Anti-
Corruption Laws and (ii) prevent and detect violations of Anti-Corruption
Laws.

  



  

Section 3.22   _Customs and International Trade Laws_.

  



  

(a)  Since January 1, 2017, the Company and its Subsidiaries have
been in compliance in all material respects with all applicable Customs and
International Trade Laws and there are no unresolved formal claims concerning
the liability of any of the Company or its Subsidiaries under such Laws.
Without limiting the foregoing, (i) at all times since January 1, 2017, the
Company and its Subsidiaries and, to the Knowledge of the Company, Persons
acting on their behalf have obtained all import and export licenses and all
other consents, notices, waivers, approvals, Orders, authorizations,
registrations, declarations, classifications and filings required for the
export, import, re-export or transfer of goods, services, software and
technology required for the operation of the respective businesses of the
Company and its Subsidiaries, including Customs and International Trade
Authorizations; (ii) since January 1, 2017, no Governmental Authority has
initiated any Proceedings or imposed any civil or criminal fine,
penalty, seizure, forfeiture, revocation of a Customs and International Trade
Authorization, debarment or denial of future Customs and International Trade
Authorizations against any of the Company or its Subsidiaries or any of their
respective directors, officers, employees or agents in connection with any
actual or alleged violation of any applicable Customs and International Trade
Laws; and (iii) since January 1, 2017, there have been no claims,
investigations or requests for information by a Governmental Authority with
respect to the Company's and its Subsidiaries' Customs and International Trade
Authorizations and compliance with applicable Customs and International Trade
Laws.

  



   

41

 



    



  

  

(b)  Neither the Company nor any of its Subsidiaries, and no
director, officer or employee of any of the Company or its Subsidiaries, (i)
is a Sanctioned Person; or (ii) has pending or, to the Knowledge of the
Company, threatened claims against it with respect to Sanctions.

  



  

Section 3.23   _FDA and Related Matters_.

  



  

(a)   _Section 3.23(a)_ of the _Company Disclosure Letter_ lists
all Registrations held by the Company and each of its Subsidiaries. Since
January 1, 2016, the Company and its Subsidiaries possess all Registrations
required to conduct their respective businesses as currently conducted. Each
such Registration is valid and subsisting in full force and effect. To the
Knowledge of the Company, as of the date hereof, neither the United States
Food and Drug Administration (the "FDA") nor any comparable Regulatory
Authority or Governmental Authority is considering limiting, suspending or
revoking any such Registration or changing the marketing classification or
labeling of the products of the Company and any of its Subsidiaries. To the
Knowledge of the Company, there is no material false or misleading
information or material omission in any product application or other
submission to the FDA or any comparable Regulatory Authority or Governmental
Authority. Since January 1, 2016, the Company and each of its Subsidiaries
are in material compliance with, and have fulfilled and performed in all
material respects their respective obligations under, each such Registration
(including applicable European legislation (e.g. Directive 93/42/EEC (MDD),
Directive 2011/65/EU (RoHS), Regulation 1907/2006/EC (REACH))), and, as of
the date hereof, to the Knowledge of the Company, no event has occurred
or condition or state of facts exists which would constitute a breach or
default or would cause revocation or termination of any such Registration.
Further, the Company has implemented all necessary steps needed to secure the
enduring marketability of its products under Regulation (EU) 2017/745 (MDR,
application date May 26, 2020) or Regulation (EU) 2017/746 (IVDR, application
date May 26, 2022). To the Knowledge of the Company, any third Person that is
a manufacturer or contractor for the Company or any of its Subsidiaries is in
material compliance with all Registrations insofar as they pertain to the
manufacture of product components or products for the Company or any of its
Subsidiaries, as applicable.

  



  

(b)  Since January 1, 2016, all products and services developed,
tested, investigated, produced, manufactured, labeled, promoted, distributed,
marketed, stored, sold, imported, exported or used by or on behalf of the
Company or any of its Subsidiaries that are subject to the jurisdiction of
the FDA or any comparable Regulatory Authority have been and are being
developed, tested, investigated, produced, manufactured, labeled, promoted,
distributed, marketed, stored, sold, imported and exported, supervised and
maintained as applicable, in all material respects, in compliance with Device
Laws, and any comparable Laws enforced by any other Regulatory Authority that
has jurisdiction over the operations of the Company or any of its
Subsidiaries, including those regarding non-clinical research, clinical
research, establishment registration, device listing, pre-market notification,
good manufacturing practices, labeling, advertising, record-keeping, device
importation and exportation, security, cybersecurity, adverse event
reporting and reporting of corrections and removals. To the Knowledge of the
Company, except as would not be material to the Company and its Subsidiaries,
taken as a whole, since January 1, 2016, any third Person that is a
manufacturer or contractor for the Company or any of its Subsidiaries is in
material compliance with all Device Laws or any other applicable Law insofar
as they pertain to the manufacture, promotion, marketing, sale, or
maintenance of product components or products for the Company or any of its
Subsidiaries.

  



  

   

42

 



    



  

(c)  As of the date hereof, there are no Proceedings pending or, to
the Knowledge of the Company, threatened by or on behalf of any Regulatory
Authority that has jurisdiction over the operations of the Company and any of
its Subsidiaries. Since January 1, 2016, neither the Company nor any of its
Subsidiaries, nor, to the Knowledge of the Company its contractors
providing services by or on behalf of the Company or its Subsidiaries, has
received any Form FDA-483, notice of adverse finding, FDA warning letter,
notice of violation or "untitled letter," notice of FDA action for import
detention or refusal, or any other notice from the FDA or any other
Governmental Authority alleging or asserting noncompliance with any applicable
Laws or Registrations. Neither the Company nor any of its Subsidiaries is
subject to any obligation arising under an administrative or regulatory
action, FDA inspection, FDA warning letter, FDA notice of violation letter or
other notice, response or commitment made to or with the FDA or any
comparable Regulatory Authority. Since January 1, 2016, each of the Company
and its Subsidiaries has made all notifications, submissions, responses and
reports required by Device Laws, including any such obligation arising under
any administrative or regulatory action, FDA inspection, FDA warning letter,
FDA notice of violation letter, or other notice, response, or commitment made
to or with the FDA or any comparable Regulatory Authority or Governmental
Authority and, to the Knowledge of the Company, all such
notifications, submissions, responses and reports were true, complete and
correct in all material respects as of the date of submission to the FDA or
any comparable Regulatory Authority or Governmental Authority. To the
Knowledge of the Company, as of the date hereof, no basis for material
liability exists with respect to regulatory requirements concerning
notifications, submissions and reports.

  



  

(d)  Since January 1, 2016, no product distributed or sold by or on
behalf of the Company or any of its Subsidiaries has been seized, withdrawn,
recalled, detained or subject to a suspension of manufacturing, and as of the
date hereof, to the Knowledge of the Company, there are no facts or
circumstances reasonably likely to cause (i) the seizure, denial, withdrawal,
recall, detention, field notification, field correction, safety alert or
suspension of manufacturing relating to any such product; (ii) a change
in the labeling of any such product; or (iii) a termination, seizure,
limitation, restriction, modification or suspension of the marketing or
distribution (including for commercial, investigational or any other use) of
any such product. As of the date hereof, no Proceedings in the United States
or any other jurisdiction seeking the withdrawal, recall, correction,
suspension, import detention, seizure or similar action of any such product
are pending or, to the Knowledge of the Company, threatened against the
Company or any of its Subsidiaries. Since January 1, 2016, neither the
Company nor any of its Subsidiaries has received any written or, to the
Knowledge of the Company, verbal notice from a Regulatory Authority or other
Governmental Authority that any product distributed or sold by or on behalf
of the Company or any of its Subsidiaries cannot be developed, tested,
investigated, produced, manufactured, labeled, promoted, distributed,
marketed, stored, sold, imported or exported substantially in the manner
presently performed or contemplated by or on behalf of the Company.

  



   

43

 



    



  

  

(e)  Since January 1, 2016, all preclinical and clinical
investigations sponsored or conducted by or on behalf of the Company or any
of its Subsidiaries (including post-marketing studies) have been and are being
conducted in material compliance with all applicable Laws and other
requirements, including Good Clinical Practices requirements, other Device
Laws, applicable research protocols, corrective action plans, and Data
Protection Laws. No clinical trial sponsored or conducted by or on behalf of
the Company or any of its Subsidiaries has been terminated, materially
delayed, limited or suspended prior to completion by the FDA, any other
applicable Regulatory Authority, or any institutional review board that has or
has had jurisdiction over such clinical trial, and neither the FDA nor any
other applicable Regulatory Authority, nor any institutional review board that
has or has had jurisdiction over a clinical trial conducted or sponsored by
or on behalf of the Company or any of its Subsidiaries, has ordered or
commenced, or, to the Knowledge of the Company, threatened to initiate, any
action to place a clinical hold order on, or otherwise terminate, materially
delay, limit, modify or suspend, any proposed or ongoing clinical trial
conducted or proposed to be conducted by or on behalf of the Company or any
of its Subsidiaries, or, to the Knowledge of the Company, alleged any
violation of any Device Law in connection with any such clinical trial.

  



  

Section 3.24   _Healthcare Regulatory Compliance_.

  



  

(a)  Neither the Company nor any of its Subsidiaries or any of its
or their respective officers, directors, managing employees (as such terms
are defined in 42 C.F.R.  1001.2), nor to the Knowledge of the Company, any
agent (as such term is defined in 42 C.F.R.  1001.2) of the Company or any
of its Subsidiaries, is a party to, or bound by, any Order, individual
integrity agreement, corporate integrity agreement or other formal or
informal agreement with any Governmental Authority concerning compliance with
Federal Health Care Program Laws.

  



  

(b)  Neither the Company nor any of its Subsidiaries nor any of its
or their respective officers, directors, managing employees (as those terms
are defined in 42 C.F.R.  1001.2), nor to the Knowledge of the Company, any
agent (as such term is defined in 42 C.F.R.  1001.2) of the Company or any
of its Subsidiaries (i) has been charged with or convicted of any criminal
offense relating to the delivery of an item or service under any Federal
Health Care Program; (ii) has been debarred, excluded or suspended from
participation in any Federal Health Care Program; (iii) has had a civil
monetary penalty assessed against it, him or her under Section 1128A of the
Social Security Act of 1935, codified at Title 42, Chapter 7, of the United
States Code (the "SSA"); (iv) is currently listed on the U.S. General
Services Administration published list of parties excluded from federal
procurement programs and non-procurement programs; or (v) to the Knowledge of
the Company is the target or subject of any current or potential
investigation relating to any Federal Health Care Program-related offense.
"Federal Health Care Program" has the meaning specified in Section 1128B(f)
of the SSA and includes the Medicare, Medicaid and TRICARE programs.

  



  

   

44

 



    



  

(c)  Neither the Company nor any of its Subsidiaries nor any of its
or their respective officers, directors, managing employees (as those terms
are defined in 42 C.F.R.  1001.2), nor to the Knowledge of the Company, any
agent (as such term is defined in 42 C.F.R.  1001.2) of the Company or any
of its Subsidiaries has engaged in any activity that is in violation of, or
is cause for civil or criminal penalties, mandatory or permissive exclusion
from a Federal Health Care Program or other administrative sanction under,
the federal Medicare or federal or state Medicaid statutes, Section 1128,
1128A, 1128B, 1128C or 1877 of the SSA (42 U.S.C.  1320a-7, 1320a-7a,
1320a-7b, 1320a-7c and 1395nn), the federal TRICARE statute (10 U.S.C.  1071
et seq.), the civil False Claims Act of 1863 (31 U.S.C.  3729 et seq.),
criminal false claims statutes (e.g., 18 U.S.C.  287 and 1001), the Program
Fraud Civil Remedies Act of 1986 (31 U.S.C.  3801 et seq.), the anti-
fraud and related provisions of the Health Insurance Portability and
Accountability Act of 1996 ("HIPAA") (e.g., 18 U.S.C.  1035 and 1347), the
Physician Payment Sunshine Act (42 U.S.C.  1320a-7h), or related regulations,
or any other Laws that govern the health care industry or relationships among
health care providers, suppliers, distributors, manufacturers and patients,
including all state laws analogous to the foregoing (collectively, "Federal
Health Care Program Laws").

  



  

(d)  To the Knowledge of the Company, no Person has filed or has
threatened to file against the Company or any of its Subsidiaries an action
relating to any Device Law or Federal Health Care Program Law under any
federal or state whistleblower statute, including under the False Claims Act
of 1863 (31 U.S.C.  3729 et seq.).

  



  

(e)  Neither the Company nor any of its Subsidiaries is a "covered
entity" as that term is defined in HIPAA, has entered into a business
associate contract where required by 45 C.F.R.  164.504(e), and is not in
breach of any such business associate contract.

  



  

(f)  To the extent the Company and any of its Subsidiaries provide
to customers or others reimbursement coding or billing advice regarding
products offered for sale or the provision of services by the Company or any
of its Subsidiaries and procedures related thereto, such advice is (i) true,
complete and correct; and (ii) in material compliance with all Federal Health
Care Program Laws.

  



  

(g)  The Company has adopted a code of ethics and has an operational
healthcare compliance program consistent in all material respects with the
Compliance Program Guidance published by the Office of Inspector General, U.S.
Department of Health and Human Services, which governs all employees,
including sales representatives and their interactions with their physician
and hospital customers.

  



  

   

45

 



    



  

(h)  Except as has not been, and would not reasonably be expected to
be, individually or in the aggregate, material to the Company and its
Subsidiaries, taken as a whole, (i) all agreements or other arrangements
between the Company or any of its Subsidiaries on the one hand and any
physician on the other hand for services are in writing, describe bona fide
services required by the Company or its Subsidiaries, as the case may be,
provide for compensation that is no more than fair market value for
such services determined as of the effective date of such agreement, and are
in material compliance with the Federal Anti-Kickback Statute (42 U.S.C. 
1320a-7b(b)) ("AKS"); (ii) all agreements or arrangements with health care
professionals for services to or investments in the Company or any of its
Subsidiaries, directly or indirectly, to which the Company or any of
its Subsidiaries is a party as of the date of this Agreement are listed on
_Section 3.24(h)_ of the _Company Disclosure Letter_ , including true,
complete and correct details as to amounts paid thereunder in 2019; (iii) all
payments made and things of value provided by the Company or any of its
Subsidiaries to any health care professional for services rendered by such
health care professional have been made at fair market value determined as of
the effective date of any such agreement and are in material compliance
with the AKS; and (iv) all such agreements, arrangements, payments and things
of value are in material compliance with all applicable Laws, including all
Federal Health Care Program Laws.

  



  

(i)  The Company has timely, accurately, and completely reported
all payments and transfers of value made to physicians and teaching
hospitals, as required by the Physician Payment Sunshine Act (42 U.S.C. 
1320a-7h); and the Company is in material compliance with all analogous state
laws requiring the reporting of financial interactions with health care
providers.

  



  

Section 3.25   _Insurance_. _Section 3.25_ of the _Company Disclosure
Letter_ lists all insurance policies maintained by or on behalf of the Company
or any of its Subsidiaries as of the date of this Agreement. The Company and
each of its Subsidiaries have paid, or caused to be paid, all premiums due
under all such insurance policies of the Company and each of its
Subsidiaries, and all such insurance policies are, as of the date of this
Agreement, in full force and effect. As of the date of this Agreement, since
January 1, 2016, none of the Company or any of its Subsidiaries has received
(i) notice that they are in default with respect to any obligations under such
insurance policies or (ii) notice of cancellation or termination with respect
to any such existing insurance policy.

  



  

Section 3.26 _Takeover Statutes_. Assuming the accuracy of the
representations contained in _Section 4.9_ , the Company Board has taken such
actions and votes as are necessary to render the provisions of any "fair
price," "moratorium," "control share acquisition" or any other takeover or
anti-takeover statute or similar federal or state Law (including Section 203
of the DGCL) inapplicable to this Agreement, the Voting and
Support Agreement, the Merger or any other transactions contemplated by this
Agreement.

  



  

Section 3.27 _Brokers_. No investment banker, broker, finder or other
intermediary (other than Citigroup Global Markets Inc., the fees and expenses
of which will be paid by the Company) is entitled to any investment banking,
brokerage, finder's or similar fee or commission in connection with this
Agreement or the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of the Company or any of its Affiliates.
True, correct and complete copies of all agreements between the Company and
Citigroup Global Markets Inc. have been delivered to Parent.

  



  

Section 3.28 _Opinion of Financial Advisors_. The Company Board has
received the opinion of Citigroup Global Markets Inc., as to the fairness of
the Merger Consideration, from a financial point of view, to the holders of
Company Common Stock (other than Parent and Merger Sub or any of their
Affiliates). A true, correct and complete copy of the written opinion
described above has been or will be delivered or made available to Parent
promptly after delivery thereof, it being understood and agreed that such
opinion is for the sole benefit of the Company Board and may not be relied
upon by Parent or Merger Sub.

  



   

46

 



    



  

  

Section 3.29   _No Other Representations or Warranties_. Except for the
representations and warranties expressly made by the Company in this _Article
III_ , neither the Company nor any other Person makes any representations or
warranties on behalf of the Company with respect to the Company or any of its
Subsidiaries. The Company acknowledges and agrees that except for the
representations and warranties expressly set forth in _Article IV_ , (A) none
of Parent, Merger Sub or any of their respective Subsidiaries makes, or has
made, any representations or warranties relating to itself or its business or
otherwise in connection with the Merger and the Company is not relying on any
representation or warranty except for those expressly set forth in _Article
IV_ and (B) no Person other than Parent and Merger Sub has been authorized by
Parent, Merger Sub or any of their respective Subsidiaries, as applicable, to
make any representation or warranty relating to Parent, Merger Sub or any of
their respective Subsidiaries or the business of any of Parent, Merger Sub or
any of their respective Subsidiaries or otherwise in connection with the
Merger, and if made, such representation or warranty must not be relied upon
by the Company as having been authorized by such party.

  



  

ARTICLE IV 
  
 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  



  

Parent and Merger Sub hereby, jointly and severally, represent and warrant to
the Company as follows:

  



  

Section 4.1   _Organization; Qualification_. Each of Parent and
Merger Sub is (a) a corporation duly organized and validly existing under the
laws of the jurisdiction of its respective incorporation and has the
requisite corporate power and authority to conduct its business as it is now
being conducted and to own, lease and operate its properties and assets in
the manner in which its properties and assets are currently operated and (b)
duly qualified or licensed to do business and is in good standing in each
jurisdiction in which the character or location of the property owned, leased
or operated by it or the nature of the business conducted by it makes such
qualification or licensing necessary, except where the failure to be so duly
qualified or licensed and in good standing would not reasonably be expected
to, individually or in the aggregate, impair in any material respect the
ability of Parent or Merger Sub, as the case may be, to perform its
obligations under this Agreement or to consummate the Merger and pay the
Aggregate Merger Consideration and other amounts required to be paid by
Parent and Merger Sub hereunder, or otherwise prevent, materially delay or
materially impair the consummation of the Merger and the other transactions
contemplated by this Agreement (a "Parent Material Adverse Effect").

  



  

Section 4.2   _Authority Relative to Agreement_. Each of Parent
and Merger Sub has all necessary corporate power and authority to execute,
deliver and perform their respective obligations under this Agreement and to
consummate the transactions contemplated by this Agreement. The execution,
delivery and performance of this Agreement by Parent and Merger Sub, and the
consummation by Parent and Merger Sub of the transactions contemplated by this
Agreement, have been duly and validly authorized by all necessary corporate
action by Parent and Merger Sub, and (in the case of the Merger, except for
the filing of the Certificate of Merger with the Delaware Secretary of State),
no other corporate action or proceeding on the part of Parent or Merger Sub
is necessary to authorize the execution, delivery and performance of this
Agreement by Parent and Merger Sub and the consummation by Parent and Merger
Sub of the transactions contemplated by this Agreement. This Agreement
has been duly executed and delivered by Parent and Merger Sub and, assuming
due authorization, execution and delivery of this Agreement by the Company,
constitutes a legal, valid and binding obligation of each of Parent and Merger
Sub, enforceable against each of Parent and Merger Sub in accordance with its
terms, subject to the Enforceability Exceptions.

  



   

47

 



    



  

  

Section 4.3   _No Conflict; Required Filings and Consents_.

  



  

(a)  Neither the execution and delivery of this Agreement by Parent
and Merger Sub nor the consummation by Parent and Merger Sub of the
transactions contemplated by this Agreement, nor compliance by Parent and
Merger Sub with any of the terms or provisions of this Agreement, will (i)
violate any provision of the Parent Organizational Documents, (ii) assuming
that the Consents, registrations, declarations, filings and notices
referenced in _Section 4.3(b)_ have been obtained or made, conflict with or
violate any Law applicable to Parent or Merger Sub or by which any property or
asset of Parent or Merger Sub is bound or affected; or (iii) violate,
conflict with or result in any breach of any provision of, or loss of any
benefit, or constitute a default (with or without notice or lapse of time, or
both) under, give rise to any right of termination, acceleration or
cancellation of or require the Consent of, notice to or filing with any third
Person pursuant to any of the terms or provisions of any material Contract to
which Parent or Merger Sub is a party or by which any property or asset of
Parent or Merger Sub is bound, or result in the creation of a material Lien,
other than any Permitted Lien, upon any of the property or assets of
Parent or Merger Sub, other than, in the case of clauses (ii) and (iii), as
would not reasonably be expected to have, individually or in the aggregate, a
Parent Material Adverse Effect.

  



  

(b)  No Consent of, registration, submission, declaration or filing
with or notice to any Governmental Authority is required to be obtained or
made by or with respect to Parent or Merger Sub in connection with the
execution, delivery and performance of this Agreement or the consummation of
the transactions contemplated by this Agreement, other than (i) the filing and
recordation of the Certificate of Merger with the Delaware Secretary of
State, (ii) such filings and approvals as may be required by any federal or
state securities Laws, including compliance with any applicable requirements
of the Exchange Act, (iii) Consents required under, and compliance with any
applicable requirements of the HSR Act and the Antitrust Laws and rules and
regulations of other applicable Governmental Authorities, and (iv) such other
Consents, registrations, declarations, filings or notices the failure of which
to be obtained or made would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect.

  



  

Section 4.4   _Litigation_. As of the date of this Agreement, (a)
there is no Proceeding pending or, to the knowledge of Parent, threatened
against Parent or any of its Subsidiaries or any asset or property of Parent
or any of its Subsidiaries, and (b) there is no Order outstanding against, or
involving, Parent or any of its Subsidiaries or any asset or property of
Parent or any of its Subsidiaries that, in each case of clauses (a) and (b),
would reasonably be expected to have, individually or in the aggregate, a
Parent Material Adverse Effect.

  



  

   

48

 



    



  

Section 4.5   _Information Supplied_. None of the information
with respect to Parent and its Subsidiaries that is or will be furnished to
the Company by or on behalf of Parent in writing specifically for inclusion
in the Proxy Statement will contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading at the time such Proxy Statement
or any amendment or supplement thereto is first mailed to the stockholders of
the Company and at the time of the Company Stockholders' Meeting.

  



  

Section 4.6   _Brokers_. No investment banker, broker, finder or other
intermediary (except for UBS Europe SE, the fees and expenses of which will be
paid by Parent or its Affiliate) is entitled to any investment banking,
brokerage, finder's or similar fee or commission in connection with this
Agreement or the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of Parent or Merger Sub or any of their
Affiliates.

  



  

Section 4.7   _Sufficient Funds_. Parent or Siemens Healthineers AG
("Siemens Healthineers") has available, and will continue to have available
through and at the Closing, unencumbered cash or cash equivalents, lines of
credit or other sources of immediately available funds that are sufficient to
permit Parent to fund the Aggregate Merger Consideration contemplated by
_Article II_ and any other amounts payable by Parent, Merger Sub, the
Surviving Corporation or any of their respective Subsidiaries in connection
with this Agreement and the transactions contemplated hereby. The obligations
of Parent and Merger Sub hereunder are not subject to any condition regarding
Parent's or Merger Sub's ability to obtain financing for the Merger and the
other transactions contemplated by this Agreement. As of the date of this
Agreement there is no Law, Order or obligation (contractual or otherwise) in
effect which would prevent or materially restrict, delay or otherwise limit
(or would have the effect of preventing or materially restricting, delaying or
otherwise limiting) Parent's ability to fund the Aggregate Merger
Consideration contemplated by Article II and any other amounts payable by
Parent, Merger Sub, the Surviving Corporation or any of their respective
Subsidiaries in connection with this Agreement and the transactions
contemplated hereby.

  



  

Section 4.8   _Merger Sub_. All of the issued and outstanding
capital stock of Merger Sub is, and at the Effective Time will be, owned by
Parent or a wholly owned Subsidiary of Parent. Merger Sub has no outstanding
options, warrants, rights or any other agreements pursuant to which any Person
other than Parent may acquire any Security of Merger Sub. Merger Sub has not
engaged in any business activities or conducted any operations and has no, and
prior to the Effective Time will have no, assets, liabilities or obligations
of any nature other than pursuant to the Merger and the other transactions
contemplated by this Agreement.

  



  

Section 4.9   _No Interested Stockholder_. Neither Parent nor any of
its Subsidiaries nor any "affiliate" or "associate" (as each such term is
defined in Section 203 of the DGCL) of Parent or any of its Subsidiaries, is,
or has been at any time during the period commencing three (3) years prior to
the date hereof through the date hereof, an "interested stockholder" (as such
term is defined in Section 203 of the DGCL) of the Company. None of Parent,
Merger Sub or any of their controlled Affiliates directly or indirectly
beneficially owns any Company Stock or other Securities convertible into,
exchange into or exercisable for shares of Company Stock.

  



  

   

49

 



    



  

Section 4.10   _No Vote of Parent Shareholders_. Except for the
adoption of the Agreement by Parent as the sole shareholder of Merger Sub, no
vote of the shareholders of Parent or the holders of any other securities of
Parent (equity or otherwise), is required by any applicable Law, the Parent
Organizational Documents (or similar organizational documents) or the
applicable rules of any exchange on which securities of Parent are traded, in
order for Parent to consummate the transactions contemplated by this
Agreement.

  



  

Section 4.11   _No Other Representations or Warranties_. Except for the
representations and warranties made by Parent and Merger Sub in this _Article
IV_ , none of Parent, Merger Sub or any other Person makes any
representations or warranties on behalf of Parent or Merger Sub with respect
to Parent or any of its Subsidiaries. Parent and Merger Sub each acknowledges
and agrees that except for the representations and warranties expressly set
forth in _Article III_ , (a) neither the Company nor any of its Subsidiaries
makes, or has made, any representations or warranties relating to itself or
its business or otherwise in connection with the Merger and Parent and Merger
Sub are not relying on any representation or warranty except for those
expressly set forth in _Article III_ ; (b) no Person other than the Company
has been authorized by the Company or any of its Subsidiaries, as applicable,
to make any representation or warranty relating to the Company or any of its
Subsidiaries or the business of the Company or any of its Subsidiaries or
otherwise in connection with the Merger, and if made, such representation or
warranty must not be relied upon by Parent or Merger Sub as having been
authorized by such party; and (c) except to the extent the subject of any
representation or warranty expressly set forth in _Article III_ ,
any estimates, projections, predictions, data, financial information,
memoranda, presentations or any other materials or information provided to
Parent, Merger Sub or any of their representatives whether orally or in
writing are not, and shall not be deemed to be or include, representations or
warranties. Each of Parent and Merger Sub acknowledges and agrees that it (i)
has had an opportunity to discuss the business of the Company and its
Subsidiaries with the management of the Company; (ii) has had reasonable
access to (A) the books and records of the Company and its Subsidiaries and
(B) the electronic dataroom maintained by the Company for purposes of the
transactions contemplated by this Agreement; (iii) has been afforded the
opportunity to ask questions of and receive answers from officers of the
Company; and (iv) has conducted its own independent investigation of the
Company and its Subsidiaries, their respective businesses and the
transactions contemplated by this Agreement, and has not relied on any
representation, warranty or other statement by any Person on behalf of the
Company or any of its Subsidiaries, other than the representations and
warranties of the Company expressly contained in _Article III_ and that all
other representations and warranties are specifically disclaimed.

  



  

   

50

 



    



  

ARTICLE V 
  
 COVENANTS AND AGREEMENTS

  



  

Section 5.1   _Conduct of Business by the Company Pending the Merger_.
The Company covenants and agrees that, between the date of this Agreement and
the earlier of the Effective Time and the date, if any, on which this
Agreement is terminated in accordance with _Section 7.1_ , except (1)
as required by applicable Law, (2) as may be consented to in writing by
Parent ( _provided_ that such consent shall not be unreasonably withheld,
delayed or conditioned), (3) as may be expressly required pursuant to this
Agreement; (4) as required by the terms of any Company Material Contract set
forth on _Section 3.15_ of the _Company Disclosure Letter_ as in effect on
the date of this Agreement or (5) as set forth on _Section 5.1_ of the
_Company Disclosure Letter_ , (x) the Company shall, and shall cause each of
its Subsidiaries to, conduct the business of the Company and its Subsidiaries
in all material respects in the ordinary course of business and in a manner
consistent with past practice and, to the extent consistent therewith, use
commercially reasonable efforts to preserve its assets and business
organization intact in all material respects and maintain its existing
business relations and goodwill with customers, suppliers,
licensors, distributors, Governmental Authorities, employees and business
partners, in each case whose business relationships are material to the
Company and its Subsidiaries, taken as a whole (provided that, with respect to
clause (x), no action or failure to take action with respect to matters
specifically addressed by any of the provisions of clause (y) shall
constitute a breach of clause (x) unless such action or failure to take
action would constitute a breach of such applicable provision of clause (y)),
and (y) without limiting the generality of clause (x), the Company shall not,
and shall cause each of its Subsidiaries not to, directly or indirectly:

  



  

(a)  amend the Certificate of Incorporation or the Bylaws (or such
similar organizational or governing documents of any Subsidiary of the
Company);

  



  

(b)  adjust, split, reverse split, combine, subdivide, reclassify,
redeem, purchase, repurchase or otherwise acquire, directly or indirectly, or
amend the terms of, the Company's or any of its Subsidiaries' Securities,
including any options, equity or equity-based compensation, warrants,
convertible Securities or other rights of any kind to acquire any of
such Securities, except as may be required pursuant to the terms of Company
Preferred Stock or Company Warrants, as permitted by _Section 5.1(c)_ or
_Section 5.1(d)_ , or for any acquisitions or deemed acquisitions of any
equity Securities of the Company in connection with the forfeiture of, or the
withholding of Taxes in connection with the exercise, vesting or settlement
of, any Company Equity Award or Company Warrant;

  



  

(c)  issue, sell, pledge, modify, transfer, dispose of, encumber or
grant, or authorize the same with respect to, directly or indirectly, any of
the Company's or any of its Subsidiaries' Securities, including any options,
equity or equity-based compensation, warrants, convertible Securities or
other rights of any kind to acquire such Securities; _provided_ , _however_
, that the Company may issue shares of Company Common Stock (i) upon the
exercise of Company Options or vesting of Company RSU Awards outstanding as
of the date of this Agreement (or permitted to be granted pursuant to this
Agreement after the date hereof as set forth on _Section 5.1(c)_ of the
_Company Disclosure Letter_ ) in accordance with the respective terms of such
Company Options or Company RSU Awards, (ii) upon the conversion of Company
Preferred Stock in accordance with the terms of the Company Certificate of
Designation, and (iii) upon the exercise of Company Warrants outstanding as of
the date of this Agreement in accordance with their respective terms;

  



   

51

 



    



  

  

(d)  except (i) for cash dividends by direct or indirect wholly
owned Subsidiaries of the Company to its respective parent and (ii) ordinary
course accretion with respect to the Company Preferred Stock in accordance
with the Certificate of Designation, declare, set aside, authorize, make or
pay any dividend or other distribution payable in cash, stock, property or
otherwise with respect to the Company's or any of its Subsidiaries'
Securities;

  



  

(e)  except as required by the terms of a Benefit Plan in existence
as of the date of this Agreement, (i) establish, adopt, enter into,
materially amend or terminate any Benefit Plan, or any plan, program, policy,
practice, agreement or other arrangement that would be a Benefit Plan if it
had been in existence on the date of this Agreement (other than as expressly
permitted by _Section 5.1(e)(iv)_ ); (ii) grant or pay, or commit to grant or
pay, any bonus, incentive or profit-sharing award or payment, or increase the
base salary or cash bonus opportunity to any director, officer, employee, or
consultant of the Company or any Subsidiary, except in the case of increases
in annual base salaries for employees below the rank or title of vice
president, at times and in dollar amounts in the ordinary course of business
in connection with the Company's annual salary review process consistent
with past practice; (iii) accelerate or take any action to accelerate any
payment or benefit, or the funding of any payment or benefit, payable or to
become payable to any current or former director, officer, employee, or
consultant of the Company or any Subsidiary; (iv) enter into, extend, amend
or modify, or terminate any employment, severance, termination, change in
control, retention, individual consulting or other similar agreement with any
current or former director, officer, employee, or consultant of, or individual
service provider to, the Company or any of its Subsidiaries (other than offer
letters that provide for at-will employment without any severance, retention
or change in control benefits for newly hired employees or individual service
providers who are hired in the ordinary course of business and consistent
with past practice and whose annual base compensation does not exceed $200,000
individually (or $250,000 individually, in the case of sales
representatives)); (v) communicate with the employees of the Company or any of
its Subsidiaries regarding the compensation or benefits they will receive
following the Effective Time, unless such communication is (A) approved by
Parent in advance of such communication or (B) required by applicable Law; or
(vi) except as may be required by GAAP, materially change any actuarial or
other assumptions used to calculate funding obligations with respect to any
Benefit Plan or materially change the manner in which contributions to such
plans are made or the basis on which such contributions are determined;

  



  

(f)  hire, promote or terminate the employment of (other than for
cause, death or disability) any employee with annual base compensation above
$200,000 (or $250,000, in the case of sales representatives);

  



  

(g)  take any action requiring notice to employees, or triggering
any other obligations, under the WARN Act or any similar state, local or
foreign Law prior to the Closing;

  



  

(h)  waive, release or limit any restrictive covenant of any current
or former employee or independent contractor of the Company or any
Subsidiary;

  



   

52

 



    



  

  

(i)  make any loan or advance to (other than travel and similar
advances to its employees in the ordinary course of business and consistent
with past practice), or capital contribution to, or investment (other than
purchases of inventory or supplies in the ordinary course of business
consistent with past practice or capital expenditures permitted pursuant to
_Section 5.1(r)_ ) in, any Person (other than direct or indirect wholly owned
Subsidiaries of the Company) in excess of $200,000 in the aggregate;

  



  

(j)  forgive any loans or advances to any officers, employees or
directors of the Company or its Subsidiaries, or any of their respective
Affiliates, or change its existing borrowing or lending arrangements for or on
behalf of any of such Persons pursuant to an employee benefit plan or
otherwise, except in the ordinary course of business in connection with
relocation activities to any employees of the Company or its Subsidiaries;

  



  

(k)  acquire (including by merger, consolidation, acquisition of
stock or assets or otherwise) any corporation, partnership, limited liability
company, joint venture, other business organization, any division of any of
the foregoing, any equity interest in any of the foregoing, or all or any
material portion of the assets, business or properties of any Person
(excluding ordinary course purchases consistent with past practice of
inventory, surgical instruments, and supplies);

  



  

(l)  (i) sell, pledge, dispose of, transfer, abandon, lease (as
lessor), license (except in accordance with _Section 5.1(o)_ ), mortgage,
incur any Lien (other than Permitted Liens) (including pursuant to a sale-
leaseback transaction or an asset securitization transaction) on or otherwise
transfer or encumber any portion of the tangible or intangible (other than
Intellectual Property, which is addressed in _Section 5.2(u)_ ) on material
assets, business, or real property of the Company or any of its Subsidiaries
except (A) in connection with services provided in the ordinary course of
business and consistent with past practice, (B) sales of product inventory in
the ordinary course of business and consistent with past practice, (C) for
sales of obsolete assets, (D) for transactions solely among the Company and
one or more of its direct or indirect wholly owned Subsidiaries or
solely among such Subsidiaries of the Company, (E) for sales, leases or other
dispositions of assets with a fair market value in an mount not to exceed
$100,000 in the aggregate, or (ii) enter into any new line of business that is
material to the business of the Company and its Subsidiaries, taken as a
whole;

  



  

(m)  (i) except as expressly required pursuant to the terms thereof,
pay, discharge or satisfy any Indebtedness that has a prepayment cost, "make
whole" amount, prepayment penalty or similar obligation (other than
Indebtedness incurred by the Company or its wholly owned Subsidiaries and
solely owed to the Company or its wholly owned Subsidiaries) or (ii)
cancel any material Indebtedness (individually or in the aggregate) or
settle, waive or amend any material claims or rights of substantial value;

  



  

(n)  (i) incur, create, assume or otherwise become liable or
responsible for any Indebtedness other than Indebtedness incurred by the
Company or its direct or indirect wholly owned Subsidiaries in the ordinary
course of business consistent with past practice or (ii) issue or sell any
debt securities of the Company or any of its Subsidiaries, including options,
warrants, calls or similar rights, in each case, to acquire any debt
securities of the Company or any of its Subsidiaries;

  



  

   

53

 



    



  

(o)  negotiate, amend, extend, renew (except, with respect to
software license and product development Contracts, pursuant to the renewal
provisions thereof) terminate or enter into, or agree to any material
amendment or material modification of, or waive, release or assign any
material rights under, any Company Material Contract, any Contract with a
Material Supplier, or any material Lease for any Company Leased Property, or
any Contract that would have been a Company Material Contract or a
material Lease had it been entered into prior to the date of this Agreement;
_provided_ , _however_ , that the foregoing exception shall not apply to any
Contract that requires or provides for consent, acceleration, termination or
any other material right or consequence triggered in whole or in part by the
Merger or any of the other transactions contemplated by this Agreement;

  



  

(p)  negotiate, amend, modify, enter into or terminate any Labor
Agreement, except as required pursuant to an applicable Contract in effect as
of the date of this Agreement;

  



  

(q)  make any material change to its or any of its Subsidiaries'
methods, policies and procedures of accounting, except as required by GAAP or
Regulation S-X of the Exchange Act or other applicable Law;

  



  

(r)  except (i) as set forth in the Company's existing capital
budget; or (ii) as relates to the purchase of inventory or surgical
instruments in the ordinary course of business, make or authorize any capital
expenditure exceeding $500,000 in the aggregate;

  



  

(s)  agree to release, compromise, assign, settle, or resolve any
threatened or pending Proceeding, other than settlements that result solely
in monetary obligations involving payment (without the admission of
wrongdoing) by the Company or any of its Subsidiaries of an amount not
greater than $250,000 (net of insurance proceeds) in the aggregate;

  



  

(t)  fail to use commercially reasonable efforts to maintain in
effect material insurance policies covering the Company and its Subsidiaries
and their respective properties, assets and businesses;

  



  

(u)  (i) sell, transfer, assign, lease, license or otherwise dispose
of (whether by merger, stock or asset sale or otherwise) to any Person any
rights to any Company Intellectual Property material to the Company and its
Subsidiaries, taken as a whole (except for licensing non-exclusive rights for
the primary purpose of (A) conducting clinical research, entered into with a
clinical research organization; (B) material transfer, sponsored research or
other similar matters; (C) establishing confidentiality or non-
disclosure obligations; (D) conducting clinical trials; or (E) manufacturing,
labeling or selling the Company's or any of its Subsidiaries' products or
services); (ii) fail to use all reasonable efforts not to cancel, dedicate to
the public, disclaim, forfeit, reissue, reexamine or abandon without filing a
substantially identical counterpart in the same jurisdiction with the same
priority or allow to lapse (except with respect to Patents expiring in
accordance with their terms) any Company Intellectual Property material
to the Company and its Subsidiaries, taken as a whole; (iii) fail to use all
reasonable efforts to make any filing, pay any fee, or take any other action
necessary to prosecute and maintain in full force and effect any Company
Registered IP including allowing any such patent families with pending
applications to close by not filing a continuing application; (iv) make any
change in Company Intellectual Property that is or would reasonably be
expected to materially impair the Company's or any of its
Subsidiaries' rights with respect to the Company Intellectual Property; (v)
disclose to any Person (other than Representatives of Parent and Merger Sub),
any Trade Secrets, know-how or confidential or proprietary information,
except, in the case of confidential or proprietary information, in the
ordinary course of business to a Person that is subject to confidentiality
obligations; or (vi) fail to take or maintain reasonable measures to protect
the confidentiality and value of material Trade Secrets included in the
Company Owned IP;

  



  

  

   

54

 



    



  

(v)  except as required by applicable Law, (i) make or change any
material Tax election or adopt or change any material method of Tax
accounting; (ii) file any material amended Tax Return; (iii) settle or
compromise any audit, assessment or other Proceeding relating to Taxes; (iv)
agree to an extension or waiver of the statute of limitations with respect to
Taxes; (v) enter into any "closing agreement" within the meaning of Section
7121 of the Code (or any similar provision of state, local or non-U.S. Law);
or (vi) surrender any right to claim a Tax refund;

  



  

(w)  merge or consolidate the Company or any of its Subsidiaries with
any Person or adopt a plan of complete or partial liquidation, dissolution,
restructuring, recapitalization or other reorganization of the Company or any
of its Subsidiaries;

  



  

(x)  enter into or adopt any stockholder rights plans (or similar
plans commonly referred to as a "poison pill") under which the Company is or
may become obligated to sell or otherwise issue any shares of its capital
stock or any other Securities; or

  



  

(y)  enter into any agreement, contract, commitment or arrangement
to do, or adopt any resolutions approving or authorizing, or publicly
announce an intention to do, any of the foregoing.

  



  

Nothing contained herein shall give Parent, Merger Sub or any of their
respective Affiliates, directly or indirectly, the right to control or direct
the Company's or its Subsidiaries' operations prior to the Effective Time,
and nothing contained herein shall give the Company, directly or indirectly,
the right to control or direct Parent's or its Subsidiaries' operations prior
to the Effective Time. Prior to the Effective Time, each of the Company and
Parent shall exercise, subject to the terms and conditions of this Agreement,
complete control and supervision over its and its Subsidiaries' respective
operations.

  



  

Section 5.2   _Proxy Statement; Company Stockholders ' Meeting_.

  



  

(a)  The Company shall use reasonable efforts to prepare and file
the preliminary Proxy Statement with the SEC as soon as reasonably
practicable (and in any event will file the preliminary Proxy Statement within
twenty (20) Business Days after the date hereof). The Company shall use its
reasonable efforts to respond to any comments of the SEC or its staff, to
clear the preliminary Proxy Statement with the SEC as promptly as reasonably
practicable after filing and to cause the Proxy Statement to be mailed to the
Company's stockholders as promptly as reasonably practicable after the date of
this Agreement. The Company will advise Parent promptly after receipt of any
request by the SEC or its staff for amendments or supplements to the Proxy
Statement or comments thereon and responses thereto or requests by the SEC or
its staff for additional information. The Company will promptly
provide Parent with copies of all written correspondence between the Company
(or its Representatives) and the SEC (or its staff) regarding the Proxy
Statement or the Merger. If at any time prior to the Company Stockholders'
Meeting there shall occur any event that is required to be set forth in an
amendment or supplement to the Proxy Statement, the Company shall as promptly
as reasonably practicable prepare and mail to its stockholders such an
amendment or supplement. Notwithstanding anything to the contrary in this 
_Section 5.2_ , prior to filing or mailing the Proxy Statement (or any
amendment or supplement thereto) or responding to any comments of the SEC (or
its staff) with respect thereto, the Company shall provide Parent an
opportunity to review and comment on such document or response (and the
Company shall consider in good faith any comments on such document(s) or
response reasonably proposed by Parent or its Representatives).

  



  

  

   

55

 



    



  

(b)  Each of Parent and Merger Sub shall promptly furnish the
Company with all information reasonably requested by the Company and required
pursuant to the Exchange Act and the rules and regulations promulgated
thereunder to be set forth in the Proxy Statement about Siemens Healthineers,
Parent and Merger Sub.

  



  

(c)  Each of the Company, Parent and Merger Sub agrees to promptly
(i) correct any information provided by it specifically for use in the Proxy
Statement if and to the extent that such information will have become false or
misleading in any material respect and (ii) supplement the information
provided by it specifically for use in the Proxy Statement to include any
information that will become necessary in order to make the statements in the
Proxy Statement, in light of the circumstances under which they were made,
not misleading. The Company further agrees to cause the Proxy Statement as so
corrected or supplemented promptly to be filed with the SEC and to be
disseminated to the holders of Company Common Stock, in each case as and to
the extent required by applicable Law.

  



  

(d)  Subject to the Company Board not having effected a Company
Adverse Recommendation Change pursuant to _Section 5.5_  or the earlier
termination of this Agreement in accordance with _Section 7.1_ , the Company
(i) shall duly call, give notice of, convene and hold, as promptly as
practicable after the SEC clearance of the Proxy Statement, a special meeting
of the Company's stockholders (including any adjournment or postponement
thereof, the "Company Stockholders' Meeting"), in accordance with applicable
Law, its constituent documents and the rules of the NYSE American, for the
purpose of considering and voting on the adoption of this Agreement, the
Merger and other transactions contemplated by this Agreement and shall
submit such proposal to such holders at the Company Stockholders' Meeting,
(ii) except for a proposal to adjourn the Company Stockholders' Meeting if
there are insufficient affirmative votes represented at the Company
Stockholders' Meeting to obtain the Company Stockholder Approval, shall not
submit any other proposal to such holders in connection with the Company
Stockholders' Meeting without the prior written consent of Parent (which
consent shall not be unreasonably conditioned, withheld or delayed), and
(iii) shall not adjourn or otherwise postpone or delay the Company
Stockholders' Meeting without the prior written consent of Parent; 
_provided_ , _however_ , that the Company may, without the prior written
consent of Parent, adjourn or postpone the Company Stockholders' Meeting (A)
to the extent necessary to ensure that any required supplement or amendment to
the Proxy Statement is provided to the stockholders of the Company,
_provided_ , that the Company has reasonably consulted with Parent prior
to such adjournment or postponement, (B) if as of the time for which the
Company Stockholders' Meeting is originally scheduled (as set forth in the
Proxy Statement) there are insufficient shares of Company Stock represented
(either in person or by proxy) to constitute a quorum necessary to conduct
the business of the Company Stockholders' Meeting, or (C) in order to
solicit additional proxies if necessary to obtain the Company Stockholder
Approval. Subject to the Company Board not having effected a Company Adverse
Recommendation Change pursuant to _Section 5.5_ , the Company shall, through
the Company Board, make the Company Recommendation, and shall include such
Company Recommendation in the Proxy Statement, and use its reasonable efforts
to solicit from its stockholders proxies in favor of the adoption of this
Agreement.

  



  

   

56

 



    



  

(e)  Immediately following the execution of this Agreement, Parent
shall execute and deliver, in accordance with Section 228 of the DGCL and in
its capacity as the sole direct or indirect stockholder of Merger Sub, a
written consent evidencing the approval and adoption of the Merger, this
Agreement and the other transactions contemplated hereby.

  



  

Section 5.3   _Appropriate Action; Consents; Filings_.

  



  

(a)  Subject to the terms and conditions of this Agreement, the
parties hereto will use their respective reasonable best efforts to
consummate and make effective the transactions contemplated by this Agreement
and to cause the conditions to the Merger set forth in _Article VI_ to be
satisfied, including using reasonable best efforts to accomplish the
following: (i) the obtaining of all necessary actions or non-actions,
consents and approvals from Governmental Authorities or other Persons
necessary in connection with the consummation of the transactions
contemplated by this Agreement, including the Merger, and (ii) the making of
all necessary registrations and filings (including filings with Governmental
Authorities, if any) and the taking of all reasonable steps as may be
necessary to obtain approval from, or to avoid a Proceeding by, any
Governmental Authority or other Persons necessary in connection with the
consummation of the transactions contemplated by this Agreement, including the
Merger. Each of the parties hereto shall as promptly as reasonably
practicable after the date of this Agreement, upon a date to be mutually
agreed upon by the parties hereto, make its respective filings under the HSR
Act. Each of the parties hereto shall as promptly as reasonably practicable
after the date of this Agreement, upon a date to be mutually agreed upon by
the parties hereto, make any other applications and filings as reasonably
determined by the Company and Parent under other applicable Antitrust Laws
with respect to the transactions contemplated by this Agreement as promptly
as reasonably practicable, but in no event later than as required by Law.
Notwithstanding anything to the contrary contained in this Agreement, neither
Parent nor the Company or any of their respective Affiliates shall be
required to, and without the prior written consent of Parent, none of the
Company or any of its Subsidiaries or Affiliates will, grant or offer to
grant any accommodation or concession (financial or otherwise), or make any
payment, to any third Person in connection with seeking or obtaining its
consent to the transactions contemplated by this Agreement (it being
understood that this sentence does not apply to the actions required by
_Section 5.3(d))_.

  



  

   

57

 



    



  

(b)  In connection with and without limiting the efforts referenced
in this _Section 5.3_ , each of the parties hereto will furnish to the other
such necessary information and reasonable assistance as the other may
reasonably request in connection with the preparation of any required
governmental filings or submissions and will cooperate in responding to any
investigation or other inquiry from a Governmental Authority or in connection
with any Proceeding initiated by a private party, in each case, under any
applicable Antitrust Laws, including (i) promptly informing the other party of
such inquiry or Proceeding, (ii) consulting in advance before making any
presentations or submissions to a Governmental Authority, or in connection
with any such Proceeding, to any other Person, and supplying each other with
copies of all material correspondence, filings or communications between
either party and any Governmental Authority, or in connection with any such
Proceeding, between either party and any other Person with respect to this
Agreement and (iii) providing the other party with a reasonable advance
opportunity to review and comment upon and consider in good faith the views
of the other party in connection with all written communications (including
any analyses, presentations, memoranda, briefs, arguments, opinions and
proposals) between either party and any Governmental Authority, or
in connection with any such Proceeding, between either party and any other
Person with respect to this Agreement; _provided_  that materials required to
be provided by one party to another pursuant to this _Section 5.3(b)_ may be
redacted (A) to remove references concerning the valuation of the Company,
(B) as necessary to comply with contractual arrangements, and (C) as
necessary to address reasonable attorney-client or other privilege or
confidentiality concerns or may be provided on an outside counsel basis, if
reasonably appropriate. In addition, each of the parties hereto will give
reasonable notice to and consult with the other party in advance of any
meeting or substantive telephone call or conference with any Governmental
Authority, or in connection with any such Proceeding, with any other Person,
and to the extent permitted by the Governmental Authority, give the other
party the opportunity to attend and participate in such meeting, telephone
call or conference.

  



  

(c)  The parties shall consult with each other with respect to
obtaining all permits and Consents necessary to consummate the transactions
contemplated by this Agreement, including the Merger.

  



  

(d)  Notwithstanding anything in this Agreement to the contrary,
none of Parent or any of its Affiliates shall be required to enter into one
or more agreements prior to the Closing with respect to any transaction to
divest, hold separate or otherwise take any action that limits the Parent's
or any of its Affiliates' (including, following the Closing, the Company's or
any of its Subsidiaries') freedom of action, ownership or control with respect
to, or their ability to retain or hold, directly or indirectly, any of their
respective businesses, assets, equity interests, product lines or properties
(each, a "Divestiture Action") or take any Divestiture Action or otherwise
agree to or proffer to sell, divest, hold separate, lease, license, transfer,
dispose of or otherwise encumber or impair or take any other action with
respect to Parent's or any of its Affiliates' ability to own or operate any
assets, properties, businesses or product lines of Parent or any of its
Affiliates (including, following the Closing, any assets, properties,
businesses or product lines of the Company or its Subsidiaries); and none of
Parent or any of its Affiliates shall be required to take any action
contemplated in this _Section 5.3(d)_ in connection with any Proceeding by a
Person other than a Governmental Authority, and the Company shall not, and
shall not cause or permit any of its Subsidiaries to, unless requested to do
so by Parent, commit to or effect any action contemplated in this _Section
5.3(d)_.

  



  

   

58

 



    



  

Section 5.4   _Access to Information; Confidentiality_. From the date
of this Agreement until the earlier of the Effective Time and the date, if
any, on which this Agreement is terminated in accordance with _Section 7.1_ ,
the Company shall, and shall cause each of its Subsidiaries to, afford to
Parent and Merger Sub, and their respective Representatives, reasonable
access, to be coordinated through the Company or its designated
Representatives in accordance with such reasonable procedures as they may
establish, during normal business hours and upon reasonable notice, to all of
the officers, employees, agents, properties, books, contracts and records of
the Company and its Subsidiaries, and during such period, the Company shall,
and shall cause each of its Subsidiaries to, furnish reasonably promptly all
other information concerning the business, properties and personnel of the
Company and its Subsidiaries as Parent or Merger Sub may reasonably request;
_provided_ , _that_ , notwithstanding the foregoing, the Company may restrict
or prohibit such access to the extent that (a) any applicable Law requires
the Company or its Subsidiaries to restrict or prohibit such access; (b)
granting such access would violate any Contract or material obligation of the
Company or any of its Subsidiaries with a third Person with respect to
confidentiality or otherwise breach, contravene or violate, constitute a
default under, or give a third Person the right to terminate or accelerate any
obligations under, any then-effective Contract to which the Company or any of
its Subsidiaries is a party or would disclose any information that is
competitively sensitive; or (c) granting access to such documents or
information would reasonably be expected to result in a waiver of any
attorney-client privilege, work product doctrine or other applicable privilege
in respect of such documents or information, _provided_ , _however_ , that
the Company shall use good faith efforts to communicate the applicable
information to Parent in a manner that would not violate applicable Law,
Contract or material obligation or waive such privilege or work-
product doctrine. Prior to the Effective Time, Parent and Merger Sub will
hold any information obtained pursuant to this _Section 5.4_  in accordance
with the terms of the Confidentiality Agreement. No investigation pursuant to
this _Section 5.4_ shall affect or be deemed to modify any representation or
warranty made by the Company hereunder. Notwithstanding anything contained
herein to the contrary, the Company and its Subsidiaries shall not be
required to provide any access or make any disclosure to Parent pursuant to
this _Section 5.4_ to the extent such access or information is reasonably
pertinent to a litigation where the Company or any of its Affiliates, on the
one hand, and Parent or any of its Affiliates, on the other hand, are adverse
parties.

  



  

Section 5.5   _No Solicitation_.

  



  

(a)  From the date of this Agreement until the earlier of the
Effective Time and the date, if any, on which this Agreement is terminated in
accordance with _Section 7.1_ , except as expressly provided in _Section
5.5(b)_ or _Section 5.5(d)_ , (i) the Company shall immediately cease and
cause to be terminated, and shall cause its Subsidiaries and instruct its and
its Subsidiaries' Representatives to immediately cease and cause to be
terminated, all existing activities, discussions, negotiations and
communications, if any, with any Persons (or any of their Representatives)
with respect to any Company Acquisition Proposal (other than Parent or any of
its Affiliates or Representatives with respect to the transactions
contemplated by this Agreement); and (ii) the Company shall not, and shall
not permit its Subsidiaries and its and its Subsidiaries' Representatives to,
directly or indirectly, (A) initiate, seek, solicit, facilitate or knowingly
encourage, or knowingly induce the making, submission or announcement of, any
Company Acquisition Proposal, (B) enter into, continue or otherwise
participate in any negotiations or discussions with, or furnish or cause to
be furnished any non-public information or data to, or furnish access to the
Company's (or any of its Subsidiaries') properties with respect to, any
Person (other than Parent or any of its Affiliates or Representatives)
relating to any Company Acquisition Proposal or any inquiry, proposal or
offer that would reasonably be expected to lead to any Company Acquisition
Proposal (other than informing any Persons of the provisions of this _Section
5.5_ ), or grant any waiver or release under (or terminate, amend or modify
any provision of) any confidentiality agreement to which the Company is a
party except to the extent to allow an applicable party to make a Company
Acquisition Proposal in compliance with _Section 5.5(b)_ , (C) execute or
enter into any binding or non-binding letter of intent, agreement in
principle, memorandum of understanding, merger agreement, acquisition
agreement, option agreement, joint venture agreement, partnership agreement or
other agreement, commitment, arrangement or understanding relating to or in
connection with, or that is intended to lead to, any Company Acquisition
Proposal (each, an "Alternative Acquisition Agreement"), (D) submit to the
stockholders of the Company for their approval any Company Acquisition
Proposal or Company Superior Proposal, or (E) resolve to do, or agree or
publicly announce an intention to do, any of the foregoing.

  



  

   

59

 



    



  

(b)  Notwithstanding anything to the contrary contained in _Section
5.5(a)_ , at any time prior to obtaining the Company Stockholder Approval, if
the Company or any of its Subsidiaries receives, after the date hereof, a bona
fide written Company Acquisition Proposal from a third Person that did not
result from a breach of this _Section 5.5_ , then the Company may contact such
third Person to clarify the terms and conditions thereof and (i) furnish
information concerning its business, properties or assets to such Person
pursuant to an Acceptable Confidentiality Agreement (a copy of which shall be
provided to Parent within forty-eight (48) hours after execution) and (ii)
negotiate and participate in discussions and negotiations with such Person
concerning such Company Acquisition Proposal, in each case of clause (i) and
(ii), if the Company Board (or a duly authorized committee
thereof) determines in good faith (after consultation with the Company's
financial advisors and outside legal counsel) that (A) such Company
Acquisition Proposal constitutes or could reasonably be expected to lead to or
result in a Company Superior Proposal and (B) the failure to take such action
would reasonably be expected to be inconsistent with the Company Board's
fiduciary duties under applicable Law. The Company (1) shall promptly (and in
any case within forty-eight (48) hours) provide Parent notice (x) of the
receipt of any Company Acquisition Proposal, which notice shall include, if
applicable, a complete, unredacted copy of such Company Acquisition Proposal,
and (y) of any inquiries, proposals or offers received by the Company, any of
its Subsidiaries or any of its or its Subsidiaries' Representatives
concerning a Company Acquisition Proposal or proposal that is
reasonably likely to constitute or lead to or result in a Company Acquisition
Proposal, and disclose the identity of the other party (or parties) and, if
applicable, the material terms (including any amendments thereto) of such
inquiry, offer or proposal (2) shall promptly (and in any case within forty-
eight (48) hours) make available to Parent all information, including copies
of all written materials, provided by the Company or any of its Subsidiaries
or its or its Subsidiaries' Representatives to such party but not
previously made available to Parent and (3) shall keep Parent reasonably
informed on a reasonably prompt basis (and, in any case, within forty-
eight (48) hours) of any significant development, discussions or negotiations
(including amendments and proposed amendments) relating to any such Company
Acquisition Proposal or any material change to the financial or other material
terms of any such Company Acquisition Proposal or such other inquiry, offer
or proposal (including by providing copies of all required proposals related
thereto that have not already been provided pursuant to clauses (1)(x) or (y)
above, respectively).

  



  

   

60

 



    



  

  

(c)  Except as expressly permitted by _Section 5.5(d)_ or _Section
5.5(e)_ , neither the Company Board nor any committee thereof shall (i)
withdraw, qualify or modify in a manner adverse to Parent, or publicly propose
to withdraw, qualify or modify in a manner adverse to Parent, the Company
Recommendation, (ii) approve, authorize, declare advisable, endorse or
recommend (or publicly propose to approve, authorize, declare advisable,
endorse or recommend) any Company Acquisition Proposal, (iii) fail to include
in the Proxy Statement the Company Recommendation, (iv) fail to recommend
against any Company Acquisition Proposal that is a tender or exchange offer
subject to Regulation 14D under the Exchange Act in a
Solicitation/Recommendation Statement on Schedule 14D-9 within ten (10)
Business Days after the commencement (within the meaning of Rule 14d-2 under
the Exchange Act) of such tender or exchange offer (any action described in
clauses (i) through (iv) of this sentence being referred to as a "Company
Adverse Recommendation Change"), or (v) adopt or approve, or propose to adopt
or approve, or allow the Company or any of its Subsidiaries to execute or
enter into, any Alternative Acquisition Agreement (other than an Acceptable
Confidentiality Agreement permitted under _Section 5.5(b)_ ).

  



  

(d)  Notwithstanding anything in this Agreement to the contrary, if
at any time prior to the receipt of the Company Stockholder Approval, the
Company or the Company Board receives a Company Superior Proposal, the Company
Board may authorize and cause the Company to (i) effect a Company Adverse
Recommendation Change and/or (ii) terminate this Agreement pursuant to
_Section 7.1(c)(ii)_ and concurrently with such termination enter into a
definitive agreement providing for such Company Superior Proposal (subject to
the satisfaction of its obligations under _Section 7.3_ ) if (A) the Company
Board determines in good faith, after consultation with the Company's outside
legal counsel, that the failure to take such action would reasonably be
expected to be inconsistent with the Company Board's fiduciary duties under
applicable Law; (B) the Company has notified Parent in writing that it
intends to take such action; (C) the Company has provided Parent a copy of the
proposed definitive agreements (and any related agreements) relating to such
Company Superior Proposal (and has informed Parent of the identity of the
Person making such Company Superior Proposal); and (D) if prior to 11:59
p.m., New York City time, on the second (2nd) Business Day following the
notice delivered pursuant to clause (B) of this _Section 5.5(d)_ , the Company
and its Representatives shall have received a written proposal made by Parent
to amend this Agreement or enter into an alternative transaction with the
Company, the Company Board shall have determined in good faith (after
consultation with the Company's financial advisor and outside legal counsel),
after considering and taking into account the terms of any proposed amendment
or modification to this Agreement or a possible alternative transaction made
by Parent in writing solely during such period, that (1) the Company
Acquisition Proposal that is the subject of the notice described in clause
(B) of this _Section 5.5(d)_ still constitutes a Company Superior
Proposal and (2) the failure to take such action would reasonably be expected
to be inconsistent with the Company Board's fiduciary duties under applicable
Law.

  



  

(e)  Notwithstanding anything in this Agreement to the contrary,
other than in connection with a Company Superior Proposal (which shall be
subject to _Section 5.5(d)_ and shall not be subject to this _Section 5.5(e)_
), prior to obtaining the Company Stockholder Approval, the Company Board
may, in response to a Company Intervening Event, effect a Company Adverse
Recommendation Change if (i) the Company Board determines in good faith,
after consultation with the Company's outside legal counsel, that the failure
to take such action would reasonably be expected to be inconsistent with the
Company Board's fiduciary duties under applicable Law; and (ii) the Company
has notified Parent in writing that it intends to effect such Company Adverse
Recommendation Change pursuant to this _Section 5.5(e)_ (which notice shall
reasonably specify the facts and circumstances providing the basis of the
Company Intervening Event and for the Company Board's determination to effect
the Company Adverse Recommendation Change).

  



   

61

 



    

  



  

(f)  Nothing contained in this Agreement shall prohibit the Company
or the Company Board from (i) taking and disclosing to its stockholders a
position contemplated by Rules 14d-9 and 14e-2(a) promulgated under the
Exchange Act, or from issuing a "stop, look and listen" statement pending
disclosure of its position thereunder or (ii) making any disclosure to its
stockholders if the Company Board determines in good faith, after
consultation with the Company's outside legal counsel, that the failure of
the Company Board to make such disclosure would reasonably be expected to be
inconsistent with the Company Board's fiduciary duties under applicable Law;
_provided_ , _however_ , that (A) in no event shall this _Section 5.5(f)_
permit the Company or the Company Board to make a Company Adverse
Recommendation Change except as otherwise permitted pursuant to
_Section 5.5(d)_ or _Section 5.5(e)_ , (B) in no event shall this _Section
5.5(f)_ affect, modify or supplement the definition of Company Adverse
Recommendation Change herein (or to the consequences thereof in accordance
with this Agreement) and (C) any such disclosure (other than issuance by the
Company of a "stop, look and listen" communication of the type
contemplated by Rule 14d-9(f) under the Exchange Act) that addresses or
relates to the approval, recommendation or declaration of advisability by the
Company Board with respect to this Agreement or a Company Acquisition Proposal
shall be deemed to be a Company Adverse Recommendation Change unless the
Company Board in connection with such communication publicly states that its
recommendation with respect to this Agreement has not changed or refers to
the prior recommendation of the Company Board, without disclosing any Company
Adverse Recommendation Change; _provided further_ that any factually accurate
public statement that describes the Company's receipt of a
Company Acquisition Proposal and the operation of this Agreement with respect
thereto shall not be deemed to be a Company Adverse Recommendation Change.
The Company shall provide Parent with a copy of the text of any disclosure
proposed to be made pursuant to this _Section 5.5(f)_ reasonably in advance
of such disclosure.

  



  

Section 5.6   _Directors ' and Officers' Indemnification and
Insurance_.

  



  

(a)  From and after the Effective Time through the sixth (6th)
anniversary of the date on which the Effective Time occurs, Parent and the
Surviving Corporation will jointly and severally indemnify and hold harmless
each director and officer of the Company at or prior to the Effective Time
(the "DandO Indemnified Parties") with respect to all claims, liabilities,
losses, damages, judgments, fines, penalties, costs (including amounts paid in
settlement or compromise) and expenses (including fees and expenses of legal
counsel) in connection with any Proceeding, whenever asserted, based on or
arising out of, in whole or in part, (i) the fact that a DandO Indemnified Party
was a director, officer, employee or agent of the Company or any of its
Subsidiaries, or (ii) acts or omissions by such DandO Indemnified Party in the
DandO Indemnified Party's capacity as a director, officer, employee or agent of
the Company or a Subsidiary of the Company or taken at the request of the
Company or a Subsidiary of the Company (including in connection with serving
at the request of the Company or such Subsidiary as a director, officer,
employee agent, trustee or fiduciary of another Person), in each case under
(i) or (ii), at, or at any time before, the Effective Time (including any
Proceeding relating in whole or in part to the Merger or the enforcement of
this provision or any other indemnification or advancement right of any DandO
Indemnified Party), to the fullest extent permitted or required by applicable
Law. For the avoidance of doubt, in no event will Parent have any obligations
or liabilities to DandO Indemnified Parties under this _Section 5.6(a)_ , other
than those obligations or liabilities that the Surviving Corporation will
have to DandO Indemnified Parties under this _Section 5.6(a)_.

  



   

62

 



    



  

  

(b)  Parent and Merger Sub agree that all rights to indemnification
and exculpation from liabilities, including advancement of expenses, for acts
or omissions occurring at or prior to the Effective Time now existing in favor
of the DandO Indemnified Parties as provided in the Certificate of
Incorporation, the Bylaws, or any indemnification Contract between such DandO
Indemnified Parties and the Company set forth on _Section 5.6(b)_ of the
_Company Disclosure Letter_ and a copy of which was provided to Parent, (in
each case, as in effect on the date of this Agreement) shall survive the
Merger and shall continue in full force and effect. Without limiting the
foregoing, for a period of six (6) years from the Effective Time, the
Surviving Corporation shall, and Parent shall cause the Surviving Corporation
to, maintain in effect the exculpation, indemnification and advancement of
expenses provisions equivalent to the provisions of the Certificate of
Incorporation and Bylaws as in effect immediately prior to the Effective Time
solely with respect to acts or omissions occurring prior to the Effective Time
and shall not amend, repeal or otherwise modify any such provisions in any
manner that would adversely affect the rights thereunder of any DandO
Indemnified Parties; _provided_ ,  _however_ , that all rights to
indemnification in respect of any action pending or asserted or any claim made
for indemnification within such period shall continue until the disposition
of such action or resolution of such claim. From and after the
Effective Time, Parent shall guarantee and stand surety for, and shall cause
the Surviving Corporation to honor, in accordance with their respective
terms, each of the covenants contained in this _Section 5.6_. In addition,
from the Effective Time until six (6) years from the Effective Time, Parent
will, and will cause the Surviving Corporation to, advance any expenses
(including fees and expenses of legal counsel) of any DandO Indemnified Party
under this _Section 5.6_ (including in connection with enforcing the
indemnity and other obligations referred to this in this _Section 5.6_ ) as
incurred to the fullest extent permitted under applicable Law, provided that
the individual to whom expenses are advanced provides an undertaking to repay
such advances if it is determined that such Person is not entitled to be
indemnified pursuant to this _Section 5.6(b)._

  



  

(c)  Prior to the Effective Time, the Company shall or, if the
Company is unable to, Parent shall cause the Surviving Corporation as of or
after the Effective Time to, purchase a six (6)-year prepaid "tail" policy
with reputable insurers, with terms, conditions, retentions and limits of
liability that are no less favorable than the coverage provided under the
Company's existing policies of directors' and officers' liability insurance
and fiduciary liability insurance, with respect to matters arising on or
before the Effective Time (including in connection with this Agreement and the
transactions or actions contemplated by this Agreement), and Parent shall
cause such policy to be maintained in full force and effect, for its full
term, and cause all obligations thereunder to be honored by the Surviving
Corporation, and no other party shall have any further obligation to purchase
or pay for insurance hereunder; _provided_ , _however_ , that the Company
shall not pay, and the Surviving Corporation shall not be required to pay, in
excess of 300% of the last annual premium paid by the Company prior to the
date of this Agreement in respect of such "tail" policy. If the Company or
the Surviving Corporation for any reason fails to obtain such
"tail" insurance policies prior to, as of or after the Effective Time, Parent
shall, for a period of six (6) years from the Effective Time, cause the
Surviving Corporation to maintain in effect the current policies of directors'
and officers' liability insurance and fiduciary liability insurance
maintained by the Company with respect to matters arising on or before the
Effective Time; _provided_ , _further_ , _however_ , that after the Effective
Time, Parent shall not be required to pay annual premiums in excess of 300%
of the last annual premium paid by the Company prior to the date of this
Agreement in respect of the coverage required to be obtained pursuant hereto,
but in such case shall purchase as much coverage as reasonably practicable
for such amount.

  



  

   

63

 



    



  

(d)  The covenants contained in this _Section 5.6_ shall survive the
consummation of the Merger and are intended to be for the benefit of, and
shall be enforceable by, each of the DandO Indemnified Parties and their
respective heirs and representatives, and are in addition to, and not in
substitution for, any other rights to indemnification or contribution that any
such individual may have under the Company's constituent documents, by
Contract or otherwise. The obligations of Parent and the
Surviving Corporation under this _Section 5.6_ may not be terminated or
modified in such a manner as to adversely affect the rights of any of the DandO
Indemnified Parties to whom this _Section 5.6_ applies unless (i) such
termination or modification is required by applicable Law or (ii) the
affected DandO Indemnified Parties will have consented in writing to such
termination or modification (it being expressly agreed that the DandO
Indemnified Parties to whom this _Section 5.6_ applies will be third-party
beneficiaries of this _Section 5.6_ ).

  



  

(e)  In the event that Parent or the Surviving Corporation or any
of their respective successors or assigns (i) consolidates with or merges
into any other Person and shall not be the continuing or surviving corporation
or entity of such consolidation or merger or (ii) transfers or conveys all or
substantially all of its properties and assets to any Person, then, and in
each such case, Parent and the Surviving Corporation shall cause proper
provision to be made so that the successors or assigns of Parent or the
Surviving Corporation, as the case may be, shall assume the obligations set
forth in this _Section 5.6_.

  



  

Section 5.7   _Notification of Certain Matters_. The Company shall give
prompt notice to Parent of (a) the occurrence or non-occurrence of any event
whose occurrence or non-occurrence, as the case may be, could reasonably be
expected to cause any condition set forth in _Section 6.1_ or _Section 6.2_
not to be satisfied at any time from the date of this Agreement to the
Effective Time; and (b) any notice or other communication from any third
Person alleging that the consent of such third Person is or may be required
in connection with the Merger or the other transactions contemplated by this
Agreement. Parent shall give prompt notice to the Company of (i) the
occurrence or non-occurrence of any event whose occurrence or non-occurrence,
as the case may be, could reasonably be expected to cause any condition set
forth in _Section 6.1_ or _Section 6.3_ not to be satisfied at any time from
the date of this Agreement to the Effective Time; and (ii) any notice or other
communication from any third Person alleging that the consent of such third
Person is or may be required in connection with the Merger or the other
transactions contemplated by this Agreement. Notwithstanding anything in this
Agreement to the contrary, no such notification shall affect the
representations, warranties, covenants or agreements of the parties hereto or
the conditions to the obligations of the parties hereto hereunder and any
failure to give such notice with respect to clauses (b) or (c) above, or (ii)
or (iii) above, as applicable, shall not constitute a breach of this _Section
5.7_ for purposes of _Section 6.2(b)_ or _Section 6.3(b)_.

  



  

   

64

 



    



  

Section 5.8   _Public Disclosure_. Parent and the Company shall
mutually agree on the initial press release or releases with respect to the
execution of this Agreement. Thereafter, during the period that this
Agreement remains in effect, except as otherwise expressly permitted by this
Agreement, neither the Company nor Parent, nor any of their respective
Affiliates, shall issue any press release or other announcement with respect
to the Merger, the other transactions contemplated by this Agreement or this
Agreement without the prior consent of the other party (such consent not to be
unreasonably conditioned, withheld or delayed), except as such press release
or other announcement may be required by Law or the rules of a national
securities exchange or trading market on which such party's Securities are
listed, in which case the party required to make the release or announcement
shall use its reasonable efforts to provide the other party with a reasonable
opportunity to review and comment on such release or announcement in advance
of its issuance. Notwithstanding the foregoing, (a) the restrictions set
forth in this _Section 5.8_ shall not apply to any press release or other
announcement (i) made by the Company with respect to or in connection with a
Company Adverse Recommendation Change effected by the Company Board in
accordance with this Agreement, (ii) made by the Company or Parent concerning
this Agreement, the Merger or the other transactions contemplated hereby in
connection with a determination by the Company or the Company Board in
accordance with _Section 5.5(b)_ or _Section 5.5(d)_ that a Company
Acquisition Proposal constitutes, or is reasonably likely to constitute, a
Company Superior Proposal, or (iii) made by the Company or Parent in
connection with any dispute between the parties regarding this Agreement, the
Merger or the transactions contemplated hereby, _provided_ , _however_ , that
in the case of the preceding clause (i) or (ii), to the extent not
prohibited by applicable Law, the disclosing party gives the other party
reasonable advance notice of (including the contents of) its intended press
release or other announcement, and (b) to the extent the content of any press
release or other announcement has been previously approved and made in
accordance with this _Section 5.8_ , no separate approval shall be required in
respect of such content to the extent such content is substantially
replicated in a subsequent press release or other announcement or
substantially consistent with a previously approved press release or
announcement.

  



  

Section 5.9 _Intellectual Property Matters_. The Company shall, prior
to the Closing use reasonable best efforts to ensure that title in all
Company Registered IP is recorded in the name of the Company or one or more
of its Subsidiaries, as applicable, and to the extent that any such Company
Registered IP is recorded in any governmental registry in the name of any
Person other than the Company or any of its Subsidiaries, or there are
outstanding encumbrances of any type against such Company Registered IP, use
reasonable best efforts to obtain appropriate assignments, discharges or
other documents intended to place record ownership in the name of the Company
or any of its Subsidiaries or effect the discharge prior to the Closing, as
applicable. The Company shall use reasonable efforts to ensure that all
maintenance, annuity and other fees and all filings necessary to assure the
continued enjoyment of any issued Company Registered IP, and all amendments,
responses to office actions, issue fees and other fees and filings
necessary to maintain the pendency of and pursue the prosecution of any
pending applications have been and will be paid or filed on a timely basis
through the Closing.

  



   

   

65

 



    

    



  

Section 5.10 _Employee Matters_.

  



  

(a) For the period commencing at the Effective Time and ending on
the earlier of (i) the date that is twelve (12) months following
the Effective Time and (ii) the date on which the employment of an employee
of the Company or any of its Subsidiaries who continues his or her employment
with Parent, the Surviving Corporation or any of their respective Affiliates
following the Effective Time (each, a "Continuing Employee") terminates,
Parent, the Surviving Corporation or any of their respective Affiliates shall
provide each Continuing Employee with (A) an annual base salary at least equal
to the annual base salary provided to such Continuing Employee immediately
prior to the Effective Time, (B) cash bonus and cash incentive opportunities
that are no less favorable than the cash bonus and cash incentive
opportunities provided to such Continuing Employee as of immediately prior
to the Effective Time, (C) severance payments and benefits that are no less
favorable than the severance payments and benefits to which such Continuing
Employee would be entitled under the applicable Benefit Plan in effect as of
immediately prior to the Effective Time, and (D) employee benefits that are
no less favorable (in the aggregate) to the employee benefits (excluding for
such purposes any defined benefit pension benefits and any equity based
compensation plans) provided to such Continuing Employee as of
immediately prior to the Effective Time.

  



  

(b) If the Closing occurs (i) prior to the completion of the 2019
fiscal year or (ii) after the completion of the 2019 fiscal year but prior to
the payment of bonuses with respect to such fiscal year, Parent or its
Subsidiaries (including the Surviving Corporation) shall pay an annual bonus
under the applicable bonus plans of the Company and its Subsidiaries in
respect of the 2019 fiscal year to each eligible employee of the Company or
any of its Subsidiaries based on actual performance levels as of the date of
this Agreement, extrapolated through the last day of the 2019 fiscal year (if
applicable), as calculated by the Company in good faith, which payment shall
be made at the time such bonuses would ordinarily be paid to eligible
employees by the Company and its Subsidiaries pursuant to the terms of such
plans and in compliance with Section 409A of the Code. If the Closing occurs
during the 2020 fiscal year, Parent or its Subsidiaries (including the
Surviving Corporation) shall pay a pro-rated annual bonus under the
applicable bonus plans of the Company and its Subsidiaries in respect of the
portion of the 2020 fiscal year that occurs prior to the Closing Date to each
eligible employee of the Company or any of its Subsidiaries based on target
level performance through the Closing Date, which payment will be made within
thirty (30) days following the Closing Date.

  



  

(c) Parent agrees that each Continuing Employee shall, as of the
Effective Time, receive full credit for service with the Company or any of
its Subsidiaries prior to the Effective Time for purposes of determining
eligibility to participate, vesting and benefit accrual under the employee
benefit plans, programs and policies of Parent, the Surviving Corporation or
any of their respective Affiliates in which such Continuing Employee becomes
a participant (excluding, for the avoidance of doubt, with respect to any
defined benefit pension plan or employer subsidized retiree medical
benefits); _provided_ , _however_ , that nothing herein shall result in the
duplication of any benefits for the same period of service. With respect to
each health or welfare benefit plan maintained by Parent, the Surviving
Corporation or any of their respective Affiliates for the benefit of
Continuing Employees (including any medical, dental, pharmaceutical or vision
benefit plans), Parent shall (i) cause to be waived any eligibility waiting
periods, any evidence of insurability requirements or required physical
examinations, actively-at-work requirements and the application of any pre-
existing condition limitations under such plan to the extent such were waived
or satisfied under the comparable health or welfare benefit plan of the
Company or any of its Subsidiaries immediately prior to the Effective Time;
and (ii) cause each Continuing Employee to be given credit under any such
plans for all amounts paid (or otherwise deemed paid) by such
Continuing Employee under any similar Benefit Plan for the plan year that
includes the Effective Time for purposes of applying deductibles, co-payments
and out-of-pocket maximums as though such amounts had been paid in accordance
with the terms and conditions of the plans maintained by Parent, the
Surviving Corporation or any of their respective Affiliates, as applicable,
for the plan year in which the Effective Time occurs; _provided_ , _however_
, that Parent's obligations under this clause (ii) shall be subject to its
receipt of all necessary information, from either the Company or such
Continuing Employee, related to such amounts paid by such Continuing
Employee.

  



  

   

66

 



    



  

(d) If directed in writing by Parent at least ten (10) Business Days
prior to the Effective Time, the Company shall terminate, effective as of
immediately prior to the Closing, any and all Benefit Plans intended to
include a Code Section 401(k) arrangement (each, a "Company 401(k) Plan"). No
later than five (5) Business Days prior to the Closing Date, the Company
shall provide Parent with evidence that the Company has taken action to
terminate each Company 401(k) Plan (effective as of immediately prior to the
Closing) pursuant to resolutions of the Company Board, as the case may be. The
form and substance of such resolutions shall be subject to review and
approval of Parent (which shall not be unreasonably withheld or delayed). If
the Company terminates each Company 401(k) Plan at the written direction of
Parent as described in the immediately preceding sentence, Parent shall, or
shall cause one of its Subsidiaries or Affiliates to, cause a Code Section
401(k) arrangement sponsored or maintained by the Parent or any such
Subsidiary or Affiliate (each, a "Parent 401(k) Plan") to permit each
Continuing Employee participating in such a terminated Company 401(k) Plan as
of immediately prior to the Closing Date to elect to rollover his or her
account balances in such Company 401(k) Plan (including earnings through the
date of transfer and promissory notes evidencing all outstanding loans) to an
applicable Parent 401(k) Plan, in each case in accordance with the terms of
the applicable Company 401(k) Plan and Parent 401(k) Plan. The Company and
Parent shall use commercially reasonable efforts to cooperate to
effectuate any such rollovers, including by exchanging any necessary
participant records or engaging any recordkeepers, administrators,
providers, insurers, or other third parties.

  



  

(e) The provisions of this _Section 5.10_ are solely for the benefit
of the parties to this Agreement, and no Continuing Employee (including any
beneficiary or dependent thereof) shall be regarded for any purpose as a
third-party beneficiary of this Agreement, and no provision of this _Section
5.10_ shall create such rights in any such Persons. Nothing herein shall (i)
guarantee employment for any period of time or preclude the ability of
Parent, the Surviving Corporation or any of their respective Affiliates, as
applicable, to terminate the employment of any Continuing Employee at any time
and for any reason; (ii) require Parent, the Surviving Corporation or any of
their respective Affiliates, as applicable, to continue any Benefit Plans, or
other employee benefit plans or arrangements or prevent the amendment,
modification or termination thereof after the Effective Time; or (iii) amend
any Benefit Plans or other employee benefit plans or arrangements.

  



  

   

67

 



    



  

Section 5.11 _Merger Sub_. Parent will take all actions necessary to
cause Merger Sub to comply with and perform all of its obligations under or
relating to this Agreement, including causing Merger Sub to consummate the
Merger upon the terms and subject to the conditions set forth in this
Agreement.

  



  

Section 5.12 _Rule 16b-3 Matters_. Prior to the Effective Time, the
Company shall use reasonable best efforts to take all such steps as may be
reasonably necessary or advisable (to the extent permitted under applicable
Law and no-action letters issued by the SEC) to cause any dispositions of
Company Common Stock (including derivative Securities with respect to Company
Common Stock) resulting from the transactions contemplated by this Agreement
by each individual who is subject to the reporting requirements of Section
16(a) of the Exchange Act with respect to the Company immediately prior to the
Effective Time to be exempt under Rule 16b-3 promulgated under the Exchange
Act.

  



  

Section 5.13 _Repayment and Termination of Existing Credit Agreement_.
The Company shall use its reasonable best efforts to deliver to Parent, at
least two (2) Business Days prior to the Closing Date, a draft of, and on or
prior to the Closing Date, an executed copy of, a customary payoff letter
from the agents under the Existing Credit Agreement in form and
substance reasonably satisfactory to Parent relating to the repayment in full
of all obligations thereunder or secured thereby, the termination of all
commitments in connection therewith and the release of all Liens securing the
obligations thereunder (the "Payoff Letter"). The Company shall, and shall
cause its Subsidiaries to, use commercially reasonable efforts to deliver
to Parent (or the agent under the Existing Credit Agreement, in the case of
prepayment and termination notices) on or prior to the Closing, in form and
substance reasonably satisfactory to Parent, all the documents, filings and
notices required for the termination of commitments under the Existing Credit
Agreement and the release of all Liens securing the obligations thereunder,
including the filing of UCC termination statements, terminations of control
agreements, terminations of Intellectual Property security agreements and
delivery of possessory collateral, which shall in each case be subject to the
occurrence of the Closing and the repayment in full of all obligations then
outstanding under the Existing Credit Agreement. At the Closing, Parent shall
pay or shall cause to be paid, in full and in immediately available funds,
any and all amounts outstanding and then due and payable under the
Existing Credit Agreement in accordance with the Payoff Letter.

  



  

Section 5.14 _Stock Exchange Delisting; Deregistration_. Prior to the
Effective Time, the Company shall cooperate with Parent and use its
reasonable best efforts to take, or cause to be taken, all actions, and do or
cause to be done all things, necessary, proper or advisable on its part under
Laws and the rules and policies of the NYSE American to cause the delisting
of the Company and of the shares of Company Common Stock from the NYSE
American as promptly as practicable after the Effective Time and the
deregistration of the shares of Company Common Stock under the Exchange Act as
promptly as practicable after such delisting. The Company shall not cause the
Company Common Stock to be delisted from the NYSE American prior to
the Effective Time.

  



  

Section 5.15 _State Takeover Laws_. If any state takeover statute
becomes or is deemed to become applicable to the Company, the Voting and
Support Agreement, the Merger or the other transactions contemplated by this
Agreement, then the Company Board shall take any and all actions within its
control as are necessary to render such statutes inapplicable to the
foregoing.

  



  

   

68

 



    



  

Section 5.16 _Stockholder Litigation_. The Company shall give Parent
notice as soon as possible of, and the opportunity to participate in (subject
to a customary joint defense agreement), but not control, the defense or
settlement of, any stockholder litigation against the Company or its
directors or executive officers relating to or in connection with
this Agreement, the Merger or any other transactions contemplated by this
Agreement, whether commenced prior to or after the execution and delivery of
this Agreement. The Company agrees that it shall not settle or offer to
compromise or settle any such litigation commenced prior to or after the date
of this Agreement against the Company or any of its directors or executive
officers relating to or in connection with this Agreement, the Merger or any
other transaction contemplated by this Agreement, in each case, without the
prior written consent of Parent (which consent shall not be unreasonably
withheld, delayed or conditioned). The Company shall promptly notify Parent
of any such litigation and shall keep Parent reasonably and promptly informed
with respect to the status thereof.

  



  

Section 5.17 _Resignations_. Prior to the Effective Time, upon Parent's
request, the Company shall use commercially reasonable efforts to cause any
director of the Company and any director of a Subsidiary of the Company, to
execute and deliver a letter effectuating his or her resignation as a
director of such entity effective as of the Effective Time.

  



  

Section 5.18 _Tax Returns._ The Company shall file all Tax Returns that
it is required to file prior to the Closing in the ordinary course of
business, and all such Tax Returns shall be true, correct and complete in all
material respects and prepared in accordance with the Company's past practice
unless otherwise required by applicable law. At the time that such Tax
Returns are filed, the Company shall provide a copy to the Parent.

  



  

ARTICLE VI

  



  

CONDITIONS TO THE MERGER

  



  

Section 6.1 _Conditions to the Obligations of Each Party_. The
respective obligations of each party hereto to consummate the Merger and the
other transactions contemplated by this Agreement are subject to the
satisfaction or (to the extent permitted by Law) waiver by the Company and
Parent, as the case may be, at or prior to the Effective Time of the
following conditions:

  



  

(a) the Company shall have obtained the Company Stockholder
Approval;

  



  

(b) any applicable waiting period (and any extension thereof) under
the HSR Act relating to the consummation of the Merger shall have expired or
termination thereof shall have been granted; and

  



  

(c) no Governmental Authority of competent jurisdiction shall have
issued or entered any Order after the date of this Agreement, and no Law
shall have been enacted or promulgated after the date of this Agreement, in
each case, that is then in effect and has the effect of restraining,
enjoining or otherwise prohibiting the consummation of the Merger or the other
transactions contemplated by this Agreement.

  



  

   

69

 



    



  

Section 6.2 _Conditions to the Obligations of Parent and Merger Sub_.
The obligations of Parent and Merger Sub to effect the Merger and the other
transactions contemplated by this Agreement are subject to the satisfaction or
(to the extent permitted by Law) waiver by Parent at or prior to the
Effective Time of the following additional conditions:

  



  

(a) (i) the representations and warranties of the Company contained
in _Section 3.2(a)_ , _Section 3.2(c)_ and _Section 3.7(b)_ shall be true and
correct in all respects (except in the case of _Section 3.2(a)_ and _Section
3.2(c)_  for any _de minimis_ inaccuracy) both as of the date of this
Agreement and as of the Effective Time as if made at and as of such time
(other than any such representation or warranty that is made as of a specified
date, which representation or warranty shall be so true and correct as of
such specified date), (ii) the representations and warranties of the
Company contained in _Section 3.1(a)_ , _Section 3.3_ , _Section
3.5(a)(i)(A)_ , _Section 3.26_ , _Section 3.27_  and _Section 3.28_ (without
giving effect to any materiality, Company Material Adverse Effect or similar
qualifiers contained therein) shall be true and correct in all material
respects both as of the date of this Agreement and as of the Effective Time
as if made at and as of the Effective Time (other than any such representation
or warranty that is made as of a specified date or time, which representation
or warranty shall be so true and correct as of such specified date or
time), and (iii) the other representations and warranties of the Company
contained in _Article III_ of this Agreement (without giving effect to any
materiality, Company Material Adverse Effect or similar qualifiers contained
therein) shall be true and correct both as of the date of this Agreement and
as of the Effective Time as if made at and as of the Effective Time
(other than any such representation or warranty that is made as of a
specified date or time, which representation or warranty shall be so true and
correct as of such specified date or time), except where the failure of such
representations and warranties to be true and correct, individually or in the
aggregate, has not had, and would not reasonably be expected to have, a
Company Material Adverse Effect;

  



  

(b) the Company shall have performed or complied in all material
respects with its covenants and agreements contained in this Agreement to be
performed or complied with on or prior to the Effective Time;

  



  

(c) since the date of this Agreement, there shall not have been any
effect, change, development, event, circumstance, occurrence, condition, fact
or state of facts that has had or would reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect;

  



  

(d) the Company shall have delivered executed Preferred Stockholder
Letters from each holder of Company Preferred Stock; and

  



  

(e) Parent shall have received a certificate signed by an executive
officer of the Company certifying as to the matters set forth in
_Section 6.2(a)_ , _Section 6.2(b)_ , and _Section 6.2(c)_.

  



  

   

70

 



    



  

Section 6.3 _Conditions to the Obligations of the Company_. The
obligations of the Company to effect the Merger and the other transactions
contemplated by this Agreement is subject to the satisfaction or (to the
extent permitted by Law) waiver by the Company at or prior to the Effective
Time of the following additional conditions:

  



  

(a) each of the representations and warranties of Parent and Merger
Sub contained in _Article IV_ of this Agreement (without giving effect to any
materiality, Parent Material Adverse Effect or similar qualifiers contained
therein) shall be true and correct both as of the date of this Agreement and
as of the Effective Time as though made on and as of the Effective Time (other
than any such representation or warranty that is made as of a specified date,
which representation or warranty shall be so true and correct as of such
specified date), except where the failure of such representations and
warranties to be true and correct, individually or in the aggregate, has not
had, and would not reasonably be expected to have, a Parent Material Adverse
Effect;

  



  

(b) Parent and Merger Sub shall have performed or complied in all
material respects with each of their respective covenants and
agreements contained in this Agreement to be performed or complied with by it
on or prior to the Effective Time; and

  



  

(c) the Company shall have received a certificate signed by an
executive officer of Parent certifying that the conditions set forth in 
_Section 6.3(a)_ and _Section 6.3(b)_ have been satisfied.

  



  

Section 6.4 _Frustration of Closing Conditions_. Neither Parent or
Merger Sub, on the one hand, nor the Company, on the other hand, may rely on
the failure of any condition set forth in _Section 6.1_ , _Section 6.2_ or 
_Section 6.3_ , as the case may be, to be satisfied to excuse it from its
obligation to effect the Merger if such failure was caused by such party's
failure to comply with its obligations to consummate the Merger and the other
transactions contemplated by this Agreement to the extent required by this
Agreement.

  



  

ARTICLE VII

  



  

TERMINATION, AMENDMENT AND WAIVER

  



  

Section 7.1 _Termination_. Notwithstanding anything contained in this
Agreement to the contrary, this Agreement may be terminated at any time prior
to the Effective Time, whether before or after the Company Stockholder
Approval is obtained (except as otherwise expressly noted), as follows:

  



  

(a) by mutual written consent of each of Parent and the Company; or

  



  

(b) by either Parent or the Company:

  



  

(i) if the Merger shall not have been consummated on or before 5:00
P.M. (New York City time) on August 7, 2020 (the "Termination Date");
_provided_ , _however_ , that the right to terminate this Agreement
pursuant to this _Section 7.1(b)(i)_ shall not be available to any party
where the breach of or the failure to fulfill, perform or comply with any of
its obligations under this Agreement in any material respect, has been the
principal cause of, or principally resulted in, the failure of the Closing to
have occurred on or before the Termination Date;

  



  

   

71

 



    



  

(ii) if any Governmental Authority of competent jurisdiction shall
have issued or entered any Order after the date of this Agreement or any Law
shall have been enacted or promulgated after the date of this Agreement that
has the effect of permanently restraining, enjoining or otherwise prohibiting
the Merger or other transactions contemplated by this Agreement, and in the
case of such an Order, such Order shall have become final and non-appealable;
_provided_ , _however_ , that the right to terminate this Agreement under
this _Section 7.1(b)(ii)_ shall not be available to a party where the breach
of or failure to fulfill, perform or comply with any of its obligations under
this Agreement, in any material respect, has been the principal cause of, or
principally resulted in, the issuance of such Order; or

  



  

(iii) if the Company Stockholder Approval shall not have been
obtained in accordance with the Certificate of Incorporation and DGCL,
whether (to the extent permitted) by written consent or at a duly convened
Company Stockholders' Meeting, or at any adjournment or postponement thereof,
at which a vote on the adoption of this Agreement was taken.

  



  

(c) by the Company:

  



  

(i) if Parent or Merger Sub shall have breached or failed to
perform any of their respective representations, warranties, covenants
or other agreements set forth in this Agreement, which breach or failure to
perform (A) would result in the failure of a condition set forth in _Section
6.3(a)_ or _Section 6.3(b)_ and (B) is not capable of being cured by Parent or
Merger Sub, as applicable, by the Termination Date, or, if capable of being
cured, shall not have been cured by Parent or Merger Sub on or before the
earlier of (1) the Termination Date and (2) the date that is thirty (30)
calendar days following the Company's delivery of written notice to Parent of
such breach or failure to perform; _provided_ , _however_ , that the Company
shall not have the right to terminate this Agreement pursuant to this
_Section 7.1(c)(i)_ if it is then in material breach of any of its
representations, warranties, covenants or agreements under this Agreement so
as to result in the failure of a condition set forth in _Section 6.2(a)_ or
_Section 6.2(b)_ ; or

  



  

(ii) at any time prior to receipt of the Company Stockholder
Approval, in order to enter into a definitive agreement with respect to
a Company Superior Proposal, to the extent permitted by, and, subject to
complying with the applicable terms and conditions of _Section 5.5(d)_ ;
_provided_ , _however_ , that immediately prior to or concurrently with such
termination, the Company pays to Parent the Company Termination Fee (it being
understood that the Company may enter into such definitive written agreement
concurrently with the termination of this Agreement).

  



  

(d) by Parent:

  



  

(i) if the Company shall have breached or failed to perform any of
its representations, warranties, covenants or other agreements set forth in
this Agreement, which breach or failure to perform (A) would result in the
failure of a condition set forth in _Section 6.2_ and (B) is not capable of
being cured by the Company by the Termination Date or, if capable of being
cured, shall not have been cured by the Company on or before the earlier of
(1) the Termination Date and (2) the date that is thirty (30) calendar days
following Parent's delivery of written notice to the Company of such breach or
failure to perform; _provided_ ,  _however_ , that Parent shall not have the
right to terminate this Agreement pursuant to this _Section 7.1(d)(i)_
if Parent or Merger Sub is then in material breach of any of its
representations, warranties, covenants or agreements under this Agreement so
as to result in the failure of a condition set forth in _Section 6.3(a)_ or
_Section 6.3(b)_ ; or

  



  

   

72

 



    



  

(ii) on or prior to the date of the Company Stockholders' Meeting,
if (A) the Company Board shall have made a Company Adverse
Recommendation Change or (B) the Company or the Company Board, as applicable,
shall have materially breached any of its obligations under _Section 5.5(a)_.

  



  

Section 7.2 _Effect of Termination_. In the event that this Agreement is
terminated and the Merger abandoned pursuant to _Section 7.1_ , written
notice thereof shall be given by the terminating party to the other party,
specifying the provisions hereof pursuant to which such termination is made,
and this Agreement shall forthwith become null and void and of no effect
without liability on the part of any party hereto, and all rights and
obligations of any party hereto shall cease;  _provided_ , _however_ , that
no such termination shall relieve (a) any party hereto of any liability or
damages resulting from any material and intentional breach of this Agreement
or fraud or (b) Parent or Merger Sub of any liability or damages
resulting from not having, for any reason, sufficient cash available on the
date that the Closing is required to occur pursuant to _Section 1.2_ hereof
to consummate the transactions contemplated hereby in accordance with the
terms of this Agreement, in which case, the aggrieved party shall be entitled
to all remedies available at law or in equity; and _provided_ , _further_ ,
_however_ , that the Confidentiality Agreement, this _Section 7.2_ , _Section
7.3_ , and _Article VIII_ shall survive any termination of this Agreement
pursuant to _Section 7.1_. For purposes of this Agreement, "material and
intentional breach" shall mean an action or omission taken or omitted to be
taken that the breaching party intentionally takes (or fails to take) and
knows would, or knows would reasonably be expected to, cause a material breach
of this Agreement.

  



  

Section 7.3 _Termination Fees_.

  



  

(a) If this Agreement is terminated by:

  



  

(i)  (A) Parent pursuant to _Section 7.1(d)(i)_ on the basis of a
breach of a covenant or agreement contained in this Agreement or (B) either
Parent or the Company pursuant to _Section 7.1(b)(i)_ or _Section 7.1(b)(iii)_
and in any such termination under clauses (A) or (B), (1) prior to such
termination, a Company Acquisition Proposal made after the date of this
Agreement has been publicly disclosed and not publicly withdrawn or otherwise
abandoned at least three (3) Business Days prior to the Company Stockholders'
Meeting in the case of termination pursuant to _Section 7.1(b)(iii)_ or is
otherwise known to the Company Board and not withdrawn (publicly, if publicly
disclosed) prior to such termination in the case of termination pursuant to
either  _Section 7.1(b)(i)_ or _Section 7.1(d)(i)_ , and (2) within twelve
(12) months after any such termination of this Agreement (pursuant to the
foregoing clauses (A) or (B)) the Company consummates a Company Acquisition
Proposal with the party that made such Company Acquisition Proposal (
_provided_ , _however_ , that for purposes of this _Section 7.3(a)(i)_ , the
references to "fifteen percent (15%)" in the definition of Company
Acquisition Proposal shall be deemed to be references to "fifty percent
(50%)");

  



  

   

73

 



    



  

(ii) the Company pursuant to _Section 7.1(c)(ii)_ ; or

  



  

(iii) Parent pursuant to _Section 7.1(d)(ii)_ ;

  



  

then, in any such case, the Company shall pay to Parent the Company
Termination Fee.

  



  

Any payments required to be made under this _Section 7.3_ shall be made by
wire transfer of same-day funds to the account or accounts designated by
Parent, (1) in the case of clause (i) above, within five (5) Business Days,
following the consummation of the transaction contemplated therein, (2) in
the case of clause (ii) above, immediately prior to or concurrently with
such termination and (3) in the case of clause (iii) above, promptly, but in
no event later than two (2) Business Days after the date of such termination.

  



  

(b) Notwithstanding anything to the contrary set forth in this
Agreement (i) the parties hereto agree that in no event shall the Company be
required to pay the Company Termination Fee on more than one occasion and
(ii) following receipt by Parent of the Company Termination Fee in accordance
with this _Section 7.3_ as a result of a termination by Parent, the Company
shall have no further liability with respect to this Agreement or the
transactions contemplated hereby to Parent or Merger Sub.

  



  

(c) The Company acknowledges that (i) the agreements contained in
this _Section 7.3_ are an integral part of the transactions contemplated by
this Agreement, and (ii) without these agreements, Parent would not enter into
this Agreement. Accordingly, if the Company fails to timely pay any amount
due pursuant to this _Section 7.3_ and, in order to obtain such payment,
Parent commences a suit that results in a judgment against the Company for
the payment of any amount set forth in this _Section 7.3_ , the Company shall
pay Parent its costs and expenses in connection with such suit (including
reasonable attorneys' fees), together with interest on such amount at an
annual rate equal to the prime rate as published in The Wall Street Journal in
effect on the date such payment was required to be made through the date such
payment was actually received, or such lesser rate as is the
maximum permitted by applicable Law.

  



  

Section 7.4 _Amendment_. This Agreement may be amended by mutual
agreement of the parties hereto in writing at any time before the Closing
Date, whether before or after receipt of the Company Stockholder Approval;
_provided_ ,  _however_ , that after the Company Stockholder Approval has
been obtained, no amendment may be made that either by applicable Law or
pursuant to the applicable rules of any applicable stock exchange requires
further approval by the stockholders of the Company without such further
approval of such stockholders having been obtained.

  



  

   

74

 



    



  

Section 7.5 _Extension; Waiver_. At any time prior to the Effective
Time, subject to applicable Law, any party hereto may (a) extend the time for
the performance of any obligation or other act of any other party hereto, (b)
waive any inaccuracy in the representations and warranties of the other party
contained herein or in any document delivered pursuant hereto and (c) waive
compliance by any other party hereto with any agreement or condition of such
party contained herein. Any such extension or waiver shall only be valid if
set forth in an instrument in writing signed by the party or parties to be
bound thereby. Notwithstanding the foregoing, no failure or delay by the
Company, Parent or Merger Sub in exercising any right hereunder shall operate
as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise of any other right hereunder.

  



  

ARTICLE VIII

  



  

GENERAL PROVISIONS

  



  

Section 8.1 _Non-Survival of Representations and Warranties_. The
representations and warranties in this Agreement and any certificate
delivered pursuant hereto by any Person shall terminate at the Effective Time,
and only the covenants that by their terms survive the Effective Time shall
so survive the Effective Time in accordance with their respective terms.

  



  

Section 8.2 _Expenses_. Except as expressly set forth herein (including
_Section 7.3_ ), all fees, costs and expenses (including all legal,
accounting, broker, finder or investment banker fees) incurred in connection
with this Agreement and the transactions contemplated by this Agreement shall
be paid by the party incurring such expenses, whether or not the Merger and
the transactions contemplated by this Agreement are consummated.

  



  

Section 8.3 _Notices_. All notices, consents and other communications
hereunder shall be in writing and shall be given (and shall be deemed to have
been duly given upon receipt) by hand delivery, by prepaid overnight courier
(providing written proof of delivery) or by confirmed electronic mail,
addressed as follows:

  



  

if to Parent or Merger Sub: 
  
 Siemens Medical Solutions USA, Inc.

  

Address: 40 Liberty Blvd., Malvern, PA 19355

  

Attention: General Counsel

  

Email:  _kevin.royer@siemens-healthineers.com_

  



  

with a copy (which shall not constitute notice) to: 
  
 Blank Rome LLP 
 1271 Avenue of the Americas 
 New York, NY 10020 
 Attention: Gary Goldenberg; Alan Lieblich; Shaun Snitman

  

Email:  _goldenberg@blankrome.com; lieblich@blankrome.com;
ssnitman@blankrome.com_

  



  

   

75

 



    



  

if to the Company:

  



  

Corindus Vascular Robotics 
 309 Waverley Oaks Road, Suite 105 
 Waltham, MA 02452 
 Attention: Mark J. Toland 
 Email: mark.toland@corindus.com

  



  

with a copy (which shall not constitute notice) to:

  



  

Cadwalader, Wickersham and Taft LLP 
 One World Financial Center 
 New York, NY 10281 
 Attention: Christopher Cox; William P. Mills; Gregory P. Patti 
 Email: chris.cox@cwt.com; william.mills@cwt.com; greg.patti@cwt.com

  



  

or to such other address or electronic mail address for a party as shall be
specified in a notice given in accordance with this _Section 8.3_ ;
_provided_ , _however_ , that any notice received by electronic mail or
otherwise at the addressee's location on any Business Day after 5:00 P.M.
(addressee's local time) or on any day that is not a Business Day shall be
deemed to have been received at 9:00 A.M. (addressee's local time) on the
next Business Day; _provided_ , _further_ , _however_ , that notice of any
change to the address or any of the other details specified in or pursuant to
this _Section 8.3_ shall not be deemed to have been received until, and shall
be deemed to have been received upon, the later of the date specified in such
notice or the date that is five (5) Business Days after such notice would
otherwise be deemed to have been received pursuant to this _Section 8.3_.

  



  

Section 8.4 _Interpretation; Certain Definitions_.

  



  

(a) The parties hereto have participated collectively in the
negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be
construed as if drafted collectively by the parties hereto, and no
presumption or burden of proof shall arise favoring or disfavoring any party
by virtue of the authorship of any provisions of this Agreement.

  



  

   

76

 



    



  

(b) The words "hereof," "herein," "hereby," "hereunder" and
"herewith" and words of similar import shall refer to this Agreement as a
whole and not to any particular provision of this Agreement. References to
articles, sections, paragraphs, exhibits, annexes and schedules are to the
articles, sections and paragraphs of, and exhibits, annexes and schedules to,
this Agreement, unless otherwise specified, and the table of contents and
headings in this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement. Whenever
the words "include," "includes" or "including" are used in this Agreement,
they shall be deemed to be followed by the phrase "without limitation." Words
describing the singular number shall be deemed to include the plural and vice
versa, words denoting any gender shall be deemed to include all genders, words
denoting natural persons shall be deemed to include business entities and
vice versa, and references to a Person are also to its permitted successors
and assigns. The term "or" is not exclusive. The word "extent" in the phrase
"to the extent" shall mean the degree to which a subject or other thing
extends, and such phrase shall not mean simply "if." The phrases "the date of
this Agreement" and "the date hereof" and terms or phrases of similar import
shall be deemed to refer to August 6, 2019, unless the context requires
otherwise. References to any information or document being "made
available" or "furnished" and words of similar import shall include such
information or document having been posted to the "Corindus Financing" online
data room hosted on behalf of the Company by Intralinks Inc. by 11:59 pm New
York City time on the day prior to the date of this Agreement. Terms defined
in the text of this Agreement have such meaning throughout this
Agreement, unless otherwise indicated in this Agreement, and all terms
defined in this Agreement shall have the meanings when used in
any certificate or other document made or delivered pursuant hereto unless
otherwise defined therein. Any Law defined or referred to herein or in any
agreement or instrument that is referred to herein means such Law as from time
to time amended, modified or supplemented, including (in the case of
statutes) by succession of comparable successor Laws ( _provided_ , _however_
, that for purposes of any representations and warranties contained in this
Agreement that are made as of a specific date or dates, references to any
statute shall be deemed to refer to such statute, as amended, and to any rules
or regulations promulgated thereunder, in each case, as of such date). All
references to "dollars" or "$" refer to currency of the United States.

  



  

Section 8.5 _Severability_. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction or
other authority to be invalid, void or unenforceable, all other terms,
provisions, covenants and restrictions of this Agreement shall remain in full
force and effect and shall in no way be affected, impaired or
invalidated. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties hereto as closely as possible in a mutually acceptable
manner in order that the Merger be consummated as originally contemplated to
the fullest extent possible.

  



  

Section 8.6 _Assignment_. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties
hereto (whether by operation of Law or otherwise) without the prior written
consent of the other parties hereto, except that Merger Sub may assign any or
all of its rights, interests and obligations hereunder to (a) one or more
direct or indirect wholly owned Subsidiaries of Parent, or a combination
thereof, so long as such assignment would not have a Parent Material Adverse
Effect and no such assignment shall release Parent or Merger Sub, as the case
may be, from any of its obligations hereunder and (b) as collateral security
to any lenders or financing sources (as agent or trustee therefor) to Parent
or its Affiliates in connection with any bona fide financing arrangement (but
no such assignment shall release Parent or Merger Sub, as the case may be,
from any of its obligations hereunder). Subject to the preceding sentence,
this Agreement will be binding upon, inure to the benefit of and be
enforceable by the parties hereto and their respective permitted successors
and assigns. Any attempted assignment in violation of this _Section 8.6_
shall be null and void.

  



  

Section 8.7 _Entire Agreement_. This Agreement (including the exhibits,
annexes and appendices hereto) constitutes, together with the Voting and
Support Agreement, the Confidentiality Agreement and the Company Disclosure
Letter, the entire agreement, and supersedes all other prior agreements and
understandings, both written and oral, among the parties hereto, or any of
them, with respect to the subject matter hereof.

  



  

   

77

 



    



  

Section 8.8 _No Third-Party Beneficiaries_. This Agreement is not
intended to and shall not confer upon any Person other than the parties
hereto any rights or remedies hereunder; _provided_ , _however_ , that it is
specifically intended that (a) the DandO Indemnified Parties (with respect to
_Section 5.6_ and this _Section 8.8_ from and after the Effective Time) are
intended third-party beneficiaries hereof and (b) from and after the Effective
Time, the holders of Company Common Stock, Company Preferred Stock, Company
Warrants and Company Equity Awards are intended third-party beneficiaries of
_Article II_.

  



  

Section 8.9 _Governing Law_. This Agreement and all Proceedings (whether
based on contract, tort or otherwise) arising out of or relating to this
Agreement or the actions of Parent, Merger Sub or the Company in the
negotiation, administration, performance and enforcement thereof, shall be
governed by, and construed in accordance with, the Laws of the State of
Delaware, without giving effect to any choice or conflict of laws provision or
rule (whether of the State of Delaware or any other jurisdiction) that would
cause the application of the Laws of any jurisdiction other than the State of
Delaware.

  



  

Section 8.10 _Specific Performance_. The parties hereto agree that
irreparable damage for which monetary damages, even if available, would not
be an adequate remedy would occur in the event that any party hereto does not
perform the provisions of this Agreement (including failing to take such
actions as are required of it hereunder to consummate this Agreement) in
accordance with its specified terms or otherwise breaches such provisions.
Accordingly, the parties hereto acknowledge and agree that, prior to any
valid termination of this Agreement in accordance with _Section 7.1_ , in the
event of any breach or threatened breach by the Company, on the one hand, or
Parent or Merger Sub, on the other hand, of any of their respective
covenants or obligations set forth in this Agreement, the Company, on the one
hand, and Parent and Merger Sub, on the other hand, shall be entitled to an
injunction, specific performance and other equitable relief to prevent
breaches or threatened breaches of this Agreement and to enforce specifically
the terms and provisions hereof, in addition to any other remedy to which they
are entitled at law or in equity. Each of the parties hereto agrees that,
prior to any valid termination of this Agreement in accordance with  _Section
7.1_ , it will not oppose the granting of an injunction, specific performance
and other equitable relief on the basis that any other party has an adequate
remedy at law or that any award of specific performance is not an appropriate
remedy for any reason at law or in equity. Any party hereto seeking an
injunction or injunctions to prevent breaches or threatened breaches of this
Agreement and to enforce specifically the terms and provisions of this
Agreement shall not be required to provide, furnish or post any bond or other
security in connection with any such order or injunction, and each party
hereby irrevocably waives any right it may have to require the provision,
furnishing or posting of any such bond or other security.

  



  

Section 8.11 _Consent to Jurisdiction_.

  



  

(a) Each of the parties hereto hereby, with respect to any legal
claim or Proceeding arising out of this Agreement or the
transactions contemplated by this Agreement, (i) expressly and irrevocably
submits, for itself and with respect to its property, generally and
unconditionally, to the exclusive jurisdiction of the Delaware Court of
Chancery and any appellate court therefrom within the State of Delaware (or,
if the Delaware Court of Chancery declines to accept jurisdiction over a
particular matter, any state or federal court within the State of Delaware),
(ii) agrees that it will not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such courts, (iii)
agrees that it will not bring any claim or Proceeding relating to this
Agreement or the transactions contemplated by this Agreement except in such
courts and (iv) irrevocably waives, to the fullest extent it may legally and
effectively do so, and agrees not to assert, by way of motion or as a defense,
counterclaim or otherwise, any objection which it may now or hereafter have
to the laying of venue of any claim or Proceeding arising out of or relating
to this Agreement. Notwithstanding the foregoing, each of Parent, Merger Sub
and the Company agrees that a final and nonappealable judgment in any
Proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by Law.

  



  

   

78

 



    



  

(b) Each party hereto irrevocably consents to the service of process
in any claim or Proceeding with respect to this Agreement and
the transactions contemplated by this Agreement or for recognition and
enforcement of any judgment in respect hereof brought by any other party
hereto made by mailing copies thereof by registered or certified United States
mail, postage prepaid, return receipt requested, to its address as specified
in or pursuant to _Section 8.3_ , and such service of process shall be
sufficient to confer personal jurisdiction over such party in such claim or
Proceeding and shall otherwise constitute effective and binding service in
every respect.

  



  

Section 8.12 _Counterparts_. This Agreement may be executed in multiple
counterparts, all of which shall together be considered one and the same
agreement. Delivery of an executed signature page to this Agreement by
electronic transmission shall be as effective as delivery of a manually
signed counterpart of this Agreement.

  



  

Section 8.13 _WAIVER OF JURY TRIAL_. EACH OF PARENT, MERGER SUB AND THE
COMPANY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE)
BETWEEN ANY OF THEM DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE ACTIONS OF PARENT, MERGER SUB OR THE COMPANY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF.

  



  

Section 8.14 _Definitions_.

  



  

(a) As used in this Agreement, the following terms shall have the
following meanings:

  



  

"Acceptable Confidentiality Agreement" shall mean any customary
confidentiality agreement that (a) does not contain any provision prohibiting
or otherwise restricting the Company's ability to comply with any of the terms
of this Agreement and (b) contains provisions that are no less favorable in
the aggregate to the Company, or less restrictive to such third Person in the
aggregate (in comparison to Parent), than those contained in the
Confidentiality Agreement ( _provided_ , _however_ , that such agreement need
not contain any standstill agreement or similar obligation).

  



  

   

79

 



    



  

"Affiliate" shall mean, with respect to any Person, any individual,
partnership, corporation, entity or other Person that directly, or
indirectly through one or more intermediaries, Controls, is Controlled by, or
is under common Control with, the first Person specified.

  



  

"Aggregate Merger Consideration" shall mean the aggregate Merger
Consideration to which all holders of Company Stock collectively become
entitled pursuant to _Section 2.1(a)(i)_ and _Section 2.1(a)(ii)_.

  



  

"Business Day" shall mean any day other than a Saturday, Sunday or a day on
which all banking institutions in New York, New York are authorized or
obligated by Law or executive order to close.

  



  

"Code" shall mean the Internal Revenue Code of 1986, as amended.

  



  

"Company Acquisition Proposal" shall mean a proposal or offer (whether or not
in writing) from any Person (other than Parent or any of its Subsidiaries)
relating to, or that would reasonably be expected to lead to (in one
transaction or a series of transactions), any (a) merger, consolidation,
share exchange, business combination, recapitalization, reorganization,
dissolution, liquidation, joint venture or similar transaction involving the
Company or any Subsidiary of the Company, pursuant to which any Person or
group of related Persons would beneficially own or control, directly or
indirectly, fifteen percent (15%) or more (on a non-diluted basis) of any
class of equity or voting Securities of the Company or any resulting parent
company of the Company, (b) sale, lease, license or other disposition,
directly or indirectly, of assets of the Company (including capital stock or
other equity interests of any of its Subsidiaries) or any Subsidiary of the
Company, in each case, representing in the aggregate fifteen percent (15%) or
more of the consolidated assets, net revenues or net income of the Company and
its Subsidiaries taken as a whole, (c) issuance or sale or other disposition
of capital stock or other equity interests representing fifteen percent (15%)
or more (on a non-diluted basis) of any class of equity or voting Securities
of the Company, (d) tender offer, exchange offer or any other transaction
or series of transactions that, if consummated, would result in any Person or
group of related Persons, directly or indirectly, beneficially owning or
having the right to acquire beneficial ownership of capital stock or other
equity interests representing fifteen percent (15%) or more (on a non-diluted
basis) of any class of equity or voting Securities of the Company or (e) a
combination of the foregoing.

  



  

"Company Certificate of Designation" shall mean the Certificate of
Designation of Preferences, Rights and Limitations of the Series A
Convertible Preferred Stock and Series A-1 Convertible Preferred Stock of the
Company, as amended from time to time.

  



  

"Company Common Stock" shall mean the common stock of the Company, par value
$0.0001 per share.

  



  

"Company Disclosure Letter" shall mean the disclosure letter delivered by the
Company to Parent and Merger Sub simultaneously with the execution of this
Agreement.

  



  

   

80

 



    



  

"Company Equity Awards" shall mean the Company Options and the Company RSU
Awards.

  



  

"Company Equity Plans" shall mean, collectively: the Company's Amended and
Restated 2014 Stock Award Plan and the Company's 2018 Stock Award Plan, as
amended from time to time.

  



  

"Company Intellectual Property" shall mean (a) any and all Intellectual
Property owned by, or purported to be owned by, the Company or any of its
Subsidiaries and (b) any and all Intellectual Property licensed to, or
otherwise used by (with a valid right to use), the Company or any of its
Subsidiaries, in each case of (a) and (b), whether registered or unregistered.

  



  

"Company Intervening Event" shall mean any effect, change, development,
event, occurrence or circumstance that is material to the Company and its
Subsidiaries, taken as a whole, that was not known to the Company Board on the
date of this Agreement (or if known, the material consequences of which were
not known to the Company Board as of the date of this Agreement), which
effect, change, development, event, occurrence or circumstance, or any
consequence thereof, becomes known to the Company Board prior to the Company
Stockholder Approval and did not result from or arise out of the announcement
or pendency of, or any actions required to be taken by the Company (or to be
refrained from being taken by the Company) pursuant to, this Agreement;
_provided_ ,  _however_ , that in no event shall the following events,
circumstances, or changes in circumstances constitute an Intervening Event:
(a) the receipt, existence, or terms of a Company Acquisition Proposal or any
matter relating thereto or consequence thereof or any inquiry, proposal,
offer, or transaction from any third party relating to or in connection with a
transaction of the nature described in the definition of "Company Acquisition
Proposal" (which, for the purposes of the Intervening Event definition, shall
be read without reference to the percentage thresholds set forth in the
definition thereof); (b) any change in the price, or change in trading
volume, of the Company Common Stock (provided, however, that the exception to
this clause (b) shall not apply to the underlying causes giving rise to or
contributing to such change or prevent any of such underlying causes from
being taken into account in determining whether an Intervening Event has
occurred).

  



  

"Company Licensed IP" shall mean all Company Intellectual Property that is
licensed to, or otherwise used by (with a valid right to use), the Company or
any of its Subsidiaries, whether registered or unregistered.

  



  

   

81

 



    



  

"Company Material Adverse Effect" shall mean any effect, change, development,
event, circumstance, occurrence, condition, fact or state of facts that has a
material adverse effect, individually or in the aggregate, (a) on the
business, condition (financial or otherwise) or results of operations of the
Company and its Subsidiaries, taken as a whole; _provided_ , _however_ , that
any effect, change, development, event, circumstance, occurrence, condition or
state of facts directly resulting from, attributable to or arising out of the
following will not be taken into account in determining whether a Company
Material Adverse Effect has occurred: (i) changes in general United States or
other national, regional or global economic, regulatory, legislative,
credit, capital market or financial market conditions; (ii) changes in the
economic, business and financial environment generally affecting the medical
device industry; (iii) any change in the Company's trading volume or stock
price, (iv) in and of itself, any failure by the Company to meet any revenue,
earnings or other similar projections (it being understood that the underlying
effect, change, development, event, circumstance, occurrence, condition, fact
or state of facts giving rise to or contributing to such change or failure
may be taken into account in determining whether there has been a Company
Material Adverse Effect to the extent not otherwise excluded by another
exception herein); (v) an act of terrorism or sabotage or an outbreak or
escalation of hostilities or war (whether or not declared) or any natural
disasters, national emergencies or other force majeure events, including any
escalation or worsening of such conditions threatened or existing as of the
date of this Agreement; (vi) adoption, implementation,
enforcement, promulgation, repeal, modification, amendment interpretation or
other changes in applicable Law or GAAP or any regulatory environment or
regulatory enforcement environment; (vii) the execution, public announcement
or pendency of this Agreement and the anticipated consummation of the Merger
or the other transactions contemplated hereby, including (A) the identity of
Parent or the announcement by Parent or any of its Affiliates of its or their
plans or intentions with respect to the Company, (B) any departure or
termination of any officers, directors, employees or independent contractors
of the Company or any of its Subsidiaries or (C) the termination or potential
termination of (or the failure or potential failure to renew or enter into)
any Contracts with, or any other adverse development (or potential adverse
development) in the Company's relationships with any of its customers,
suppliers, distributors, partners or other business relationships of the
Company, or any litigation arising from allegations of any breach of
fiduciary duty or violation of Law relating to the Merger or this Agreement;
(viii) any action expressly required to be taken pursuant to this Agreement;
or (ix) any action taken at the express written direction of Parent given
after the date hereof; _provided_ ,  _further_ , _however_ , that if the
effects, changes, developments, events, circumstances, occurrences,
conditions, facts or states of facts set forth in clauses (i), (ii), (v) and
(vi), have a disproportionate impact on the Company and its
Subsidiaries, taken as a whole, relative to the other participants in the
medical device industry, such effects, changes, developments,
events, circumstances, occurrences, conditions, facts or states of facts may
be taken into account in determining whether a Company Material Adverse
Effect has occurred to the extent of such disproportionate impact or (b) on
the ability of the Company to perform its obligations under this Agreement or
to consummate the Merger and the other transactions contemplated by this
Agreement.

  



  

"Company Option" shall mean each option to purchase shares of Company Common
Stock, including any such option granted pursuant to a Company Equity Plan.

  



  

"Company Owned IP" shall mean all Intellectual Property that is owned or
purported to be owned by the Company or any of its Subsidiaries, whether
registered or unregistered.

  



  

"Company Recommendation" shall mean the recommendation of the Company Board
that the stockholders of the Company adopt this Agreement and approve the
transactions contemplated by this Agreement, including the Merger.

  



  

"Company Registered IP" shall mean all Company Owned IP that has been
registered, filed, certified or otherwise perfected or recorded with or by
any Governmental Authority or domain name registrar, including the United
States Patent and Trademark Office, the United States Copyright Office, or in
any like foreign or international office or agency, or any applications for
any of the foregoing.

  



  

   

82

 



    



  

"Company RSU Award" shall mean each award of restricted stock unit covering
shares of Company Common Stock, including any such restricted stock unit
granted pursuant to a Company Equity Plan.

  



  

"Company Stock" shall mean, collectively, Company Common Stock and Company
Preferred Stock.

  



  

"Company Superior Proposal" shall mean a bona fide written Company
Acquisition Proposal made after the date of this Agreement ( _provided_ ,
_however_ , that for purposes of this definition, references to fifteen
percent (15%) in the definition of "Company Acquisition Proposal" shall be
deemed to be references to fifty percent (50%)) that did not result from a
breach of _Section 5.5_ and is on terms that the Company Board determines in
good faith, after consultation with the Company's financial advisor and
outside legal counsel, (a) to be reasonably likely to be consummated if
accepted and (b) to be more favorable to the holders of Company Common Stock
from a financial point of view than the Merger and the other transactions
contemplated by this Agreement, in each case of clause (a) and (b), taking
into account at the time of determination all legal, financial, regulatory
and other aspects or conditions of such Company Acquisition Proposal as the
Company Board (or a duly authorized committee thereof) considers to be
relevant or appropriate (including any financing requirements and the ability
of the Person making such proposal to consummate the transactions
contemplated by such proposal) and of this Agreement and any proposed
amendments or modifications to the terms of this Agreement offered by Parent
in response to such Company Acquisition Proposal pursuant to _Section 5.5(d)_.

  



  

"Company Termination Fee" shall mean $32,515,000.

  



  

"Company Warrants" shall mean all outstanding warrants to purchase shares of
Company Common Stock.

  



  

"Confidentiality Agreement" shall mean that certain Mutual Non-Disclosure
Agreement, dated July 5, 2018, between Parent and the Company, to the extent
amended and modified by the applicable provisions of that certain letter,
dated July 26, 2019, between Parent and the Company.

  



  

"Contract" shall mean, in each case, whether written or oral, any legally
binding contract, agreement, assignment, subcontract, binding
arrangement, lease, sublease, conditional sales contract, purchase order,
sales order, license, indenture, note, bond, loan,
understanding, undertaking, permit, concession, franchise, commitment,
partnership, limited liability company or other agreement or other
binding instrument.

  



  

"Control" shall mean the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting Securities or partnership or other
interests, by Contract or otherwise. For purposes of this definition, a
general partner or managing member of a Person shall always be considered to
Control such Person. The terms "Controlling" and "Controlled" shall have
correlative meanings.

  



  

   

83

 



    



  

"Copyrights" shall mean all rights in copyrightable works, mask works, works
of authorship and moral rights, including copyrights in Software, and all
other rights corresponding thereto throughout the world, whether published or
unpublished, and any registrations or applications for any of the foregoing,
including renewals and extensions.

  



  

"Customs and International Trade Authorizations" shall mean any and all
licenses, registrations, and approvals required pursuant to the Customs and
International Trade Laws for the lawful export, re-export, transfer or import
of goods, software, technology, technical data, and services and
international financial transactions.

  



  

"Customs and International Trade Laws" shall mean the applicable export
control, sanctions, import, customs and trade, anti-bribery, and anti-boycott
Laws of any jurisdiction in which the Company or any of its Subsidiaries is
incorporated or does business, including the UK Bribery Act 2010, the Tariff
Act of 1930, as amended, and other Laws, regulations, and programs
administered or enforced by the U.S. Department of Commerce, U.S.
International Trade Commission, U.S. Customs and Border Protection, U.S.
Immigration and Customs Enforcement, and their predecessor agencies; the
Export Control Reform Act of 2018; the Export Administration
Regulations, including related restrictions with regard to transactions
involving Persons on the U.S. Department of Commerce Denied Persons List,
Unverified List or Entity List; the Arms Export Control Act, as amended; the
International Traffic in Arms Regulations, including related restrictions
with regard to transactions involving Persons on the Debarred List; the
International Emergency Economic Powers Act, as amended; the Trading With the
Enemy Act, as amended; the Iran Sanctions Act, as amended; the
National Defense Authorization Act for Fiscal Years 2012 - 2018; and the
embargoes and restrictions administered by OFAC; Executive Orders regarding
embargoes and restrictions on transactions with designated countries and
entities, including Persons designated on OFAC's list of Specially Designated
Nationals and Blocked Persons, and Persons designated on the U.S. Department
of State sanctions lists; the anti-boycott Laws and regulations administered
by the U.S. Department of Commerce; and the anti-boycott Laws and
regulations administered by the U.S. Department of the Treasury.

  



  

"Delaware Secretary of State" shall mean the Secretary of State of the State
of Delaware.

  



  

"Device Laws" shall mean all Laws related to health care or medical devices
applicable to the operation of the Company's and each of its Subsidiaries'
business, including (a) the Federal Food, Drug, and Cosmetic Act of 1938, as
amended (21 U.S.C.  321 et seq.); (b) the rules and regulations promulgated
and enforced by the FDA, including those requirements relating to quality
systems, good manufacturing practices, good laboratory practices, good
clinical practices, good tissue practices, medical device reporting,
corrections and removals, development, distribution, import, export,
establishment registration, investigational use, labeling, promotion,
security, and pre-market review; and (c) all comparable state, federal or
foreign Laws relating to any of the foregoing.

  



  

   

84

 



    



  

"Environmental Laws" shall mean all applicable and legally enforceable Laws
relating to pollution or protection of the environment, natural resources, or
human health and safety (as affected by exposure to Hazardous Materials),
including Laws relating to Releases of or exposure to Hazardous Materials and
the manufacture, processing, distribution, use, treatment, storage, Release,
transport or handling of Hazardous Materials, including the Federal Water
Pollution Control Act (33 U.S.C.  1251 et seq.), the Resource Conservation
and Recovery Act of 1976 (42 U.S.C.  6901 et seq.), the Safe Drinking Water
Act (42 U.S.C.  3000(f) et seq.), the Toxic Substances Control Act (15
U.S.C.  2601 et seq.), the Clean Air Act (42 U.S.C.  7401 et seq.), the Oil
Pollution Act of 1990 (33 U.S.C.  2701 et seq.), the Comprehensive
Environmental Response, Compensation and Liability Act of 1980 (42 U.S.C. 
9601 et seq.), the Endangered Species Act of 1973 (16 U.S.C.  1531 et seq.),
and other similar foreign, state and local statutes, in effect as of the date
of this Agreement.

  



  

"ERISA Affiliate" shall mean each trade or business, whether or not
incorporated, that, together with the Company or any of its Subsidiaries,
would be deemed a "single employer" within the meaning of Section 4001(b) of
ERISA or Section 414 of the Code.

  



  

"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.

  



  

"Existing Credit Agreement" shall mean that certain Loan and Security
Agreement (Revolving Line) dated as of March 16, 2018, among Silicon Valley
Bank, the Company and Corindus, Inc. and that certain Loan and Security
Agreement (Term Loan) dated as of March 16, 2018, among Silicon Valley Bank,
Solar Capital Ltd., the Company, Corindus, Inc. and the lender parties
thereto, as amended by the First Amendment to Loan and Security Agreement
(Term Loan) dated as of March 14, 2019, among Silicon Valley Bank,
Solar Capital Ltd., the Company, Corindus, Inc. and the lender parties
thereto.

  



  

"FCPA" shall mean the U.S. Foreign Corrupt Practices Act of 1977, as amended.

  



  

"GAAP" shall mean the United States generally accepted accounting principles.

  



  

"Governmental Authority" shall mean any United States (federal, state or
local) or foreign government, or any governmental, regulatory, judicial or
administrative authority, agency or commission.

  



  

"Hazardous Materials" shall mean any material, substance, chemical or waste
(or combination thereof) that (a) is listed, defined, designated, regulated
or classified as hazardous, toxic, radioactive, dangerous, a pollutant, a
contaminant, petroleum, oil or words of similar meaning or effect under any
Law relating to pollution, waste or protection of the environment or (b) can
form the basis of any liability under any Law relating to pollution, waste or
protection of the environment.

  



  

"HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and the rules and regulations thereunder.

  



  

   

85

 



    



  

"Indebtedness" shall mean (a) any indebtedness or other obligation for
borrowed money, whether current, short term or long term and whether
secured or unsecured, (b) any indebtedness evidenced by a note, bond,
debenture or other Security or similar instrument, (c) any liabilities or
obligations with respect to interest rate swaps, collars, caps and similar
hedging obligations, (d) any capitalized lease obligations, (e) any direct or
contingent obligations under letters of credit, bankers' acceptances, bank
guarantees, surety bonds and similar instruments, each to the extent drawn
upon and paid, (f) any obligation to pay the deferred purchase price of
property or services (other than trade accounts payable in the ordinary
course of business) and (g) guarantees in respect of clauses (a) through (f),
including guarantees of another Person's Indebtedness or any obligation of
another Person which is secured by assets of the Company or any of its
Subsidiaries.

  



  

"Intellectual Property" shall mean all intellectual property rights,
intangible industrial property rights, invention and design rights, and all
related priority rights protected, conceived, created or arising under the
Laws of the United States or any other jurisdiction or under any
international convention, including all Patents, Trademarks, Copyrights, Trade
Secrets, and Software, all copies of tangible embodiments of the foregoing
(in whatever form or medium) and any rights equivalent to any of the foregoing
anywhere in the world.

  



  

"Intellectual Property Agreement" shall mean any license-in, license-out,
purchasing-in, purchasing-out, assignment, consent to use, covenant not to
sue, non-assertion, coexistence, settlement or similar Contract concerning (a)
Intellectual Property that is material to the Company or its Subsidiaries,
(b) Company Owned IP, or (c) Software used by the Company or any of its
Subsidiaries, other than commercially available, non-customized, off-the-
shelf software subject to "shrink-wrap" or "click-through" type terms and
available to the Company or any of its Subsidiaries, as applicable, at a cost
of less than $100,000 per annum. Without limiting the generality of the
foregoing, the following Contracts to which the Company or any of its
Subsidiaries is a party, if any, shall be included in the definition of
"Intellectual Property Agreement": (i) each Contract pursuant to which any
Intellectual Property has been or will be developed by a third Person, either
solely by such third Person or jointly with the Company or any of its
Subsidiaries, for the benefit of the Company or any of its Subsidiaries; (ii)
each Contract pursuant to which the Company or any of its Subsidiaries
purchased, sold, transferred, or acquired, or will purchase, sell, transfer,
or acquire, any Intellectual Property; and (iii) each Contract pursuant to
which any Company Owned IP is subject to a Lien or other restriction, other
than a Permitted Lien.

  



  

"IRS" shall mean the United States Internal Revenue Service.

  



  

"Knowledge" shall mean the actual knowledge of each of the officers and
employees of the Company set forth on _Section 8.14_ of the
_Company Disclosure Letter_.

  



  

"Law" shall mean any domestic, federal, state, municipal, local, national,
supranational, foreign or other statute, law (whether statutory or common
law), constitution, code, ordinance, rule, administrative interpretation,
regulation, Order, writ, judgment, decree, directive (including those of any
self-regulatory organization), arbitration award, agency requirement, license,
permit or any other enforceable requirement of any Governmental Authority.

  



  

   

86

 



    



  

"Lien" shall mean any liens, covenants, charges, security interests, options,
claims, mortgages, pledges, encumbrances or other restrictions of any nature
whatsoever.

  



  

"Merger Consideration" shall mean, as applicable, the Common Stock
Consideration or the Preferred Stock Consideration.

  



  

"Notified Body" means an entity licensed, authorized or approved by the
applicable Governmental Authority to assess and certify the conformity of a
medical device with the requirements of Council Directive 93/42/EEC of 14 June
1993 concerning medical devices, as amended from time to time, and applicable
harmonized standards.

  



  

"NYSE American" shall mean The NYSE American LLC or any successor that is a
national securities exchange registered under Section 6 of the Exchange Act.

  



  

"OFAC" shall mean the Office of Foreign Assets Control of the U.S. Department
of the Treasury.

  



  

"Order" shall mean any decree, order, settlement, consent, stipulation,
judgment, injunction, writ, award, temporary restraining order or other order
in any Proceeding by or with any Governmental Authority.

  



  

"Parent Common Stock" shall mean the common stock, par value $1.00 per share,
of Parent.

  



  

"Parent Organizational Documents" shall mean the certificate of incorporation
and bylaws, each as amended as of the date of this Agreement, of each of
Parent and Merger Sub.

  



  

"Patents" shall mean all issued letters or design patents, reissued or
reexamined patents, patents surviving _inter partes_ review, revival of
patents, utility models, registered community designs, registered industrial
designs, certificates of invention, registrations of patents and extensions
thereof, supplemental protection certificates regardless of country issued or
formal name and all published or unpublished non-provisional and provisional
patent applications, reissue applications, reexamination proceedings,
invention disclosures and records of invention, continuation applications,
continuation-in-part applications, requests for continued examination and
divisions, divisional applications, patent term extension applications,
applications for supplemental protection certificates, all rights in respect
of utility models and certificates of invention, and all rights and priorities
and all extensions and renewals thereof, regardless of the country filed or
formal name.

  



  

   

87

 



    



  

"Permitted Lien" shall mean (a) Liens for Taxes, utilities or governmental
assessments, charges or claims of payment (i) not yet due and payable or (ii)
that are being contested in good faith and by appropriate proceedings and for
which adequate reserves have been maintained in accordance with GAAP; (b)
suppliers', workers', mechanics', materialmen's or other similar liens
arising by operation of Law or otherwise incurred in the ordinary course of
business consistent with past practice; (c) Liens arising under equipment
leases with third Persons entered into in the ordinary course of business
consistent with past practice; (d) any other Liens if the underlying
obligations are non-monetary and do not, individually or in the aggregate,
(A) materially impair the continued use and operation of the assets of the
Company and its Subsidiaries to which they relate in the conduct of the
business of the Company and its Subsidiaries, taken as a whole, as currently
conducted or (B) in the case of Liens with respect to Parent and its
Subsidiaries, do not, individually or in the aggregate, materially impair the
continued use and operation of the assets of Parent and its Subsidiaries to
which they relate in the conduct of the business of Parent and its
Subsidiaries, taken as a whole, as currently conducted; (e) Liens in favor of
customs and revenue authorities arising as a matter of Law and in the
ordinary course of business to secure payment of customs duties in connection
with the importation of goods; (f) Liens resulting from securities Laws on
Securities of the Company or its Subsidiaries; (g) Liens incurred in
connection with the Existing Credit Agreement; (h) Liens created by Parent,
Merger Sub or any of their respective Affiliates; and (i) with respect to
real property and improvements, zoning regulations, building codes and other
land use regulations or environmental regulations, ordinances or legal
requirements or similar laws imposed by any Governmental Authority (excluding
liens imposed by applicable Environmental Laws related to the investigation
or remediation of contaminated real property), to the extent not violated by
the Company's or any of its Subsidiaries' current use of such real property
(or in the case of Liens with respect to Parent or any of its Subsidiaries,
to the extent not violated by Parent's or any of its Subsidiaries' current use
of such real property); and (j) in connection with any real property leased
to the Company, all title exceptions, defects, easements, restrictions
and other matters encumbering landlord's interest in such real property,
whether or not of record, which do not, individually or in the aggregate,
materially affect the continued use and operation of the applicable property
in the conduct of the business of the Company and its Subsidiaries as
currently conducted.

  



  

"Person" shall mean an individual, a corporation, a limited liability
company, a partnership, an association, a trust or any other entity or
organization, including a Governmental Authority.

  



  

"Personal Information" means any information that (a) identifies or can
reasonably be used by the intended recipient to identify an individual, (b)
is regulated by any Data Protection Law, or (c) is considered identifiable
under the Company's or any of its Subsidiaries' privacy or security policies
or procedures, or written agreements to which the Company or any of
its Subsidiaries is a party.

  



  

"Proceedings" shall mean legal, civil, criminal, administrative, regulatory,
arbitral, enforcement, civil penalty, alternative dispute
resolution, debarment, seizure or other proceedings, litigation, suits,
actions, charges, complaints, subpoenas, prosecutions, claims,
audits, assessments, inquiries or investigations (other than internal
inquiries or investigations).

  



  

"Registrations" shall mean authorizations, approvals, clearances, consents,
licenses, permits, certificates, exemptions or registrations issued or
otherwise made available by any Regulatory Authority or Governmental Authority
(including 510(k) pre-market notification clearances, de novo
classifications, pre-market approvals, investigational device exemptions,
product recertifications, manufacturing approvals and authorizations, CE
Marks, pricing and reimbursement approvals, labeling approvals, registration
notifications or their foreign equivalent) that are required for the
research, investigation, development, production, manufacture, labeling,
distribution, marketing, storage, shipping, transportation, export, import,
use or sale of the products or services of the Company and any of its
Subsidiaries.

  



  

   

88

 



    



  

"Regulatory Authority" shall mean the FDA and any other Governmental
Authority that regulates the research, investigation,
development, production, marketing, distribution, storage, shipping,
transport, advertising, labeling, promotion, sale, export, import,
use, handling and control, safety, efficacy, reliability or manufacturing of
medical devices, and any Notified Body.

  



  

"Release" shall mean any release, spill, emission, discharge, leaking,
pumping, injection, deposit, disposal, dispersal, leaching or migration of
Hazardous Materials, including the movement of Hazardous Materials through or
into the air, soil, surface water, groundwater or real property.

  



  

"Representative" shall mean, with respect to any Person, such Person's
Affiliates and its and their respective officers, directors,
managers, partners, employees, accountants, counsel, financial advisors,
consultants and other advisors, agents or representatives.

  



  

"Sanctioned Country" shall mean, at any time, a country or territory which is
itself the subject or target of comprehensive Sanctions (at the time of this
Agreement, Crimea, Cuba, Iran, North Korea and Syria).

  



  

"Sanctioned Person" shall mean any Person that is the target of Sanctions,
including (a) any Person listed in any Sanctions-related list of designated
Persons maintained by OFAC or the U.S. Department of State, the United Nations
Security Council, the European Union, Her Majesty's Treasury of the United
Kingdom, Switzerland or any European Union member state, (b) any Person
located, organized or resident in a Sanctioned Country, or (c) any Person 50%
or more owned or otherwise controlled by any such Person or Persons described
in the foregoing clauses (a) and (b).

  



  

"Sanctions" shall mean economic or financial sanctions or trade embargoes
imposed, administered or enforced from time to time by the U.S. government
through OFAC or the U.S. Department of State, the United Nations Security
Council, the European Union or any European Union member state, Her Majesty's
Treasury of the United Kingdom or Switzerland.

  



  

"Sarbanes-Oxley Act" shall mean the Sarbanes-Oxley Act of 2002, as amended.

  



  

"SEC" shall mean the United States Securities and Exchange Commission.

  



  

"Securities Act" shall mean the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

  



  

"Security" shall mean, with respect to any Person, any series of common
stock, preferred stock and any other equity interest or capital stock of such
Person (including interests or rights of any kind convertible into or
exchangeable or exercisable for any equity interest in any such series of
common stock, preferred stock or any other equity interest or capital stock of
such Person), however described and whether voting or non-voting.

  



  

   

89

 



    



  

"Software" shall mean any and all (a) computer programs, including any and
all software implementations of algorithms, models and methodologies, whether
in source code or object code, (b) databases and compilations, including any
and all data and collections of data, whether machine readable or otherwise,
including program files, data files, computer-related data, field and data
definitions and relationships, data definition specifications, data models,
program and system logic, interfaces, program modules, routines, sub-routines,
algorithms, program architecture, design concepts, system designs, program
structure, sequence and organization, screen displays and report layouts, (c)
descriptions, flow charts and other work product used to design, plan,
organize and develop any of the foregoing, screens, user interfaces, report
formats, firmware, development tools, templates, menus, buttons and icons, and
(d) all documentation including user manuals and other training documentation
related to any of the foregoing, and any improvements, updates, upgrades or
derivative works of any of the foregoing.

  



  

"Subsidiary" of a Person shall mean any other Person with respect to which
the first Person (a) has the right to elect a majority of the board of
directors or other Persons performing similar functions or (b) beneficially
owns more than fifty percent (50%) of the voting stock (or of any other form
of voting or controlling equity interest in the case of a Person that is not a
corporation), in each case, directly or indirectly through one or more other
Persons.

  



  

"Tax" or "Taxes" shall mean any foreign, federal, state, provincial or local
income, earnings, profits, gross receipts, franchise, capital stock, net
worth, sales, use, value added, occupancy, general property, real property,
personal property, intangible property, transfer, fuel, excise, escheat,
unclaimed property (regardless of whether such escheat or unclaimed property
is considered a Tax under applicable law), payroll, withholding (including
under Section 409A of the Code), unemployment compensation, social security,
retirement, environmental (including any Taxes imposed under Section 59A of
the Code) or other tax of any nature; or any deficiency, interest or penalty
imposed with respect to any of the foregoing (or for the failure to file a Tax
Return or a complete and accurate Tax Return).

  



  

"Tax Returns" shall mean any return, report, information statement,
declaration, claim for refund or other similar filing, including any schedule
or attachment thereto, and including any amendment thereof, filed or required
to be filed with a Governmental Authority with respect to Taxes.

  



  

"Trade Secrets" shall mean all trade secrets (protectable as such in any
applicable jurisdiction), know-how and confidential or other proprietary
information relating to technical, engineering, manufacturing, processing,
marketing, financial, or business matters, including new developments,
inventions and discoveries (whether patentable or not and whether or not
reduced to practice and all improvements thereto), invention disclosures,
processes, blueprints, manufacturing, engineering and other drawings
and manuals, recipes, research data and results, flowcharts, diagrams,
schematics, chemical compositions, formulae, diaries, notebooks, lab
journals, design and engineering specifications and similar materials
recording or evidencing expertise or information, designs, methods of
manufacture, processing techniques, data processing techniques, compilation of
information, customer, vendor and supplier lists, pricing and cost
information, and business and marketing plans and proposals, all related
documents thereof, and all claims and rights related thereto.

  



  

   

90

 



    



  

"Trademarks" shall mean any and all registered or unregistered trademarks,
service marks, trade dress, trade names, corporate names, assumed financial
business names, logos, slogans, Internet domain names, and any other source or
business identifiers, and all applications, registrations and renewals in
connection therewith throughout the world, and all goodwill associated with
any of the foregoing.

  



  

"Treasury Regulations" shall mean regulations promulgated by the IRS under
the Code.

  



  

"2014 Warrant" shall mean the warrant to purchase shares of Company Common
Stock, dated as of August 12, 2014.

  



  

(b) The terms set forth below shall have the meanings ascribed
thereto in the referenced sections:

  



     Agreement  |   | Preamble 
---|---|--- 
   AKS  |   | Section 3.24(h) 
   Alternative Acquisition Agreement  |   | Section 5.5(a) 
   Anti-Corruption Laws  |   | Section 3.21(a) 
   Antitrust Laws  |   | Section 3.5(b) 
   Benefit Plan  |   | Section 3.12(a) 
   Book-Entry Shares  |   | Section 2.1(b) 
   Bylaws  |   | Section 3.1(a) 
   Canceled Shares  |   | Section 2.1(a)(iii) 
   Capitalization Date  |   | Section 3.2(a) 
   Certificate of Incorporation  |   | Section 3.1(a) 
   Certificate of Merger  |   | Section 1.3 
   Certificates  |   | Section 2.1(b) 
   Closing  |   | Section 1.2 
   Closing Date  |   | Section 1.2 
   COBRA  |   | Section 3.12(g) 
   Common Stock Consideration  |   | Section 2.1(a)(i) 
   Company  |   | Preamble 
   Company 401(k) Plan  |   | Section 5.10(d) 
   Company Adverse Recommendation Change  |   | Section 5.5(c) 
   Company Board  |   | Recitals 
   Company Leased Property  |   | Section 3.17(b) 
   Company Material Contract  |   | Section 3.15(a) 
   Company Option Grant Date  |   | Section 3.2(b) 
   Company Permits  |   | Section 3.10(a) 
   Company Preferred Stock  |   | Section 3.2(a) 
   Company SEC Documents  |   | Section 3.6(a) 
   Company Stockholder Approval  |   | Section 3.4 
   Company Stockholders' Meeting  |   | Section 5.2(d) 
   Consent  |   | Section 3.5(b) 
   Continuing Employee  |   | Section 5.10(a) 
   



  

   

91

 



    



     DandO Indemnified Parties  |   | Section 5.6(a) 
---|---|--- 
   Data Protection Laws  |   | Section 3.16(q) 
   Demand Registration Rights Agreements  |   | Section 3.2(f) 
   DGCL  |   | Recitals 
   Dissenting Shares  |   | Section 2.6 
   Divestiture Action  |   | Section 5.3(d) 
   Effective Time  |   | Section 1.3 
   Enforceability Exceptions  |   | Section 3.3(a) 
   ERISA  |   | Section 3.12(a) 
   FDA  |   | Section 3.23(a) 
   Federal Health Care Program  |   | Section 3.24(b) 
   Federal Health Care Program Laws  |   | Section 3.24(c) 
   HIPAA  |   | Section 3.24(c) 
   Labor Agreement  |   | Section 3.13(a)(ii) 
   Lease  |   | Section 3.17(b) 
   Material Supplier  |   | Section 3.19(c) 
   Merger  |   | Recitals 
   Merger Sub  |   | Preamble 
   Option Consideration  |   | Section 2.4(a) 
   Parent  |   | Preamble 
   Parent 401(k) Plan  |   | Section 5.10(d) 
   Parent Material Adverse Effect  |   | Section 4.1 
   Paying Agent  |   | Section 2.2(a) 
   Payment Fund  |   | Section 2.2(a) 
   Payoff Letter  |   | Section 5.13 
   Preferred Stock Consideration  |   | Section 2.1(a)(ii) 
   Preferred Stockholder Letter  |   | Section 2.4 
   Privacy Requirements  |   | Section 3.16(q) 
   Proxy Statement  |   | Section 3.11 
   Restrictive Business Arrangement  |   | Section 3.15(a)(xi) 
   RSU Consideration  |   | Section 2.4(b) 
   Series A Preferred Stock  |   | Section 3.2(a) 
   Series A-1 Preferred Stock  |   | Section 3.2(a) 
   Siemens Healthineers  |   | Section 4.7 
   SSA  |   | Section 3.24(b) 
   Surviving Corporation  |   | Section 1.1 
   Termination Date  |   | Section 7.1(b)(i) 
   Voting and Support Agreement  |   | Recitals 
   WARN Act  |   | Section 3.13(b) 
   Warrant Consideration  |   | Section 2.3 
  



  

[Remainder of page intentionally left blank; signature pages follow]

  



  

   

92

 



    



  

IN WITNESS WHEREOF, Parent, Merger Sub and the Company have caused this
Agreement to be executed as of the date first written above by their
respective officers thereunto duly authorized.

  



       | SIEMENS MEDICAL SOLUTIONS USA, INC. 
---|--- 
     |   | 
     | By:  | /s/ David Pacitti 
     |   | Name: David Pacitti 
     |   | Title: President 
     |   | 
     | By:  | /s/ Ann Custin 
     |   | Name: Ann Custin 
     |   | Title: Executive Vice President, Treasurer and  CFO Americas 
     |   | 
     | CORPUS MERGER, INC. 
     |   | 
     | By:  | /s/ David Pacitii 
     |   | Name: David Pacitti 
     |   | Title: President 
     |   | 
     | By:  | /s/ Ann Custin 
     |   | Name: Ann Custin 
     |   | Title: Vice President and Chief Financial  Officer 
  



  

[Signature Page to Agreement and Plan of Merger]

  



  

   



 



    



       | CORINDUS VASCULAR  ROBOTICS, INC. 
---|--- 
     |   | 
     | By:  | /s/ Mark J. Toland 
     |   | Name:  | Mark J. Toland 
     |   | Title:  | Chief Executive Officer and President 
  



  

[Signature Page to Agreement and Plan of Merger]

  



  

   



 



    



  

  

Exhibit A

  

[Omitted]

  



  



    



 



     

Exhibit B

  

[Omitted]

  



  



    



 



     

Exhibit C

  

[Omitted]

  



  



  



  



  



  



  



  



  



  



  



  



  



  



  

    



 



     

Exhibit D

  



  



  

  

FORM OF PREFERRED STOCKHOLDER LETTER

  



  

[LETTERHEAD OF CORINDUS VASCULAR ROBOTICS, INC.]

  



  

[DATE]

  



  

SENT VIA: [METHOD OF DELIVERY]

  



  

[PREFERRED STOCKHOLDER NAME] [PREFERRED STOCKHOLDER ADDRESS]

  



  



  

RE: Disposition of Company Preferred Stock and 2018 Warrants pursuant to
Merger Agreement

  



  

Dear [PREFERRED STOCKHOLDER NAME]:

  



  

This letter confirms your agreement with Corindus Vascular Robotics, Inc., a
Delaware corporation (the " _Company_ "), related to the disposition of
Company Preferred Stock (as defined in the Merger Agreement) and 2018 Warrants
(as defined below) in connection with the Agreement and Plan of Merger (the "
_Merger Agreement_ ") dated as of August 7, 2019 by and among the Company,
Siemens Medical Solutions USA, Inc., a Delaware corporation (" _Parent_ "),
and Corpus Merger, Inc., a Delaware corporation and a wholly owned subsidiary
of Parent (" _Merger Sub_ "), pursuant to which, subject to the terms and
conditions thereof, among other things, Merger Sub will merge with and into
the Company (the " _Merger_ "), with the Company surviving as a wholly owned
Subsidiary of Parent. Capitalized terms used but not otherwise defined herein
shall have the meanings ascribed to them in the Merger Agreement.

  



  

You are the sole record owner and Beneficial Owner (as defined below) of (a)
shares of Series A Preferred Stock, (b) shares of Series A-1 Preferred Stock,
or (c) warrants to purchase shares of the common stock of the Company, par
value $0.0001 per share, dated March 16, 2018 (" _2018 Warrants_ "), all of
which ownership is as set forth on the table below. For the purposes of
this agreement, " _Beneficial Owner_ " shall have the meaning given to such
term in Rule 13d-3 under the Exchange Act, without giving effect to the
limiting phrase "within sixty days" set forth in Rule 13d-3(d)(1)(i).

  



  

You agree that (i) the Company Certificate of Designation provides that, in
the Merger, all the holders of the Company Preferred Stock shall have only
the right to receive the Preferred Stock Consideration (that is cash without
interest) pursuant to Section 7(a) of the Company Certificate of Designation
(and that, notwithstanding Section 7(f) of the Company Certificate of
Designation, Section 8 of the Company Certificate of Designation shall not
apply to the Merger), (ii) the amendment of the certificate of
incorporation of the Company and the bylaws of the Company at the Effective
Time of the Merger (and the agreement to do the same upon execution of the
Merger Agreement) is hereby ratified, approved, and confirmed (assuming that
in the Merger the holders of the Company Preferred Stock receive that to
which they are entitled pursuant to Section 7(a) of the Company Certificate of
Designation), and (iii) no provision of Section 11 of the Company Certificate
of Designation requires the prior affirmative vote or written consent of
the holders of a majority of the Company Preferred Stock, voting as a
separate class, for the Company to enter into the Merger Agreement or
effectuate the Merger. To the extent that you have any rights or options under
Section 8 of the Company Certificate of Designation in connection with the
Merger, you hereby irrevocably waive any such rights or options (assuming that
in the Merger you receive that to which you are entitled pursuant to Section
7(a) of the Company Certificate of Designation).

  



  



    



 



     

You further agree that, at the Effective Time of the Merger, as contemplated
by the Merger Agreement, each of your 2018 Warrants will be cancelled and
converted, by means of a "cashless exercise", into the right to receive from
the Company at the Effective Time a cash payment (without interest) equal to
the product of (A) the excess, if any, of (1) the Common Stock Consideration
over (2) the per share exercise price of such 2018 Warrant, and (B) the
number of shares of Company Common Stock subject to such 2018 Warrant as of
the Effective Time.

  



  

This agreement shall terminate upon the earliest to occur of (a) the
termination of the Merger Agreement in accordance with its terms prior to the
Effective Time or (b) any amendment to the Merger Agreement without your prior
written consent that (i) decreases the amount or changes the form of the
Preferred Stock Consideration or the Merger Consideration, (ii) imposes any
additional material restrictions on or additional conditions on the payment
of the Preferred Stock Consideration or the Merger Consideration, or (iii)
otherwise amends the Merger Agreement in a manner materially adverse to you
relative to the other stockholders of the Company. In the event of the
termination of this agreement in accordance with this paragraph, this
agreement shall become void and have no effect. You hereby agree that Parent
is a third party beneficiary of the terms hereof.

  



  

This agreement may be executed in multiple counterparts, all of which shall
together be considered one and the same agreement. Delivery of an executed
signature page to this agreement by electronic transmission shall be as
effective as delivery of a manually signed counterpart of this agreement.

  



  

Please sign below to acknowledge your acceptance and agreement.

  



  

Sincerely,

  



  

  

[SIGNATORY NAME, TITLE]

  



  



  

Agreed to and Accepted:

  



  

[STOCKHOLDER]

  



  

Date:

   | By:| Name: 
---|---|--- 
  

Title:

  



     Shares of Series A Preferred Stock Owned by Stockholder  | 
---|--- 
   Shares of Series A-1 Preferred Stock Owned by Stockholder  | 
   2018 Warrants Owned by Stockholder  | 
  

  



  

  

   



     

    

  



  

      '

